Dendritic cell development in haematological malignancies and neoplasia by Milne, Paul
i 
 
 
 
 
 
 
 
Dendritic Cell Development in 
Haematological Malignancies and 
Neoplasia 
 
 
 
Paul Milne 
 
 
Human Dendritic Cell Lab 
Institute of Cellular Medicine 
William Leech Building 
Newcastle University 
Framlington Place 
Newcastle upon Tyne 
NE2 4HH 
 
 
 
 
 
 
A thesis submitted to the Institute of Cellular Medicine, Newcastle 
University for the degree of Doctor of Philosophy 
 
 
 
 
Submitted - December 2014  
Re-Submitted - July 2015 
Approved - August 2015 
 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
 
 
 
 
 
 
All is for the best, in the best of all possible worlds. 
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Langerhans Cell Histiocytosis Cells 
Cells flow cytometrically sorted by expression of CD1a and Langerin from a skin lesion 
of a patient with Langerhans Cell Histiocytosis (A2712). Cytospin slides were prepared 
from sorted cells and stained with May-Grünwald-Giemsa (pH 6.8) on a Sysmex SP-
1000i. Photographs were taken on a Zeiss Axioimager Z2 microscope with AxioVision 
4.8 software at 100 times magnification.  Scale as indicated.  
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Abstract: 
 
Dendritic cells (DC) play a major role in the detection of antigens, 
initiation of immunity and induction and regulation of tolerance. DCs are Bone 
Marrow (BM) derived and their development may be influenced by 
haematological malignancy in several ways.  Firstly, myelodysplastic, 
myeloproliferative or leukaemic transformation of bone marrow progenitors may 
involve DC precursors directly, when they become part of a malignant clone, or 
indirectly when neoplastic expansion of other lineages compromises the 
development of DCs.   Secondly, neoplasia of the dendritic cell lineage itself 
may occur in a heterogeneous group of histiocytic disorders including 
Langerhans cell histiocytosis (LCH) and Erdheim Chester disease (ECD). 
 
The first part of this thesis concerns the effect of haematological 
malignancies on the generation of DCs; in particular the relationship between 
DC, monocyte, B and NK lymphoid cell (DCML) deficiency, caused by GATA2 
gene mutations, sporadic myelodysplastic syndrome (MDS) and acute myeloid 
leukaemia (AML). Comprehensive flow cytometric methods for profiling of the 
DCs and monocytes in the peripheral blood (PB) and peripheral tissues, and the 
CD34+ progenitors of the BM have been developed. Using these methods, it 
was possible to see that patients with the three diseases differed on several 
grounds.  DCML deficiencies associated with a younger age of presentation, 
better preserved haemoglobin, neutrophils and platelets and much more severe 
defects of DCs, monocytes, and lymphoid cells. In patients with MDS, 
deficiencies are more moderate and mononuclear cell generation in AML 
patients is surprisingly preserved. Serum levels of Fms-like tyrosine kinase 3 
ligand (FLT3L) also differed, with massively increased levels in DCML 
deficiency, stable levels in MDS and deficiencies in AML. Finally, strategies of 
grouping of AML patients have proven to be possible by using progenitor cell or 
DC related phenotypic markers which may correlate to known cytogenetic 
abnormalities. 
 
The second part of this thesis explores the origin of the cells of LCH and 
ECD, both neoplasia involving DC-like cells.  RT-PCR assays were developed 
to detect the BRAFV600E mutation, which is present in ~60% of LCH and ECD 
viii 
 
cases.  Surprisingly, it was seen that LCH and ECD express BRAFV600E in 
differing peripheral blood fractions. In LCH, 78-94% of all BRAFV600E alleles 
were found in HLA-DR+Lineage- cells, localised to the monocytes and CD1c+ 
myeloid DCs (mDCs). However in ECD, 80-82% of mutated alleles were 
recovered from the HLA-DR-Lineage- quadrant, localised to CD33+ early 
myeloid cells, and no mutation was found in the monocytes or mDCs. 
 
The final part of the thesis examines whether the circulating cells which 
carry the BRAFV600E mutation in LCH and ECD can actually develop into LCH-
like cells. In order to do this, culture systems were developed with a variety of 
cytokines and conditions. These experiments showed that CD14+ and CD16+ 
monocytes and CD1c+ mDCs could all induce the Langerhans Cell (LC) 
markers CD1a and Langerin in response to GM-CSF, TGFβ and BMP7, 
however only the CD1c+ mDCs could express Langerin at the high levels seen 
in LCs, along with EpCam and Birbeck granules. 
 
Several techniques have been developed to study DCs in haematological 
malignancies. Throughout this thesis, these techniques have provided valuable 
data on the development and homeostasis of human DCs. 
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Chapter 1. Introduction 
 
This introduction will focus on haematopoietic progenitor subsets, 
dendritic cells (DCs) and their roles in the healthy state, haematological 
malignancies and immunodeficiencies. The introduction is split into five parts: 
 
A. Steady-State Haematopoiesis 
B. Dendritic Cell and Monocyte Subtypes 
C. Dendritic Cells in Acute Leukaemia, Myelodysplasia and 
Immunodeficiency 
D. Dendritic Cells in Histiocytic Disorders 
E. The Origins of Histiocytic Disorder Cells 
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1.1. Steady-State Haematopoiesis 
Haematopoiesis is the process of formation and development of mature 
blood cells. This process needs to be tightly controlled as many blood cells are 
short lived, and thus need to be replaced continuously in order to maintain the 
circulatory and immune systems. However, this production also needs to be 
limited, in order to prevent an over accumulation of cells which can interrupt 
normal physiological processes.  
 
An overview diagram of the locations of human haematopoiesis is given 
in Figure 1.1. In developing human embryos, blood cell formation first occurs in 
the blood islands of the foetal yolk sac (umbilical vesicle), around three weeks 
after fertilization. During gestation, the haematopoietic processes are taken on 
by the liver, spleen, lymph nodes (LN) and bone marrow (BM). Finally, by the 
time of birth, the BM has assumed all haematopoiesis, though maturation of 
lymphocytes still occurs in the lymphoid organs. In order to maintain the steady-
state, 1011-1012 new blood cells must be produced each day in adult human 
bone marrow(Parslow et al., 2001; Doulatov et al., 2012). In some pathological 
disorders, such as myelofibrosis, extramedullary haematopoiesis can occur to 
compensate for bone marrow failure (BMF). 
 
 
 
Figure 1.1. Timeline of Haematopoiesis in Humans 
Overview diagram of the sites of human haematopoiesis from fertilisation 
through to adulthood. Line colours in the postnatal section relate to specific 
bones in the skeletal diagram. (Komorniczak, 2011) 
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1.1.1. Haematopoietic Stem Cells 
At the apex of the haematopoietic hierarchy is the haematopoietic 
stem cell (HSC). These cells have capacities for self-renewal and 
multilineage differentiation, which allow them to support the entire 
haematopoietic system in healthy individuals.  
 
The concept of haematopoietic stem cells arose from observations 
of the aftermath of the Hiroshima and Nagasaki nuclear bombings. It was 
observed that the haematopoietic systems of patients with low dose 
radiation poisoning were unable to produce enough leukocytes to ward off 
opportunistic infections, or platelets to form blood clots.  
 
It was discovered that these effects could be abated in rodents by 
shielding either the spleen or a single bone from radiation(Jacobsen et al., 
1949), or by repopulating the radiation-abolished haematopoietic system 
with injected BM cells (Jacobson et al., 1951; Lorenz et al., 1952). The 
injected donor-derived BM cells were able to form colonies of clones of 
maturing haematopoietic cells in the spleen (CFU-S), which were able to 
self-replicate and were multipotent, with the ability to generate multiple 
types of haematopoietic cells (Becker et al., 1963; Siminovitch et al., 
1963). 
 
It has since been found that these cells can also form colonies in 
vitro (Johnson et al., 1977; Humphries et al., 1979), and this has been the 
basis of much human HSC work, laying the foundations for clinical 
applications such as modern bone marrow transplantations. 
 
HSCs can be identified by their small size and low side population 
staining with vital dyes (rhodamine 123 or Hoechst 33342) or their surface 
markers. CD34, which is single-pass transmembrane glycoprotein 
adhesion factor found on <5% of blood cells was the first surface marker 
used to enrich human HSCs and progenitor cells (Civin et al., 1984). 
Human HSCs are more specifically identified as Lin-CD34+CD38-
/lowCD90+CD59+CD117+ (Baum et al., 1992). As the cells differentiate into 
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multi-potent progenitors (MPP) expression of CD90 is lost, and when they 
differentiate to mature effector cells, expression of CD34 is gradually lost. 
It is important to note that at least a small proportion of human HSCs may 
be CD34-(Bhatia et al., 1998). Doulatov et al, estimated this CD34- 
population to be <1% of total HSCs (Doulatov et al., 2012). 
 
As HSCs differentiate, they follow a series of lineage restriction 
milestones before they eventually reach an endpoint as a mature cell. 
Further down the hierarchy are progenitor cells, which have a limited 
potential for proliferation and differentiation but cannot self-renew 
indefinitely. The final step before fully differentiated cells are precursor 
cells which have lost most or all of their differentiation capacity and cannot 
self-renew. All circulating blood cells and most tissue leukocytes are 
believed to originate from, and be continuously replenished by HSCs in 
the bone marrow, giving rise to all myeloid (erythrocytes, monocytes, 
macrophages, neutrophils, basophils, eosinophils, dendritic cells, 
megakaryocytes and platelets) and lymphoid (T-cells, B-cells, NK-cells) 
cell types.  
 
1.1.2. Multi-Potent Progenitors 
HSCs differentiate into multi-potent progenitors (MPPs), losing the 
ability to self-renew and gaining lineage bias but maintaining the ability to 
differentiate into any haematopoietic cell. Majeti et al, showed through the 
use of in vivo xenotransplantation as well as complementary in vitro 
assays, that the human cord blood HSC/MPP compartment can be split 
based on CD90 and CD45RA expression(Majeti et al., 2007). They 
showed that HSCs are CD90+CD45RA- and that there is a potential 
transiently engrafting MPP population which is CD90-CD45RA-. They also 
showed that further downstream of the MPP, there is a unipotent cell 
population which has acquired CD45RA expression. Doulatov et al have 
more recently improved the classification of MPPs as 
CD34+CD38−CD90−CD45RA−CD135+CD7−CD10− by clonal mapping of 
single bone marrow and cord blood progenitors(Doulatov et al., 2010). 
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CD38 (cyclic ADP ribose hydrolase) is a multifunctional 
transmembrane ectoenzyme glycoprotein which functions in signal 
transduction, calcium signalling and as an adhesion factor. CD38 is 
expressed in more than 90% of human CD34+ cells (Carvalho et al., 
2009), however multipotent cells are CD38low/-, gaining CD38 as they 
differentiate (Huang and Terstappen, 1994).  
 
1.1.3. Oligo-Potent Progenitors 
Downstream of the MPPs in the hierarchy is the oligo-potent 
progenitor (at least according to the classical haematopoiesis model, 
Figure 1.2). These cells have developed a level of lineage commitment 
and so their ability to differentiate has been reduced to a few cell types. 
These oligo-potent progenitors are defined by their function/lineage 
potential; however specific markers are required by which to isolate them. 
 
CD45 (Protein tyrosine phosphatase, receptor type, C; PTPRC) is a 
transmembrane enzyme. It has several isoforms, which when taken 
together are presented on all differentiated haematopoietic cells apart from 
erythrocytes and plasma cells. In humans, progenitor cells are CD45low, 
but the isoform CD45RA is seen on Multi-Lymphoid Progenitors (MLPs) 
and Granulocyte Macrophage Progenitors (GMPs) (Manz et al., 2002). 
CD45RA is also seen on naive T cells, while more mature memory T cells 
express the shorter CD45R0 isoform (Shah et al., 1988; Lansdorp et al., 
1990). 
 
1.1.3.1. Lymphoid Progenitors 
In humans, the closest homologue to the murine Common 
Lymphoid Progenitors (CLPs), are the CD34+38-CD90-45RA+ Multi-
Lymphoid Progenitors (MLPs), which can give rise to all lymphoid 
lineages (T, B and NK cells), but still may have some myeloid potential 
(Doulatov et al., 2010). The MLP fraction of cord blood may also 
contain a small CD7+ fraction which gives rise solely to T, B and NK 
cells (Hao et al., 2001; Hoebeke et al., 2007). 
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After the MLP step, the progenitors can become either thymic 
progenitors, which mature into T cells in the thymus and tonsils, or 
CD34+CD38+CD10+ B/NK cell progenitors (B/NK), which still have 
some CD33+ myeloid DC potential (Galy et al., 1995). 
 
CD10 (Neprilysin) is a metalloprotease enzyme involved in the 
breakdown of peptides. Work on human BM has shown that 
CD34+10+ progenitor cells can produce T, B and NK lymphocytes 
(Galy et al., 1995). The CD34+10+ progenitors can be split into CD38- 
MLPs and CD38+ B/NKs (Doulatov et al., 2010). In patients with 
DCML deficiency (see section 1.3.1) who lack B and NK cells, there is 
also a complete deficiency of MLP and B/NK progenitors (Bigley et al., 
2011). 
 
1.1.3.2. Myeloid Progenitors 
Current insights into myeloid progenitors split the fraction into 
Common Myeloid Progenitors (CMP), Granulocyte/Macrophage 
Progenitors (GMP) and Megakaryocyte/Erythroid Progenitors (MEP). 
Manz et al, 2002 prospectively isolated human homologues to murine 
CMP, GMP and MEP using CD123 (IL-3Ra) and CD45RA and showed 
directly that CMPs are clonogenic progenitors of both GMPs and 
MEPs. They also phenotyped all three populations in humans: CMP 
are Lin-CD34+CD38+CD123lowCD45RA-, GMP Lin-
CD34+CD38+CD123low CD45RA+ and MEP Lin-CD34+CD38+CD123-
CD45RA- (Manz et al., 2002). 
 
CD123 is the cell surface receptor for interleukin-3 (IL-3R), 
which when activated, induces tyrosine phosphorylation, promoting 
proliferation and differentiation in some progenitor cells. CD123 is 
found to be positive on CMPs and GMPs (Manz et al., 2002) and also 
has high expression on an ill-defined CD34+38+10-45RA+123high cell 
subset.   
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The differentiation of CMPs, GMPs and MEPs by CD123 has 
created controversy as the results do not appear to be easily 
reproducible. Doulatov et al, 2010  have attempted the separation with 
a different method, using single cell sorting with CD45RA with CD135 
(FLT3) expression; MEPs are identified as CD135-CD45RA- CMPs 
CD135+CD45RA- and GMPs CD135+CD45RA+ (Doulatov et al., 2010). 
 
CD110, thrombopoietin (TPO) is a regulator of 
megakaryopoiesis and is also a potential stem cell factor, having been 
implicated in MEP and mast cell proliferation and differentiation 
(Sungaran et al., 2000; Kirshenbaum et al., 2005), therefore this could 
be another possible target for CMP, GMP, MEP separation. 
 
In flow cytometric analysis of normal human BM samples, 
Carvalho et al have reported that early myeloid precursors in the 
CD34- compartment express CD33 and CD13, and more mature 
granulocytic cells express CD11b, CD11c and CD15 (Carvalho et al., 
2009). Therefore it is possible that some of these markers could be 
useful in the examination of the CMP/GMP/MEP phenotypic split.  
 
As part of this thesis, a multi-colour flow cytometry panel was 
set up to examine the BM CD34+ mononuclear cell fractions, involving 
examination of some of the potential markers listed above.  
 
1.1.4. Models of Haematopoiesis 
An important step in our understanding of leukaemogenesis would 
be to understand the process of normal lineage commitment of HSCs, as 
this could help identify at what stage of the process the leukaemic 
aberration has occurred.  Over the last twenty years there has been much 
progress in the understanding of HSC lineage commitment, with most 
evidence showing that commitment occurs as a stepwise process, 
however there have been several models presented demonstrating 
differing emphases on myeloid or lymphoid lineages and numerous 
alterations to progenitor subtype classifications.  
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The classical model of haematopoiesis was formulated after 
common lymphoid progenitors (CLPs) (Kondo et al., 1997) and common 
myeloid progenitors (CMPs) (Akashi et al., 2000) were isolated from mice. 
A diagrammatical representation of this model is given in Figure 1.2. 
 
 
Figure 1.2. Classic Scheme of Haematopoiesis 
Classic schema of haematopoiesis; showing an early bifurcation into lymphoid 
and myeloid branches.(Graf, 2008). 
 
The three main tenets of this model are: 
1. Cells lose the ability to self-renew prior to lineage commitment, 
becoming Multi-Potent Progenitors (MPPs). 
 
2. Downstream of the MPP step, cells commit to either lymphoid 
(Common Lymphoid Progenitors; CLP) or myeloid (Common 
Myeloid Progenitors; CMP) lineages. 
 
3. Further lineage commitments occur as a stepwise process. 
 
It is starting to become apparent that the classical system is flawed 
in the human (and mouse) setting, at least for lymphoid lineage 
commitment. For example, studies have reported by clonally mapping the 
developmental potential of single cord blood and adult bone marrow 
progenitors that myeloid commitment follows the classical model, whereas 
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so called Multi-Lymphoid Progenitors (MLPs) were still capable of giving 
rise to macrophages and DCs (Galy et al., 1995; Doulatov et al., 2010; 
Doulatov et al., 2012).  
Current evidence strongly suggests a lineage differentiation from 
MPPs to CMPs and MLPs, however several groups examining the MPP 
compartment of mice have demonstrated a Lin-Sca-1+CD117+FLT3high cell 
fraction which shows full lineage potential, with only a very rare population 
with MkE potential (Adolfsson et al., 2001; Adolfsson et al., 2005; Yang et 
al., 2005; Arinobu et al., 2007), which they term lymphoid-primed 
multipotent progenitors (LMPPs). This would suggest in mice that either 
there is a lineage commitment step prior to CMP/CLP restriction where 
cells commit entirely to MkE or at least that for some reason MkE potential 
is lost early on in the commitment process or that LMPPs and CLPs both 
exist.  
 
In human studies, it has been demonstrated that 
CD34+38+45RA+10+ MLPs do have MkE potential (Doulatov et al., 2010), 
however a CD34+38+45RA+10- fraction has been seen to functionally 
relate to the murine LMPP, lacking granulocyte potential (Goardon et al., 
2011). The Goardon et al paper splits the multi-lymphoid progenitors 
(MLP) into CD10+ myeloid-lymphoid progenitors (MLP) and CD10- 
Lymphoid-Primed Multi-Potent Progenitors (LMPP).  
 
For the purposes of this thesis, I used a model of haematopoiesis 
based on the work by Doulatov et al, earlier work demonstrating the 
isolation of CMPs using CD123 (Manz et al., 2002) and work within the 
Human Dendritic Cell Lab (HuDC Lab) (Figure 1.3).  
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Figure 1.3. Basic Representation of Unidirectional Haematopoiesis 
HSC = Haematopoietic Stem Cell; MPP = Multi-Potent Progenitor; MLP = Multi-
Lymphoid Progenitor; B/NK = B/NK Cell Progenitor; CMP = Common Myeloid 
Progenitor; MEP = Megakaryocyte/Erythroid Progenitor; GMP = Granulocyte 
Macrophage Progenitor; RBC = Red Blood Cell; T = T Cell; B = B Cell; NK = 
Natural Killer Cell; mDC = Myeloid Dendritic Cell; pDC = Plasmacytoid Dendritic 
Cell; Mono = Monocyte; LC = Langerhans Cell; Mo-MAC = 
Monocyte/Macrophage; MΦ = Macrophage. 
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1.2. Dendritic Cell and Monocyte Cell Subsets 
Dendritic cells and monocytes, as well as tissue macrophages constitute 
the mononuclear phagocytic system, though they may not be related between 
themselves. Dendritic cells have a unique function in the sensing of ‘danger’ to 
the host and initiation of appropriate immune responses (Banchereau and 
Steinman, 1998). Their role in vivo is to transport antigens to draining lymph 
nodes where they interact with T cells and are critical in stimulating immunity to 
infections, vaccines and tumours. It is now known in mice that DCs arise 
independently from monocytes in the steady-state, dependant on specific 
growth factors and genes (Liu and Nussenzweig, 2010; Collin et al., 2013), 
however, monocytes may play a role in the origin of some inflammatory DCs 
(Collin et al., 2013; Segura et al., 2013). Monocytes have roles in pathogen 
challenge and inflammation, while macrophages are involved in the resolution 
of inflammation and tissue homeostasis.  
 
1.2.1. Blood Monocyte and Dendritic Cell Subsets 
In human peripheral blood there are three known monocyte 
subsets; CD14++16- classical monocytes, CD14+16+ non-classical 
monocytes and  CD14++16+ intermediate monocytes, hereafter referred 
to as CD14+, CD16+ and CD14+16+ monocytes respectively. There are 
also at least three subtypes of dendritic cells including a CD123+ 
plasmacytoid DC (pDC) and two myeloid DCs (mDCs); CD11c+1c+ mDCs 
and CD141+ mDCs.  
 
1.2.1.1. Classical CD14+ Monocytes 
The CD14+ monocyte is the most common in human peripheral 
blood, making up ~90% of the total monocyte fraction. These 
monocytes are antigen presenting cells (APCs) which can 
phagocytose and kill microbes by means of opsonin mediated 
complement system activation, direct binding via toll-like receptors 
and/or by antibody dependant cell-mediated cytotoxicity. 
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1.2.1.2. Non-Classical CD16+ Monocytes 
There is debate as to whether the non-classical CD16+ 
monocyte is most closely related to CD14+ monocytes or mDCs, as 
there are several differences from the classical monocytes. These 
differences include morphology, cytochemistry, function and 
immunophenotype (Almeida et al., 2001), migratory properties and 
macrophage differentiation (Randolph et al., 2002). However, the gene 
expression profile of CD16+ monocytes is most similar to that of the 
CD14+ monocytes (Robbins et al., 2008). 
 
1.2.1.3. Intermediate CD14+16+ Monocytes 
The third subset of monocytes is CD14+16+, which can produce 
high levels of tumour necrosis factor and interleukin-12 (Zawada et al., 
2011). It is currently unknown whether this subset is a descendant of 
either the CD14+ or CD16+ monocytes, or a completely separate 
entity. A study by Ghattas et al has suggested that the CD14+16+ 
population is independent as it has markers representative of 
reparative processes at much higher levels than both the other 
monocyte subtypes (Ghattas et al., 2013). Observations from the 
HuDC lab have shown that CD14+ monocytes are present in the BM 
where CD16+ and CD14+16+ monocytes are absent. Also, it has 
recently been reported that a small group of patients can have a 
specific immunodeficiency of CD16+ monocytes and very low numbers 
of CD14+16+ monocytes, where CD14+ monocytes are preserved 
(Frankenberger et al., 2013).  
 
1.2.1.4. CD123+ Plasmacytoid DCs 
Plasmacytoid dendritic cells (pDCs) have been observed for 
many years in the T cell zones of lymphoid tissue and in the circulation 
as immature veiled cells, but it was only in 1999 that they were 
identified as dendritic cells rather than plasmacytoid T cells (Grouard 
et al., 1997). In humans, pDCs can be distinguished by lack of Lineage 
markers, CD14, CD16 and CD11c, and positivity for HLA-DR, CD123, 
CD303 (BDCA-2) and CD304 (BDCA-4) and constitute just 0.2-0.4% of 
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all the mononuclear cells in the peripheral blood. pDCs are part of the 
innate immune system, which can internalise and detect pathogenic 
ssDNA and CpG DNA motifs via intracellular toll-like receptors (TLR) 7 
and 9 (Sallusto and Lanzavecchia, 2002; Colonna et al., 2004). When 
stimulated with viruses, pDCs produce large amounts of IFN-α and to 
a lesser extent IFN-β (Kadowaki and Liu, 2002). Finally, pDCs express 
Fc epsilon RI (FcεRIα), the high-affinity receptor for IgE (Foster et al., 
2003; Novak et al., 2003), indicating that these cells are likely 
contributors to the inflammatory response in allergy. Currently it is 
unknown whether pDCs develop from the lymphoid or myeloid 
progenitors in the bone marrow.  
 
1.2.1.5. CD11c+1c+ Myeloid DCs 
CD11c+1c+ myeloid DCs are the most common type of DC, at 
0.3-0.5% of normal peripheral blood mononuclear cells. Most studies 
refer to the entire CD14-11c+ fraction as myeloid DCs, as the majority 
of these cells express CD1c (BDCA-1), these cells are referred to 
herein as CD1+ DCs. The remainder of the CD14-11c+ fraction are 
CD141+ myeloid DCs which are discussed below. CD1c+ DCs are 
APCs which are in an immature state in the blood (Dzionek et al., 
2000; MacDonald et al., 2002). Once stimulated, they have a high T 
cell stimulation capacity, with a tolerogenic Th1 immune response bias 
and chemokine production (Bachem et al., 2010; Haniffa et al., 2012). 
 
1.2.1.5. CD141+ Myeloid DCs 
CD141+ (BDCA-3) mDCs are the rarest form of DC, 
contributing only 0.01-0.02% of peripheral blood mononuclear cells, 
making them extremely difficult to study. These cells are 
phenotypically similar to the CD1c+ DCs, and also circulate in an 
immature state (Dzionek et al., 2000; MacDonald et al., 2002), but they 
do not express CD1c in blood, and express CD11c at a lower level. 
 
Like CD1c+ mDCs, the CD141+ mDCs can promote a Th1 
immune response by secretion of IL-12, and are involved in the 
14 
 
activation of CD8+ cytotoxic T cells by cross-presentation of 
extracellular antigens (Bachem et al., 2010; Haniffa et al., 2012). 
CD141+ mDCs are able to take up dead or necrotic cells via CLEC9A 
(Bachem et al., 2010; Collin et al., 2013) and they express TLR2 and 
TLR4 (Sallusto and Lanzavecchia, 2002), indicating a role in bacterial 
immunity. 
  
1.2.2. Dermal Monocyte and Dendritic Cell Subsets 
In the dermis of the skin there are two main dendritic cell 
populations, CD1c+ and CD14+, a smaller CD141+ DC population and 
also macrophages and T cells. Interestingly there are no skin pDCs in 
health. 
 
The largest DC population is a CD1c+ DCs which, by gene 
expression analysis, is likely to be the tissue homologue of the circulating 
CD1c+ DC (Haniffa et al., 2012). Tissue CD1c+ DCs have a wide range of 
antigen presentation capacity, including lipopolysaccharide, poly(IC), and 
flagellin (van der Aar et al., 2007) and mycobacterial glycolipids (Van Rhijn 
et al., 2013). Other functions, such as fungal recognition, Th1 and Th17 
polarisation have also been suggested (Collin et al., 2013). 
 
The second dermal DC is the CD14+ dermal dendritic cell, which is 
now known to be from the monocyte-macrophage lineage rather than DC, 
by gene expression analysis (McGovern et al., 2014). CD14+ DCs secrete 
interleukin-10 (IL-10) and IL-6 and have been shown to induce regulatory 
T cells and helper follicular T cells (Chu et al., 2012; Klechevsky et al., 
2008). A notable feature of CD14+ DCs is their poor ability to stimulate 
allogeneic T cell proliferation (Klechevsky et al., 2008; Morelli et al., 2005; 
de Gruijl et al., 2006), which is consistent with their status as a monocyte-
derived macrophage. 
 
CD14+ DCs also express variable levels of CD141, so they had 
been presumed to be related to blood CD141+ DCs (Chu et al., 2012). 
However, recently, the tissue counterpart of the blood CD141+ mDC has 
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been found to be a small population of CD14-CD11clowCD141high DC in 
skin(Haniffa et al., 2012). Unlike the blood counterpart, these cells express 
CD1c and  have been seen in haematopoietic tissues such as the BM and 
lymph nodes, and non-lymphoid tissues such as the liver (Collin et al., 
2013). These cells have a superior cross-presentation capacity and they 
secrete TNF-α and CXCL10(Haniffa et al., 2012), suggesting roles in 
inflammatory reactions. 
 
Macrophages have long been thought of as tissue monocytes, 
derived from circulating monocytes (van Furth and Cohn, 1968), though 
recent work in mice has shown that most tissue macrophages are derived 
from embryonic precursors (Ginhoux and Jung, 2014). Macrophages have 
roles in phagocytosis, but also in adaptive immunity and wound healing. 
Unlike tissue DCs, macrophages are fixed within the tissue (Collin et al., 
2013). 
 
1.2.3. Epidermal Langerhans Cells 
Langerhans cells (LCs) were first described in 1868 by the German 
anatomist and physician Paul Langerhans, during an undergraduate 
project using gold chloride staining (developed by Julius Friedrich 
Cohnheim) to analyse human epidermal skin cells (Langerhans, 1868). 
The cells were thought to be neurons, due to their branched morphology, 
and positive staining with gold chloride, which at the time was thought to 
be a marker specific for nerve tissue. It wasn’t until 1985 that the cells 
were characterised as antigen-presenting dendritic cells by the team of 
Ralph Steinman (Schuler, 1985). 
 
LCs form a network of epidermal DCs which are able to proliferate 
in the skin, dispersed throughout the epidermis (2-5% of total cells), but 
mainly in the stratum spinosum (see Figure 1.4 and Figure 1.5) and 
associated with the hair follicles. It is important to note that LCs can also 
be found in the mucosal stratified squamous epithelium of the respiratory, 
digestive, oral and genital mucosa and in the papillary dermis around 
blood vessels. 
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The hallmarks of LCs are their high expression of Langerin and 
CD1a and the presence of Birbeck granules. LCs also express major 
histocompatibility complex (MHC) Class II and low levels of CD11c, which 
are characteristic of ‘classical’ myeloid dendritic cells (Ginhoux et al., 
2010). The tissue CD1c+ DC also expresses CD1a, but at a lower level 
than LCs (Collin et al., 2013) and may also express a low level of langerin 
(Bigley et al., 2014). However, they do not express other LC-specific 
markers such as EpCam and ECadherin. (Zaba et al., 2007; Haniffa et al., 
2009). 
 
 
Figure 1.4. Langerhans Cells Forming a Network of DCs in the Skin 
Electron microscopy image of Langerhans cells in the skin, with langerin 
showing in green. The spaces around the Langerhans cells are keratinocytes 
which take up DAPI staining. (Unpublished data). 
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Figure 1.5. The Different Layers of the Epidermis 
A diagrammatic representation of the layers in the epidermis (Serephine, 2006) 
1.2.3.1. Function 
In the simplest of terms, LCs are antigen presenting cells 
(APCs) which collect antigens in the peripheral tissues, internalise 
these and transport them to the lymph nodes, where the antigens can 
be displayed to naïve T cells. LCs take up bacteria by phagocytosis 
(phagocytic cup formation) (Reis e Sousa et al., 1993), and are now 
known to have several more intricate functions such as the production 
of TGF-B, IL-1B IL-15 and IL-23 (Aliahmadi et al., 2009). 
 
1.2.3.2. Langerin (CD207/CLEC4K) 
Langerin (CD207/CLEC4K, C-type lectin domain family 4 
member K) is a type II transmembrane, calcium-dependant, 
carbohydrate-binding protein domain (See Figure 1.6), which is 
expressed on the surface of LCs and which, when internalised, 
associates with Birbeck granules (Valladeau et al., 2000; Valladeau et 
al., 2002). The extracellular region of langerin exists as a stable trimer 
held together by a coil of α-helices formed by the neck region 
(Takahara et al., 2002; Stambach and Taylor, 2003).  
 
18 
 
Langerin has mannose, fructose and N-acetylglucosamine (part 
of bacterial cell wall) binding specificity (Takahara et al., 2002; 
Stambach and Taylor, 2003), so it has been suggested that langerin 
accesses a non-classical antigen-processing pathway by the 
internalisation of these antigens into Birbeck granules. In HIV, langerin 
has been seen to co-localise with caveolin-1 (also present in BGs), 
leading to a reduction in infection rate, possibly by autophagy 
(Manches et al., 2014). 
 
It was at first thought that langerin was specific for skin 
Langerhans cells, however it has now been found on a small 
population of non-LC DCs (Bigley et al., 2014). In mice, langerin is 
expressed by dermal CD103+ DCs and splenic CD8+ DCs (Nagao et 
al., 2009). In humans, langerin can be expressed by a small proportion 
of tissue CD1c+ DCs (Romani et al., 2010; Bigley et al., 2011) and by 
DCs in the marginal zone of the spleen (Idoyaga et al, 2009), 
indicating that it is not solely an LC marker. 
 
 
Figure 1.6 Types of Transmembrane Proteins 
Schematic representation of transmembrane proteins: 1. a single 
transmembrane α-helix (bitopic membrane protein) 2. a polytopic 
transmembrane α-helical protein 3. a polytopic transmembrane β-sheet protein. 
The membrane is represented in light brown. (Foobar, 2006). Langerin is a type 
2 membrane protein. 
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1.2.3.3. CD1a 
CD1a (Leu-6) is part of a family of transmembrane 
glycoproteins (CD1a-e), structurally similar to class 1 major 
histocompatibility complex (MHC class I) proteins. The role of CD1a is 
in the formation of heterodimers with beta-2-microglobulin and the 
antigen presentation of lipids, including mycobacterial cell wall 
components to CD1a-autoreactive T cells (Brigl and Brenner, 2004; de 
Jong et al., 2010), otherwise known as invariant natural killer T cells.  
 
CD1a is found on Langerhans cells and thymocyte precursors 
(Brigl and Brenner, 2004). In LCs, CD1a is expressed very brightly, 
while CD1c+ dermal DCs and moDCs have lower CD1a expression 
with higher CD1b expression. 
 
In disease, CD1a is expressed by hairy cell leukaemia cells (De 
Panfilis et al., 1988), the alveolar macrophages in bronchial asthma 
(Agea et al., 1998) and the pathological cells in Langerhans cell 
histiocytosis (Harrist et al., 1983; Rousseau-Merck et al., 1983; 
Schuler et al., 1983). 
 
Interestingly, CD1a expression on monocyte derived DCs 
(moDCs) from normal donors is highly variable and CD1a deficiency 
caused by single nucleotide polymorphisms (SNPs) is fairly common 
(3/19 normal donors) preventing moDC mycobacterial lipid expression 
to T cells (Seshadri et al., 2013). The authors did not examine CD1a 
expression in tissue, where CD1a deficiency is rarely, if ever, seen 
(unpublished data).  
 
1.2.3.4. Birbeck Granules 
Birbeck granules (BGs) are pentilaminar, cytoplasmic 
organelles thought to be found exclusively in Langerhans Cells 
(Birbeck et al., 1961). In two dimensional electron microscopy 
sections, BGs are seen as rod or tennis-racquet shaped. However, 
when three dimensional modelling is performed from electron 
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microscopy images of single BGs from multiple serial sections, their 
structure is seen to be more complex (see Figure 1.7). BGs are 
actually likely to have a flattened or curved orthogonal net of particles, 
which is bounded externally by a limiting membrane and which may be 
disc-shaped, cup-shaped, or combinations of both shapes(Sagebiel 
and Reed, 1968), rather like a single sycamore seed or a single-bladed 
propeller.  
 
During antigen phagocytosis, langerin localises to the BGs. 
After this point, the role of the BGs is unsure, they could possibly 
migrate to the periphery for exocytosis, or receptor mediated 
endocytosis. The formation of BGs is induced by langerin 
(Kissenpfennig et al., 2005), however LCs can function even when 
BGs are abolished by disruption of the langerin gene.  
 
 
Figure 1.7. Models of Birbeck Granules 
Models of the Birbeck granules found in Langerhans cells based upon 
three dimensional modelling of multiple electron microscopy serial 
sections (Sagebiel and Reed, 1968). 
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1.2.3.5. Origin of Langerhans Cells 
In mice, Langerhans cells (LCs) are thought to be originally 
derived from early foetal progenitors (Nezelof et al., 1973; Hoeffel et 
al., 2012; Schulz et al., 2012), and self-renew in the skin in the steady-
state independently from circulating cells (Merad et al., 2002; 
Bogunovic et al., 2006). Some evidence suggests that there may 
actually be more than one LC type in murine skin, some self-renewing 
and some renewed from the bone marrow (Ginhoux et al., 2006), and 
that these cells may appear in waves, a steady-state population and 
an inflammatory population (Seré et al., 2012).  
 
The true origin of LCs in humans is unclear, though it is known 
that they can proliferate in situ within cutaneous hair follicles 
(Czernielewski and Demarchez, 1987; Gilliam et al., 1998; Chorro et 
al., 2009). It has also been seen in skin allografts that LCs can remain 
of donor origin for several years (Kanitakis et al., 2011) and recipient 
LCs can persist in bone marrow transplantation (Perreault et al., 1985; 
Collin et al., 2006). 
 
Homeostatic mechanisms of LCs are distinct from those of 
myeloid DCs  (Ginhoux and Merad, 2010) and patients without 
monocyte and DC populations such as those with DCML deficiency 
(see section 1.3.1, page 23) still maintain LCs (Bigley et al., 2011), 
indicating that LCs are able to at least partially maintain themselves for 
some time by local proliferation. 
 
Conversely, after bone marrow transplantation (BMT), LCs in 
the skin are eventually replaced by bone marrow derived cells, 
although at a slower rate than dermal DCs (Collin et al., 2006; 
Mielcarek et al., 2014). Studies have reported cells with a phenotype 
similar to LCs in monocyte colonies derived from human bone marrow 
(Goordyal and Isaacson, 1985; Gothelf et al., 1986) and in several 
studies LC-like cells have been derived from CD34+ BM progenitor 
cells and from circulating mononuclear cells (See Table 1.5, page 64, 
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for a summary of LC generation studies to date), suggesting that  LCs 
are likely to have an alternate origin from a circulating precursor. 
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1.3. Dendritic Cells in Immunodeficiencies 
There are currently few known specific deficiencies of any of the dendritic 
cell or monocyte subsets; Pitt-Hopkins syndrome has a specific dysfunction of 
pDCs caused by mutations in the E2.2 gene (Pitt and Hopkins, 1978; Amiel et 
al., 2007; Cisse et al., 2008) and more recently patients have been seen with a 
specific CD16+ monocyte deficiency (Frankenberger et al., 2013). Dendritic 
cells are found to be low or completely missing in patients with IRF8 mutations 
(Hambleton et al., 2011), and in the recently described disease Dendritic Cell, 
Monocyte, B and NK Cell (DCML) Deficiency(Bigley et al., 2011). 
 
1.3.1. Dendritic Cell, Monocyte, B and NK Cell (DCML) Deficiency 
DCML deficiency patients have diminished numbers of myeloid and 
plasmacytoid DCs, CD14+ and CD16+ monocytes and B and NK 
lymphocytes, though T cells and circulating CD34+ progenitors are 
preserved (Bigley et al., 2011). It has been seen that children with GATA2 
mutation can have normal responses to vaccines, and relatives of some 
patients have been found to carry the GATA2 mutation but are 
asymptomatic, suggesting that the patients are likely to have normal 
counts in their younger life  (Dickinson et al., 2014). The deficiency can be 
caused by a number of different mutations of the GATA2 gene (Dickinson 
et al., 2011). GATA2 is a transcription factor required for stem cell 
homeostasis and contains 2 highly conserved zinc fingers which are 
critical for the survival of HSCs through mediating protein-DNA binding.  
 
All symptomatic patients with GATA2 mutations feature the same 
pattern of DCML cellular loss (Dickinson et al., 2011; Dickinson et al., 
2014), but there are a number of associated clinical syndromes. These 
features include: monocytopenia with Mycobacterium avium complex 
(monoMAC) (Vinh et al., 2010; Hsu et al., 2011; Hsu et al., 2013); 
lymphedema, deafness and myelodysplasia (Emberger syndrome) 
(Mansour et al., 2010; Ostergaard et al., 2011); and familial 
myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)(Hahn 
et al., 2011; Holme et al., 2012; Kazenwadel et al., 2012). Recent work 
suggests that monoMAC, lymphedema and familial MDS/AML are all 
24 
 
facets of GATA2 mutation that may occur heterogeneously (Ishida et al., 
2012; Kazenwadel et al., 2012), even within a single pedigree (Mutsaers 
et al., 2013). Some historical cases of familial AML, and NK cell deficiency, 
are now also known to be due to GATA2 mutation (Kaur et al., 1972; 
Robinson et al., 1983; Horwitz et al., 1996). It is not clear which of these 
clinical features are the direct consequences of GATA2 mutation and 
which are related to the loss of mononuclear cells. 
 
Up to 50% of individuals with GATA2 mutation develop 
myelodysplasia (MDS) associated with fibrosis and megakaryocyte 
dysplasia (Calvo et al., 2011; Hsu et al., 2011; Bodor et al., 2012; Holme 
et al., 2012; Hsu et al., 2013). However, many patients present with 
clinical problems prior to their meeting the standard WHO (World Health 
Organisation) criteria for MDS, despite the mononuclear cell failure. The 
striking loss of mononuclear cells with initially well preserved BM histology 
and trilineage haematopoiesis seen in DCML deficiency leads to the 
question of whether there is a similar loss of mononuclear cells in sporadic 
MDS. 
 
It has previously been reported that fms-like tyrosine kinase 3 
ligand (FLT3L) is elevated in patients with DCML deficiency (Bigley et al., 
2011). FLT3L is an important growth factor in DC development(Shortman 
and Naik, 2007; Rahman et al., 2011), but elevated levels have also been 
reported in Fanconi anaemia and aplastic anaemia suggesting that 
hematopoietic stress is a trigger (Lyman et al., 1995; Haidar et al., 2002). 
Further evaluation may indicate whether this is a useful marker for 
diagnosis and monitoring of GATA2 mutation.  
 
Later in this thesis is presented an analysis of a European cohort of 
DCML deficiency patients with GATA2 mutation from a range of clinical 
backgrounds, alongside classical MDS patients and de novo AML 
patients. This work describes in detail the evolution of cellular deficiency, 
the utility of FLT3L and specific deficiencies in differential diagnosis and 
the effects of failing mononuclear cell development upon peripheral 
mononuclear cell homeostasis. 
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1.4. Dendritic Cells in Haematological Malignancies 
The roles of DCs in haematological malignancies such as 
myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) are 
uncertain, though it has been reported that DC-like cells can be derived from 
blast cells in vitro(Robinson et al., 1998; Harrison et al., 2001; Panoskaltsis et 
al., 2002).  
 
One study shows a decrease of mDCs and pDCs in the peripheral blood 
of MDS patients (Ma et al., 2004) and another showed a reduction in DC 
precursors in the BM, associated with higher risk patients (Saft et al., 2013). In 
AML, levels of DCs have been seen to be vastly variable, some patients with 
expansions and others with absolute losses (Mohty et al., 2001). All of these 
studies were performed using limited flow cytometric analysis. As part of this 
thesis, a number of different multiparameter flow cytometry panels were set up 
to analyse in detail the mononuclear components of the peripheral blood and 
bone marrow of MDS and AML patients for DC numbers. 
 
1.4.1. Myelodysplastic Syndromes 
The myelodysplastic syndromes are conditions of clonal stem cells 
in the marrow which cause an ineffective production of one or more 
myeloid cell types and can lead to bleeding, anaemia and infection. MDS 
is usually a disease of the elderly, with a median age of diagnosis of ~70 
years (Corey et al., 2007; Germing et al., 2008). The prognosis is fairly 
poor, with worsening progression over time. Mean survival rates are 
between 6-24 months dependant on risk factors such as cytogenetics, BM 
blast counts and cytopenias (Greenberg et al., 1997), and allogeneic stem 
cell transplantation is the only potential curative therapy available (Zeidan 
et al., 2013). Diagnosis is based on the observation of a dysplastic 
hypercellular bone marrow with or without blast cells and peripheral blood 
cytopenia. Cytogenetic abnormalities are present in around 50% of MDS 
patients, quite often including trisomy 5, 7 or 8 (Haase, 2008). One third of 
MDS patients later progress to acute myeloid leukaemia (AML) (Adès et 
al.). The cut-off point for blast counts between a diagnosis of MDS or AML 
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is 20% by World Health Organisation (WHO) criteria (Vardiman et al., 
2009). 
 
1.4.2. Acute leukaemia 
Acute leukaemia (AL) is an umbrella term for a cancer which arises 
from the haematopoietic system of the bone marrow. AL is a life 
threatening condition where abnormal, immature leukocytes accumulate in 
the bone marrow and interfere with normal blood cell production. Whilst 
commonly confined to bone marrow and blood, leukaemic cells can invade 
other tissues including the central nervous system, skin, lung and gum.  
 
Patients often present with clinical features of BMF (bleeding, 
anaemia, infection) and malignancy (weight loss, sweats, tiredness etc.), 
which is reflected in a full blood count showing anaemia, 
thrombocytopenia and neutropenia. Circulating blasts can often be seen 
on a blood film, though diagnosis is confirmed by finding >20% leukaemic 
blast infiltration in a BM smear or trephine. Leukaemic blasts, (and hence 
the leukaemia) are classified according to their morphology, cytochemical 
stains, cell surface antigen expression assessed by flow cytometry, and 
genetic abnormalities assessed by cytogenetics and fluorescent in situ 
hybridization. 
 
Two to three thousand new cases of adult AL are diagnosed in the 
UK each year (Milligan et al., 2006), which is up to ten times higher than 
the incidence rates seen in children (see Figure 1.8). In the Northern 
region of the UK, there are approximately 100 new cases of MDS and 50 
new cases of AML per annum. About half of these present to the 
Newcastle Hospitals NHS Foundation Trust. In the UK, there are ~10,000 
adults living with AL, ~50% of who will likely die from this disease, 43% of 
women and 57% of men (CancerResearchUK, 2014b). Hence, it can be 
seen that AL has a significant impact on the UK population and the high 
mortality rate indicates that further research into this disease is required.  
 
 
 
27 
 
 
 
Figure 1.8. Leukaemia Incidence Rates, UK 
Average Number of New Cases per Year and Age-Specific Incidence Rates per 
100,000 Population, UK. (CancerResearchUK, 2014a) 
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1.4.2.1. Leukaemia Classifications 
Leukaemia has several different but complementary forms of 
classifications. The leukaemia can be of the lymphocytic or myeloid (or 
biphenotypic) lineage and can be acute; a rapid accumulation of 
immature blood cells which prevents normal blood cell production, or 
chronic; where the accumulation of cells is of a more mature, but still 
abnormal phenotype.  
 
Acute leukaemia can be classified using the differentiation 
morphology of the blasts (FAB Classification; Table 1.1), cytogenetics 
(Grimwade et al., 2010);Table 1.2), or a combination of both (WHO 
Classification; Table 1.3). It is important to note that not all leukaemias, 
such as the rare acute basophilic leukaemia are included in the FAB 
classifications. This study is focused on myeloid cells and their roles in 
acute myeloid leukaemia. 
 
 
Table 1.1.French-American-British (FAB) Leukaemia Classifications 
The myeloid leukaemias are divided into eight types (M0-7) and the 
lymphoblastic leukaemias into three (L1-3). These classifications are based on 
examining the differentiation state appearance of the leukaemic cells (light 
microscopy and cytogenetics) and which normal progenitors they most likely 
resemble.(Bennett et al., 1976) 
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Table 1.2. AML Cytogenetic Risk Status Classifications 
AML Cytogenetic Risk Status Classifications based on multivariable analyses of 
cytogenetic results seen in 5876 acute myeloid leukaemia patients (16-59 years 
of age) (Grimwade et al., 2010) 
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Table 1.3. World Health Organisation (WHO) AML/ALL 
Classifications 
Based on cytogenetics and cellular morphology (Falini et al., 2010) 
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1.4.3. Acute Myeloid Leukaemia (AML) 
Acute myeloid leukaemia is a haematopoietic disorder of the bone 
marrow where precursors of myeloid cells are arrested early in 
development and accumulate at a high rate, which may cause BMF. AML 
is the most commonly diagnosed form of AL in adults and has a similar 
median age of diagnosis as MDS, at 69 years (Juliusson et al., 2009). In 
the UK, AML has a poor average 5 year survival rate of around 25%, 
compared to ALL with a 5 year survival rate of around 40% 
(CancerResearchUK, 2013b; CancerResearchUK, 2013a). Cytogenetics 
in AML are highly heterogeneous (Grimwade et al., 2010). 
 
It is becoming apparent that it can be possible to define leukaemia 
based on the similarity of the clonal cells to progenitor subsets. Most 
experimentation of this type has employed transplanting AML cells into 
immunodeficient mouse models, such as NOD/SCID mice, to observe in 
vivo differentiation ability based on cell markers. Some markers appear to 
be expressed at corresponding levels in HSCs and AML cells (e.g. CD34, 
CD38, HLA-DR and CD71 (Bonnet and Dick, 1997) whereas others are 
aberrantly expressed in AML cells (CD33 (Appelbaum et al., 2001), CD96 
(Hosen et al., 2007), CD123 (Lapidot et al., 1994; Bonnet and Dick, 1997), 
or absent in LSCs (CD66 (Appelbaum et al., 2001), CD90 (Blair et al., 
1997). Also, some AML cells show markers consistent with a more mature 
phenotype (Goardon et al., 2011). 
 
These investigations have shown interesting preliminary results; 
however there are several issues with employing mouse models for the 
study of human AML, such as low levels of engraftment of human 
leukaemic cells into xenograft mouse models (50-70%), and the debatable 
relevance of induced murine AML. Cook and Pardee recently published a 
review of the available animal models for the study of AML, with detailed 
descriptions of their strengths and weaknesses (Cook and Pardee, 2013). 
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1.4.3.1. Classifying Leukaemic Clones 
An interesting recent study attempted to divide AML based on 
the progenitor immunophenotype of the blast cells (Goardon et al., 
2011). Looking specifically in CD34+ AML patients, they found that two 
distinct progenitor immunophenotypes were apparent. In the larger 
group of patients (87.8%, 65/74), most CD34+38+ cells were 
CD123+CD45RA+ (similar to normal granulocyte macrophage 
progenitors; GMPs) and most CD34+38- cells were CD90-CD45RA+ 
(similar to normal multi-lymphoid progenitors; MLPs) and thus are 
referred to as GMP/MLP type patients in this thesis. In the smaller 
group of patients (13.8%, 10/74), most CD34+38+ cells were 
CD123+CD45RA- (similar to normal common myeloid progenitors; 
CMPs) and most CD34+38- cells were CD90-CD45RA- (similar to 
normal multi-potent progenitors) and thus are referred to as CMP/MPP 
type patients in this thesis. 
 
1.4.4. Blastic Plasmacytoid Dendritic Cell Neoplasm 
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a 
subtype of AML defined as a CD4+CD56+ tumour with a high expression 
of HLA-DR and CD123 (IL-3 receptor) and a lack of T and B cell lineage 
specific markers (e.g. CD3, CD19, CD20). The first reported case in 1995, 
was thought to be an aggressive cutaneous immature cell lymphoma 
(Brody et al., 1995), due to the markers CD4+56+2-. This was redefined 
as Blastic Natural Killer Cell Lymphoma or CD4+/CD56+ NK-Cell 
Lymphoma, in the 2001 WHO reviews, (Jaffe, 2001) due toCD56 positivity 
and lymphoid like morphology indicating NK cells.  
 
The first connection between the tumour cells and pDCs was 
highlighted in 2001, where it was seen that when stimulated with IL-2 and 
CD40-ligand, the leukaemic cells matured to DCs with functional 
capabilities similar to pDCs, such as IFN-α production and TH2 
polarisation(Pilichowska et al., 2007). Therefore the disease was re-
classified as BPDCN in the 2008 WHO reviews (Swerdlow et al., 2008). 
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BPDCN is most often a leukaemia of the elderly, with a mean 
diagnosis age of 67, and a gender bias to males (2M/1F). BPDCN can 
occur in children, where there is a better prognosis to adults(Jegalian et 
al., 2010), who have an aggressive disease with a very poor survival of 
median 13 months (Lucioni et al., 2011).  
 
The most frequent symptom (85%) at presentation is cutaneous 
lesions. These can vary from one or two nodules to disseminated 
cutaneous lesions associated with superficial lymphadenopathy and 
occasionally systemic symptoms, such as weakness and weight loss 
(Jegalian et al., 2010; Borchiellini et al., 2012). This is followed by a 
leukaemic transformation of CD4+56+ cells in almost all cases (Borchiellini 
et al., 2012). 
 
The pathogenic cells seen in the cutaneous lesions are medium 
sized with lack of granules and little cytoplasm (see Figure 1.9). The 
nucleus tends to be regular within distinct or absent nucleoli and fine 
chromatin (Petrella, 2010; Borchiellini et al., 2012). A diagnostic criterion 
for BPDCN has been set out by Tsagarakis et al (see Table 1.4), including 
the markers CD4+56+HLA-DR+123brightto differentially diagnose from 
other CD56+ leukaemias. 
 
The most effective treatment for BPDCN is ALL type chemotherapy 
regimens followed by haematopoietic stem cell transplantation (HSCT), 
which gives the patients a median survival of 60 months (Tsagarakis et al., 
2010; Lucioni et al., 2011). However, relapses post-chemotherapy are 
frequent at median 9-11 months (Jegalian et al., 2010), and due to the late 
age of onset of this disease, most patients are not eligible to receive 
HSCT.10-20% of BPDCN patients have a co-existence of AML and/or 
MDS (Herling and Jones, 2007), which is strong evidence of a myeloid 
origin of the disease.  
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Figure 1.9. Blastic pDC in a patient with BPDCN 
Haematoxylin and Eosin staining. X400 magnification (Petrella, 2010) 
 
 
 
 
Table 1.4. BPDCN Diagnosis Algorithm (Tsagarakis et al., 2010) 
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1.4.5. Acute Leukaemia Treatment Related Mortality Risk Markers 
AML treatment related mortality during induction chemotherapy has 
substantially decreased over the last two decades (~17% in 1991; ~3.5% 
in 2009), most likely due to improved supportive clinical practices (Othus 
et al., 2014).  However, complications related to sustained disease and 
treatment still cause significant adverse event and mortality rates in AML 
and MDS patients, due to prolonged general cytopenias leading to 
infections and uncontrolled bleeding (Gaydos et al., 1962; Bodey et al., 
1966; Bodey et al., 1978; Pagano et al., 2012; Buckley et al., 2014; 
Buckley et al., 2015). These studies are limited to analysis of bulk cell 
populations such as ‘lymphocytes’ and ‘monocytes’, and focus on post-
chemotherapy markers to ascertain patient prognosis and outcome. There 
is a surprising scarcity of data documenting pre-chemotherapy markers or 
the role of specific immunodeficiencies in leukaemia. Clinical trials have 
shown that routine use of prophylactic anti-infection drugs such as colony 
stimulating factors do not increase overall survival or decrease infection 
rates in AML patients (Gurion et al., 2012), although these trials were 
inclusive of all AML patients, and so may not have been able to identify 
small groups of specific patients who would benefit from such treatment. 
Identification of markers which could be used to stratify patients for 
likelihood of treatment-related mortality and/or infection risk, before the 
induction of chemotherapy would be a major step forward in the clinical 
management of patients. Such markers could be used to tailor 
prophylactic treatments against likely infections, strategies to reduce the 
severity of other treatment-related adverse events and treatment regimens 
for haematopoietic system recovery post-chemotherapy. They could also 
be used to inform patients of the likelihood of such events. One such 
marker could be the extended phenotype of leukaemia at diagnosis.  
 
1.4.6. Acute Leukaemia and the Extended Phenotype 
Leukaemia is directly linked to bone marrow failure in some cases. 
Part of this thesis investigates leukaemogenesis by examining not only the 
leukaemic clone cells but also the specific cellular deficiency that arises 
with the leukaemia; it’s ‘extended phenotype’ of cellular immunodeficiency. 
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This information is almost always neglected by current analyses, although 
it is clear that leukaemia phenotyping is capable of identifying ‘residual 
normal cells’. The extent of mononuclear cell differentiation in AL has not 
previously been examined; however it is possible that the frequency of 
each mononuclear subtype, and in particular any deficiencies in specific 
subtypes, could have an important impact on prognosis in terms of 
infection risk at presentation and during early treatment. Immunodeficiency 
may increase the incidence of severe sepsis or fungal infection, 
responsible for the majority of induction deaths (Lech-Maranda et al., 
2010).   
 
An extended phenotype of Immunodeficiency could potentially be 
caused by the blast cells blocking the generation of specific cell subsets or 
causing a global reduction in mononuclear cells by BMF. Alternatively, 
there could be an expansion of specific cellular subsets as part of the 
leukaemic clone, which may or may not have aberrant functionality (See 
Figure 1.10).  
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Figure 1.10. Potential Extended Phenotypes of Leukaemia 
A) Generation of specific subsets blocked by the leukaemic clone. The idea 
that the expansion of the malignant cells may block specific downstream 
progeny related to the blast cell progenitor immunophenotype, while 
progeny from other progenitor types remain unaffected. In this example, an 
expansion of GMPs has blocked the maturation of mDCs.  
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B) Global reduction of mononuclear cells caused by bone marrow failure. The 
idea that the expansion of any malignant cell type will cause a universal 
reduction on all haematopoietic progeny due to the blast cells occupying the 
majority of the haematopoietic niche of the bone marrow. 
C) Expansion of specific subsets which are part of the leukaemic clone. The 
idea that the expansion of malignant cells with a specific blast cell 
immunophenotype  will lead to an expansion of the downstream progeny of 
that progenitor type. In this example, an expansion of GMPs has led to an 
expansion of monocytes.   
 
HSC = Haematopoietic Stem Cell; MPP = Multi-Potent Progenitor; MLP = Multi-
Lymphoid Progenitor; B/NK = B/NK Cell Progenitor; CMP = Common Myeloid 
Progenitor; MEP = Megakaryocyte/Erythroid Progenitor; GMP = Granulocyte 
Macrophage Progenitor; RBC = Red Blood Cell; T = T Cell; B = B Cell; NK = 
Natural Killer Cell; mDC = Myeloid Dendritic Cell; pDC = Plasmacytoid Dendritic 
Cell; Mono = Monocyte; LC = Langerhans Cell; Mo-MAC = 
Monocyte/Macrophage; MΦ = Macrophage. 
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The concept of an extended phenotype of acute leukaemia is a 
novel and potentially important idea. It is possible that total mononuclear 
cell profiling will identify a different profile of immunodeficiency associated 
with each biological type of acute leukaemia. This hypothesis stemmed 
from the following observations. Firstly, that human leukaemic blasts are 
phenotypically similar to specific progenitor subsets but are unable to 
differentiate into mature cells in vivo (Goardon et al., 2011); so there is 
likely to be a deficiency of the normal progeny of the related progenitors. 
Secondly, that there is evidence of loss of MLP and GMP progenitors and 
mononuclear cells in the pre-leukaemic disease DCML deficiency prior to 
AML development (Vinh et al., 2010; Dickinson et al., 2014). The 
difference in DCML deficiency being that there is a loss of progenitor cells 
rather than an expansion of abnormal progenitors as seen in AML. 
 
The caveat of this concept is that it relies on the clonality of the BM 
in AML patients before leukaemia develops. If the majority of the BM is not 
clonal, then the accessory phenotype is unlikely to be seen. However, if 
the majority of the BM is clonal before onset of AML, such as is the case in 
DCML deficiency (Dickinson et al., 2014) and MDS (Koeffler and Golde, 
1978; Raskind et al., 1984), then I expect to see specific 
immunodeficiencies.  
 
These immunodeficiencies can be observed using the flow 
cytometry panels set up previously and in this thesis (Bigley et al., 2011). 
Testing of this hypothesis will increase our understanding of 
leukaemogenesis; test current models of human haematopoietic hierarchy 
and may be very useful in the prognosis of leukaemia and leukaemia 
biology itself. 
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1.5. Dendritic Cells in Histiocytic Disorders 
Histiocytic Disorders (Histiocytosis) is a collective term for a group of 
diseases characterised by an abnormal accumulation of histiocytes, (or ‘tissue 
cells’), a term usually encompassing tissue macrophages and mature activated 
DCs. 
 
The most common histiocytosis is Langerhans Cell Histiocytosis (LCH), 
which is rare, but has an incidence in children similar to Hodgkin's Lymphoma 
and acute myelogenous leukaemia at around 5 cases/million. Other non-LCH 
histiocytoses include Erdheim Chester Disease (ECD), Hemophagocytic 
Lymphohistiocytosis (HLH), Juvenile Xanthogranuloma (JXG), Rosai-Dorfman 
Disease (RDD), and much rarer Sea-Blue Histiocytic Syndrome, Histiocytic 
Sarcomas and Interdigitating Dendritic Cell Sarcomas. The work in this thesis 
focuses on the histiocytoses with high levels of BRAF mutation; LCH, which is 
the most common histiocytosis, and ECD. 
 
It is currently unclear how these diseases are related, as some can occur 
in the same patient at the same time. A common hematopoietic aetiology of 
LCH and ECD is suggested by the occasional coincidence of these diseases 
and the discovery of mutated BRAF in both diseases, even though ECD is 
clinically and pathologically distinct from LCH (Haroche et al., 2012b; Yin et al., 
2013; Hervier et al., 2014). In the study by Hervier et al, approximately 19% of 
the ECD patient cohort also had evidence of LCH. Histiocytoses may also occur 
concurrently with other pathologies including AML, lymphoma, or viral infection 
(Egeler et al., 1994; Hwang et al., 2013).  
 
As with all rare diseases, there are inherent problems in the study of 
histiocytic disorders. There is a relative lack of clinical recognition of the 
disorder prior to biopsy, with common misdiagnosis as other skin diseases (e.g. 
dermatitis, eczema, burns) or other diseases such as osteomyelitis or 
malignancies. This makes attaining fresh material very difficult, with patients 
presenting to virtually any specialty (dermatology, haematology, respiratory, 
neurology, endocrinology, rheumatology, orthopaedics, oncology etc.). 
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1.5.1. Disease Cells and Target Organs 
LCH cells are large (15-25 micrometres), express langerin and  
CD1a, contain Birbeck granules (Figure 1.14) and cause granulomatous 
lesions predominantly in the bone, epithelia, haematopoietic organs, lung, 
liver and CNS(Nezelof et al., 1973; Laman et al., 2003; Abla et al., 2010; 
Allen et al., 2010; Badalian-Very et al., 2013).  ECD lesions show 
abundant CD68+ foamy macrophages and affect the distal long bones, 
skin (xanthelasmata) and cardiovascular tissue (Haroche et al., 2012b). 
See Figure 1.14, page 51 for a brief description of the main differences 
between LCH and ECD. 
 
In LCH, there is an admixed infiltrate of T cells, activated 
macrophages, eosinophils, neutrophils, fibroblasts and osteoclast-like-
multinucleate giant cells in the granulomas. This is similar to the infiltrate 
seen in Hodgkin’s Lymphoma, but without the classic Reed-Sternberg 
cells and plasma cells. ECD lesions have a Th1-type lymphocyte infiltrate  
(Stoppacciaro et al., 2006), variable fibrosis and the occasional Touton or 
Foreign body fatty multinucleated giant cells (Figure 1.14), which contain a 
central eosinophilic cytoplasmic area surrounded by a ring of nuclei and 
clear peripheral cytoplasm.  
 
1.5.2. Prevalence 
LCH is most commonly found in children aged 1-15 years old 
(Incidence of 5-15/million per year<10yrs old) and less common in adults, 
but may be underdiagnosed (Lipton and Arceci, 2008). ECD is less 
common, just over five hundred cases have been described since the first 
in 1930, and it mostly occurs in adult patients (age 40-60) (Haroche et al., 
2012b). There is a male to female ratio of 2:1 in LCH(Herring, 2013), 1:1 in 
ECD (Mazor et al., 2013). 
 
1.5.3. Sub-Classifications 
ECD patients are heterogeneous, but due to the limited number, 
there are no sub-classifications. LCH has two main sub-classifications:  
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Unifocal – Single bone lesions containing a slowly expanding 
accumulation of abnormal cells. These lesions can most often be cured by 
curettage.  
 
Multifocal – Multiple lesions in various organs of the body. Multifocal LCH 
can be further subdivided based on the organs of involvement.  
 
Low-Risk Organs– Skin, bone, lung, gastrointestinal tract, pituitary 
gland and/or central nervous system. Patients with lesions 
confined to low/non-risk organs have an almost 100% survival rate 
(Gadner et al., 2008). 
 
High-Risk Organs – Bone marrow, liver, spleen. Paediatric 
patients with lesions in high-risk organs have a higher mortality 
rate of around 20% (Gadner et al., 2008). 
 
1.5.4. LCH Symptoms, Prognosis and Treatment 
Symptoms and presentation of LCH can be wide-ranging from 
those related to the lesion such as bone swelling, pain or skin rashes (see 
Figure 1.11); a more general inflammatory response such as fever, 
lethargy or weight loss; or organ impairment such as pancytopenia or 
diabetes insipidus. LCH can be classified based on which ‘risk’ organs are 
involved.  
 
The liver, spleen, haematopoietic system and lung are considered 
high risk organs; patients with LCH lesions in these organs have a worse 
overall prognosis (Gadner et al., 2008). If LCH lesions are found in the 
central nervous system (CNS) risk organs such as the ears, eyes, oral 
cavity or craniofacial zones, or if the patient has diabetes insipidus, then 
there is higher risk of LCH involvement in the CNS (Grois et al., 1998; 
Grois et al., 2006; Mittheisz et al., 2007). Finally there are ‘special sites’ 
where disease (and/or local treatment) will directly cause significant 
problems because they are located in anatomically and/or functionally 
critical sites e.g. vertebral and/or intraspinal lesions with or without soft 
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tissue extensions (Girschikofsky et al., 2013). All other organs are 
considered low risk. 
 
1.5.4.1. Childhood LCH 
Treatment of childhood LCH depends on the location and 
number of lesions. Single lesions can often be surgically removed with 
a low chance of recurrence. Other treatments include steroid 
injections, chemotherapy and radiation therapy.  
 
Hashimoto-Pritzker Disease (Congenital self-healing 
reticulocytosis) is a self-limited form of LCH restricted to skin 
involvement (Hashimoto and Pritzker, 1973). This disease is only seen 
in neonates, displaying reddish-brown papulovesicular lesions which 
spontaneously resolve within 3 months.  The skin specificity and self-
resolution of this disease has interesting connotations when thinking 
about cell of origin of these diseases. 
 
1.5.4.2. Adult LCH 
Adult LCH frequently causes unifocal or multifocal bone disease 
that responds to surgical treatment, anti-inflammatory drugs or 
bisphosphonates.  A limited form of multisystem (MS) LCH involving 
the skin, bone and pituitary axis is recognized and smoking-related 
pulmonary LCH also occurs.  A small number of adults have high risk 
MS LCH involving the hematopoietic system, spleen or liver that may 
be refractory to intensive chemotherapy and has a poor outcome 
(Teng et al., 2005).  Treatment algorithms are less well defined than in 
children, particularly for high risk MS disease (Aricò et al., 2003; 
Girschikofsky et al., 2013).  
 
1.5.5. ECD Symptoms, Prognosis and Treatment 
The most common symptom of ECD is mild bone pain, followed by 
retroperitoneal fibrosis, diabetes insipidus, exophthalmos, xanthomas and 
neurological, kidney, liver and cardiovascular problems (Veyssier-Belot et 
al., 1996). Treatment options again depend on the extent of the disease 
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and location, but due to the rarity of the disease, no large scale clinical 
studies have been performed. The most common treatments for ECD are 
corticosteroids, chemotherapy, surgical debulking or immunotherapy with 
interferon-α, which has shown to improve prognosis (Haroche et al., 
2012b). More recently, and with the discovery of the BRAFV600Emutation in 
~50-60% of ECD patients (Haroche et al., 2012a), the BRAF inhibitor 
Vemurafenib has been employed for treatment of ECD, with dramatic and 
reproducible results (Haroche et al., 2013; Haroche et al., 2015). Some of 
the patients with ECD lesions in these studies also had coexisting LCH 
lesions (skin/lymph node), which likewise improved with vemurafenib 
treatment, indicating that this could be a useful treatment option for LCH 
patients. Therefore clinical trials are currently underway studying the 
efficacy of vemurafenib and other BRAF inhibitors such as dabrafenib in 
histiocytoses. 
 
 
Figure 1.11. Example Images of Histiocytosis Symptoms 
A. Cranial lesions in a patient with LCH(Sethi, 2004) 
B. Extensive skin rash in a patient with LCH(Mortazavi et al., 2002) 
C. Exophthalmos in a patient with ECD(Gaillard, 2007) 
D. Xanthoma in a patient with ECD(Tayani, 1998) 
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1.5.6. The MAPK Pathway in Cancer and Histiocytosis 
The MAPK (or RAS-RAF-MEK-ERK) pathway is involved in gene 
regulation; transcription and preventing apoptosis (See Figure 1.13). In 
mice, deficient MAPK signalling leads to a general anaemia, leukopenia 
and bone marrow aplasia (Warburg, 1924; Chan et al., 2013). More 
specifically, in murine haematopoiesis, the MAPK pathway is known to 
play an essential role in the differentiation of thymocytes (Pages et al., 
1999), cytokine-induced myeloid cell differentiation (Miranda et al., 2005) 
and EPO-induced erythroid differentiation (Matsuzaki et al., 2000). 
Furthermore, MAPK signalling has been implicated in megakaryocyte 
differentiation in human leukaemia cell line models (Racke et al., 1997; 
Whalen et al., 1997). 
 
A recent review concluded that the pathway is hyper-activated in 
~30% of cancers (Roberts and Der, 2007). Surprisingly this pathway is 
over-activated in the LCH cells of 100% of LCH patients (Badalian-Very et 
al., 2010) and in the ECD cells and a small fraction (1-3%) of monocytes in 
ECD patients (Cangi et al., 2014). 
 
 
 
Figure 1.12. Schematic of BRAF Gene 
Schematic representation of BRAF gene structure showing domains and some 
of the common BRAF mutations. CRD: Cystine-Rich Domain, RBD: RAS 
Binding Domain, CR. (Govender and Chetty, 2012) 
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Figure 1.13. The MAPK (RAS-RAF-MEK-ERK) Pathway 
A schematic of the MAPK Pathway(Chin, 2003).Briefly, when the GTPase RAS 
is activated by a growth factor binding to a cell surface receptor, it swaps it’s 
GDP for a GTP which causes activation of the serine/threonine kinases of the 
RAF family. RAF then phosphorylates and activates the serine/threonine kinase 
MEK which in turn phosphorylates and activates the tyrosine/threonine kinase 
ERK.   Finally, MEK can activate various transcription factors such as Myc, 
Elk1, Fos, Ets, Cyclin D for regulation of cell cycle and transcription and SPRY 
and DUSP for negative feedback. 
 
1.5.6.1. BRAF Mutations in Malignancies  
BRAF is one of the three members of the RAF family and is a 
member of the MAPK pathway. BRAF is known to have mutations in 
7% of human cancers (Davies et al., 2002) and can cause birth defects 
when inherited. There are more than 30 BRAF mutations associated 
with cancers (see Figure 1.12) but a thymine to adenine (T to A) 
substitution at nucleotide 1799, causing a valine (V) to glutamine (E) 
substitution at codon 600, and hence named BRAFV600Eon 
chromosome 7q32.7, constitutes 90% of BRAF mutations seen 
(Davies et al., 2002).   
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This mutation is in the activation segment of the gene (Tan et 
al., 2008) causing a constitutive activation of BRAF, leading to a RAS 
independent dysregulation of transcription, proliferation and feedback 
control. BRAFV600E mimics the phosphorylation of the neighbouring 
T599 and S602 residues, which normally promotes BRAF activity 
(Michaloglou et al., 2008), and give the gene almost 500 times the 
endogenous kinase activity of the wild-type allele (Curry et al., 2012). 
 
In cancers, BRAFV600E is seen in 100% of Hairy Cell Leukaemia 
(HCL) patients (Tiacci et al., 2011), ~80% of melanomas (Rubinstein et 
al., 2010; Lovly et al., 2012) and ~8% of colorectal cancers (Richman 
et al., 2009; Tol et al., 2009). However BRAFV600E can also occur at 
high frequency in benign tumours such as melanocytic naevi, where 
82% of tumours carry the mutation (Pollock et al., 2003). 
 
1.5.6.2. BRAF Mutations in Histiocytosis  
Oncogene profiling has identified the same activating point 
mutation; BRAFV600E, in approximately 50-60% of the LCH and ECD 
lesions of adults and children (Badalian-Very et al., 2010; Haroche et 
al., 2012b; Sahm et al., 2012; Satoh et al., 2012; Berres et al., 2014). 
As previously discussed (section 1.5.6.1), the BRAFV600E mutation 
causes the BRAF gene to be in a constitutively active state, causing a 
hyperactivation of the MAPK pathway.  
 
In LCH, mutated BRAF appears to be confined to neoplastic 
cells, with a high but not completely uniform concordance with 
expression of the characteristic markers of LCH cells, including CD1a 
and Langerin (Badalian-Very et al., 2010; Sahm et al., 2012; Satoh et 
al., 2012; Berres et al., 2014).  
 
Interestingly, in LCH and ECD patients who have BRAFV600E 
positivity, the mutation is seen in all lesions, and in BRAFV600E positive 
crossover patients with both LCH and ECD, the mutation is seen in 
both types of disease lesion (Hervier et al., 2014).  
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There is no overall survival difference in either LCH or ECD 
patients associated with the BRAFV600E mutation (Rolland et al., 2005; 
Haroche et al., 2012b). However, BRAFV600Epositive LCH patients 
have a higher rate of relapse (Berres et al., 2014) and BRAFV600E 
positive ECD patients have higher risk of comorbidities such as 
diabetes Insipidus (Haroche et al., 2012) compared to BRAFWT 
patients with the same diseases. 
 
To date, there is no evidence of BRAFV600E in other histiocytic 
disorders such as RDD (total 32 cases analysed), JXG (total 19 cases 
analysed) (Badalian-Very et al., 2010; Sahm et al., 2012; Satoh et al., 
2012; Berres et al., 2014) or HLH. The absence of BRAFV600E in RDD 
and JXG does not exclude a connection between these diseases and 
LCH/ECD, as some patients have been found with further mixed 
histiocytosis diseases. 
 
As 100% of HCL patients carry the BRAFV600E mutation in their 
peripheral blood, samples from these patients will be used as controls 
throughout this thesis. A general comparison of LCH, ECD and HCL is 
given in Figure 1.14. 
 
1.5.6.3. Other Mutations 
The presence of MAPK pathway over-activation in 100% of LCH 
and ECD patients, but the lower presence of BRAFV600Emutations, 
implies that there are multiple mechanisms of activation. 
 
Two recent studies using whole exome/targeted genome 
sequencing have identified high frequencies of MAP2K1 mutations in 
LCH patients which are mutually exclusive to BRAFV600Emutations 
(Brown et al., 2014; Chakraborty et al., 2014). In both studies, no 
significance was seen between BRAF or MAP2K1 mutations and 
clinical characteristics; however, in the study by Chakraborty et al, 
functional studies showed that the efficacy of various MAPK pathway 
inhibitors did depend on which gene was mutated. 
49 
 
Using targeted sequencing, other mutations have been seen in 
the BRAF gene of BRAFV600E wild-type LCH patients; including a 
somatic insertion BRAFV600DLAT, a germ line BRAFT599A(Satoh et al., 
2012)and BRAFV600D(Kansal et al., 2013), each in one patient. 
 
The RAF family of proteins includes ARAF, BRAF and CRAF. 
BRAF has the highest basal level of kinase activity, 15-20 times that of 
the other RAFs, and therefore requires less mutational activation to 
become fully promoting (Govender and Chetty, 2012). ARAF has the 
lowest basal kinase activity, although two LCH patients have been 
described with compound mutations in ARAF, which are able to 
promote pathway activation at a much higher rate than wild-type ARAF 
(Chakraborty et al., 2014; Nelson et al., 2014). The final RAF protein is 
CRAF, which unlike the other RAF proteins, has not been implicated in 
any known cancers or histiocytic disorders. 
 
Finally, one single case of BRAFWT LCH has been seen with a 
mutation in the ERBB3 gene (Chakraborty et al., 2014), which encodes 
a membrane bound epidermal growth factor receptor, which can 
activate the MAPK pathway  (Citri et al., 2003). 
 
Due to the scarcity of samples, whole exome sequencing has 
not been performed on samples from ECD patients, though recent 
targeted sequencing studies have revealed that ECD patients can 
express mutations in the NRAS (3/25 patients) and PIK3CA (3/25 
patients) genes (Emile et al., 2014). In this study, the NRAS mutation 
was seen specifically in the CD14+ myeloid cell types by Sanger 
sequencing and not in the CD3+ T cells. 
 
There are other possible mechanisms causing MAPK pathway 
hyper-activation, some of which have recently been explored. Although 
not explored in detail, no recurrent abnormalities in karyotype have 
been seen (Chu et al., 2012), neither has BRAF locus duplication 
(Badalian-Very et al., 2010). Other possible mechanisms could include 
overexpression of receptor tyrosine kinase on the disease cells, or 
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activation ligand overproduction by the disease cells or others 
(Badalian-Very et al., 2012), indeed an unexplained overexpression of 
the protein osteopontin has been observed(Allen et al., 2010).  
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Figure 1.14. General Comparison of LCH, ECD and HCL 
A. The main differences seen between LCH, ECD and HCL 
LCH = Langerhans Cell Histiocytosis 
ECD = Erdheim Chester Disease 
HCL = Hairy Cell Leukaemia  
HCL is used as a control in this thesis due to 100% of the patients being 
positive for the BRAFV600E mutation in the peripheral blood. LCH and HCL cells 
stained with May-Grünwald-Giemsa (pH 6.8).ECD cell stained with CD68 
antibody. 
 
B. i) Birbeck granules in LCH (Birbeck et al., 1961); ii) Emperipolesis in 
RDD(Vujhini et al., 2012); iii) Haemophagocytosis in HLH (Koul, 2010); iv) 
Osteoclast giant cell in LCH (Pernick, 2014); v) Touton giant cell in ECD 
(Nephron, 2011); vi) Foreign body giant cell in ECD (Shankar, 2012).  
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1.6. Histiocytosis as Inflammatory or Malignant Disorders  
There has been a longstanding question of whether LCH and ECD 
are reactive inflammatory disorders or malignancies, as they do not quite 
fit into either category. The WHO Classification of tumours of hematologic 
and lymphoid tissue, was last updated (4th edition) in 2008 (Swerdlow et 
al., 2008). In this edition, LCH, ECD and JXG are listed as haematological 
malignancies. However, as of November 2014, patient information from 
organisations such as the Histiocytosis Association of America and the 
Histiocytosis Research Trust (UK) are careful not to explicitly label these 
diseases as leukaemic, in fact the Cancer Research UK - LCH-III clinical 
trial website explicitly states that “LCH is not cancer,” just that “it can 
behave in a similar way to cancer and is usually treated by cancer 
specialists” (Windebank, 2012).  
 
LCH and ECD patients have vastly varying clinical characteristics, 
ranging from spontaneously regressing disease, to systemic organ failure 
and death. Not all LCH/ECD patients respond well to regular treatments. 
These patients, particularly those with multi-system disease, are treated 
with chemotherapeutic regimens, but still have a poor prognosis with high 
rates of relapse and reactivation (Gadner et al., 2008). Therefore, there is 
still a lot of controversy as to whether these diseases are inflammatory or 
malignant.  
 
1.6.1. Histiocytosis as an Aberrant Immune Response 
There is speculation that the disorders could be caused by a 
dysfunctional immune response to infection. This is due to the 
manifestations of disease in most patients, which are not characteristic of 
malignancies. Patients can often respond to biopsy alone or minimal 
treatment, or spontaneously resolve without any treatment at all. Also, it 
has been seen that the cellular makeup of the lesions only carries a small 
proportion of LCH cells (median 8%), the remainder comprising of other 
inflammatory cells (Berres et al., 2014).  
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There is some potential evidence that viral infections such as 
human herpesvirus (HHV) and Epstein–Barr virus (EBV) may be involved 
in an aberrant immune response in RDD and HLH (Luppi et al., 1998; 
Mehraein et al., 2006; Bohne et al., 2013). In msLCH, there are some 
indications of the involvement of Merkel cell polyomavirus in pathogenesis 
(Murakami et al., 2014; Murakami et al., 2015b), although these cohorts 
were small and the results have yet to be confirmed. 
 
1.6.2. Histiocytosis as a Malignancy 
In their seminal reviews, Douglas Hanahan and Robert Weinberg 
laid down 8 central hallmarks of cancer (Hanahan and Weinberg, 2000). 
Each of these hallmarks (as well as aspects of DNA instability, cell 
clonality and oncogenic driver mutations) in the context of histiocytosis are 
given in the following sections. 
 
1.6.2.1. Self-Sufficiency in Growth Signals 
Cancer cells are able to multiply without the requirement of 
external signals such as growth factors. Generally, LCH cells do not 
survive long in in vitro culture, only two LCH cell lines have been 
purported to be established; DOR-1 and PRU-1 (Gogusev et al., 2005; 
Murakami et al., 2015a), though neither of these cell lines showed the 
characteristic LCH cell markers: CD1a, Langerin or Birbeck granules. 
This suggests that LCH cells do require some external stimulus for 
growth. 
 
1.6.2.2. Insensitivity to Anti-Growth Signals 
Cancer cells are characteristically resistant to anti-proliferative 
signals from their neighbouring cells. In melanoma, it has been 
established that exogenous SPRY2, a protein which is a negative 
feedback regulator of the MEK/ERK pathway, is capable of inhibiting 
the pathway in BRAFWT melanocytes and melanoma cells, but not in 
cells carrying the BRAFV600E mutation (Tsavachidou et al., 2004). 
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1.6.2.3. Evading Apoptosis 
The ability to avoid apoptosis is a major factor in the survival of 
cancer cells. In immunohistochemistry studies, LCH lesions have been 
seen to have very few TUNEL (Terminal deoxynucleotidyl transferase 
dUTP nick end labelling), reactive cells (Petersen et al., 2003), and 
exhibit only low levels of nuclear apoptotic changes (Marchal et al., 
2004), indicating levels of apoptosis are low. Furthermore, in LCH 
cells, levels of the anti-apoptotic factors Bcl-2 are high and pro-
apoptotic factor caspase-3 are low (Marchal et al., 2004; Amir and 
Weintraub, 2008). Interestingly, these differences were not observed in 
LCs in nearby non-lesional material, and expression differences were 
more apparent in patients with high risk disease. These results have 
been validated recently in gene expression studies showing that anti-
apoptotic genes such as BCL2L1 and CFLAR are overexpressed in 
LCH cells compared to normal LCs (Allen et al., 2010). Finally, the 
study by Petersen et al, 2003, showed that a small number of LCH 
cells co-expressed Fas and Fas-L, and suggested that this could lead 
to an ‘autocrine apoptotic shortcut’ possibly leading to spontaneous 
regression of LCH in some patients. 
 
1.6.2.4. Limitless Replicative Potential 
The Hayflick limit is the number of replications a cell can have 
before senescence, where no further cell division occurs (Hayflick and 
Moorhead, 1961), controlled by telomere shortening during replication. 
Most cancer cells are able to escape this limit and therefore have 
limitless replicative potential.  In LCH, the aberrant cells appear to 
have very low rates of mitosis (Berres et al., 2014), though similar low 
rates of mutation are seen in hairy cell leukaemia, a cancer where 
100% of patients carry the BRAFV600E mutation (Tiacci et al., 2006; 
Tiacci et al., 2011). 
 
One result of the activated MAPK pathway in LCH is an 
upregulation of telomerase activity (Goueli and Janknecht, 2004; 
Dwyer et al., 2007), thereby preventing telomere shortening, and thus 
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likely increasing the replicative potential of the cells carrying this 
mutation. However, LCH cells have been seen to have significant 
telomere shortening (da Costa et al., 2007; Bechan et al., 2008), which 
is characteristic of several cancers (Arceci, 2014) indicating that LCH 
cells must employ a mechanism to avoid shortened-telomere 
associated senescence and apoptosis.   
 
Alternatively, BRAFV600E has been suggested to promote cell 
senescence in benign naevi, and that a transformation to malignant 
melanoma occurs when a second growth and survival pathway (e.g. 
PI3K-Akt pathway) is over-activated by a decrease in tumour 
suppressors proteins (e.g. phosphatase and tensin homolog, PTEN)  
(Michaloglou et al., 2005).  
 
1.6.2.5. Sustained Angiogenesis 
In most solid cancers, the cancer cells are able to promote 
angiogenesis, ensuring the supply of oxygen and nutrients to the 
tumour. Levels of the pro-angiogenic factor; vascular endothelial 
growth factor (VEGF) are increased in the serum of paediatric msLCH 
patients (Pavlakovic et al., 2001). Furthermore, immunohistochemistry 
studies have shown that VEGF expression is present in msLCH 
lesions (5/5 lesions), some SS-LCH lesions (2/5 lesions) and more 
specifically on LCH cells, and that blood vessel density is significantly 
increased within lesions compared to normal margins (Dina et al., 
2005). In mouse models, it has been shown that BRAF deficient 
tumour cells are able to proliferate but are unable to promote 
angiogenesis at a high enough level for tumour expansion, leading to 
hollow tumour masses (Sobczak et al., 2008). This indicates that an 
over-activation of the BRAF gene could very well lead to an increase in 
angiogenesis. 
 
1.6.2.6. Tissue Invasion and Metastasis 
Although some tumours can be benign, a characteristic of 
cancerous cells is their ability to metastasise; to invade adjacent tissue 
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or migrate to distant tissues and cause new lesions. Metalloproteases 
play a role in tumour migration through the rearrangement of the 
extracellular matrix. Some metalloproteases have been shown to have 
increased expression in pulmonary LCH (Hayashi et al., 1997), and an 
increased expression of metalloprotease and adhesion factors, 
coinciding with a reduced expression of metalloprotease inhibitors has 
been seen in paediatric LCH (Allen et al., 2010). 
 
Heparanase, an enzyme required for cell penetration through 
the endothelial cell layer, is expressed in LCH (21/25 patients), 
although there was no association with disease activity (Dvir et al., 
2014). A review by Maurer et al, 2011; highlights several other 
mechanisms by which the BRAFV600E mutation may potentially promote 
metastasis, such as inducing the production of TGFb and interleukin-8 
and increasing the contractility of cells, all of which increase the ability 
of cells to migrate into the vasculature.  
 
Interestingly, in LCH and ECD patients who have BRAFV600E 
positivity, the mutation is seen in all lesions, and in BRAFV600E positive 
crossover patients with both LCH and ECD, the mutation is seen in 
both types of disease lesion (Hervier et al., 2014). Although this does 
not prove that co-existing lesions were initiated from metastasising 
cells from one original lesion, it seems unlikely that the multiple sites 
will develop the same mutation at the same time.  
 
1.6.2.7. Abnormal Metabolic Pathways 
The Warburg hypothesis of cancer growth is that due to a 
decreased respiratory function of mitochondria, cancer cells do not 
generate energy from the normal oxidative breakdown of pyruvate 
during glycolysis, and therefore must create energy by abnormal non-
oxidative breakdown of glucose.  Diabetes insipidus is frequently 
observed in LCH (Grois et al., 2006), at around 6% of patients at 
diagnosis and carrying a 20% risk of developing later in the course of 
the disease. Anterior pituitary dysfunction is also commonly seen in 
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adult LCH patients (Kaltsas et al., 2000). This indicates that abnormal 
carbohydrate and lipid metabolism pathways may be involved in LCH. 
 
1.6.2.8. Evading the Immune System 
A key aspect of cancer cells is their ability to evade the immune 
system, such as by the downregulation of differentiation antigens, 
resistance to cytotoxic T cell mediated death or by repressing the 
response of normal immune cells. 
 
LCH patients have increased numbers of T regulatory cells 
(Tregs) in their peripheral blood, and a high proportion of the T cells in 
LCH lesions are Tregs (Senechal et al., 2007). This high degree of 
Tregs in lesions is anticipated on the grounds that LCH cells express 
RANK, a potent stimulator of Treg proliferation (Senechal et al., 2007). 
Tregs are able to suppress the action of T cells, likely preventing an 
immune response against the aberrant LCH cells.  Tregs of paediatric 
LCH patients do in fact inhibit the immune system, as these patients 
have an impaired delayed-type hypersensitivity response (Senechal et 
al., 2007). 
 
In experiments with the BRAFV600E+ melanoma cell line A375, 
inhibition of BRAFV600E causes a significant reduction in levels of the 
immunosuppressive cytokines IL-6, IL-10 and VEGF (Sumimoto et al., 
2006). Increased levels of IL-10 are seen in LCH lesions (Senechal et 
al., 2007), indicating a cancer cell induced immune evasion 
mechanism.   
 
1.6.2.9. Unstable DNA 
Due to the ability of cancer cells to escape senescence, the 
cells can proliferate more times than they are normally able. The 
normal limit of cell proliferation prevents cells with damaged 
chromosomes from proliferating, whereas immortal cancer cells 
generally pick up more chromosome damage over time.  
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Early studies showed cytogenetic abnormalities in small (5-7 
patient) LCH cohorts (Betts et al., 1998; Murakami et al., 2002), 
whereas a more recent and extensive study, using an array of different 
cytogenetics analysis techniques revealed no gross chromosomal 
abnormalities (e.g. aberrations in DNA ploidy, karyotype, copy number 
variations or single nucleotide polymorphisms) (da Costa et al., 2009). 
Also, LCH and ECD patient lesions have extremely low rates of 
somatic mutations (median 1 mutation per sample) (Nelson et al., 
2014), which contrasts with high amounts of somatic mutations seen in 
most leukaemias, including HCL (Tiacci et al., 2011). 
 
1.6.2.10. Clonality 
Although tumour cells can be heterogeneous, an original 
monoclonal or polyclonal population is an essential feature of cancer 
cells. From X chromosome inactivation studies in female patients, LCH 
and ECD are now known to be ‘clonal’ proliferations of cells, (Willman 
et al., 1994; Yu et al., 1994; Vencio et al., 2007). These data are 
supported by the high enrichment of BRAFV600E/MAP2K1 mutations in 
sorted lesional LCH cells (Chakraborty et al., 2014). However not all 
clonal populations are cancer, such as those seen in benign naevi.  
 
1.6.2.11. BRAFV600E as an Oncogenic Driver Mutation 
A driver mutation is one which gives a selective advantage to a 
clone cell in terms of survival and/or proliferation in its 
microenvironment and thus leads to the initiation and progression of 
malignancies. The high rate of BRAFV600E mutation in LCH and ECD 
(Badalian-Very et al., 2010; Haroche et al., 2012b), the fact that in the 
majority of cases, no other somatic mutations are present (Nelson et 
al., 2014), and its presentation as a single allele, suggests that this is a 
dominant oncogenic driver of LCH and ECD.  
 
In mouse models, expression of BRAFV600E during embryonic 
development is lethal, whereas expression in somatic tissues leads to 
a histiocytic neoplasia (Mercer et al., 2005) or adenomas (Dankort et 
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al., 2007).  In a paper by Berres et al in 2014, the authors developed 
two more specific mouse models, expressing BRAFV600E in DCs at 
differing states of maturation, to determine for certain whether 
BRAFV600E is a driver mutation. Both models induced an LCH-like 
disease, indicating for certain that BRAFV600E is a driver mutation in 
mice. Also it was seen that the BRAFV600E mutation was consistent in 
coexistent tumours and serial relapse samples from human patients, 
indicating that BRAFV600E is also a key early event in human disease. 
Interestingly, when BRAFV600E was expressed under the CD11c 
promoter (less mature DCs), the mice developed a rapid and 
aggressive msLCH-like disease, whereas mice with BRAFV600E 
expressed under the langerin promoter (more mature DCs) exhibited 
less severe disease.  
 
1.6.3. Histiocytosis as an Inflammatory Myeloid Neoplasm 
LCH has aspects of most of the tenets of cancer listed above, albeit 
the division of cells is much lower than other cancers, and the cells are 
difficult to grow in culture. Interestingly though, hairy cell leukaemia (HCL), 
which has BRAF mutations in 100% of cases (Tiacci et al., 2011), also has 
a very low rate of proliferation (Tiacci et al., 2006). The main arguments for 
a dysregulated immunological origin are that LCH has an obvious 
inflammatory and granulomatous pathology and in some cases is able to 
spontaneously regress. However the presence of a defined driver mutation 
which is known to be able to induce multiple oncogenic factors, would lead 
to the conclusion that LCH is a cancer. These separate conclusions may 
be united by the fact that LCH cells are able to promote an explicit 
inflammatory response, which has led some researchers to deduce that 
both a malignant and an inflammatory component may be essential for 
LCH pathogenesis, and therefore have determined to term the disease an 
‘Inflammatory Myeloid Neoplasm’ (Berres et al., 2014).  
 
This is not yet a universally accepted notion and due to the highly 
variable manifestations of LCH, I believe that it is still possible that the 
disease could exist in malignant, inflammatory and combined forms.  In 
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fact, the case may be that an original oncogenic driver mutation needs to 
be coupled with a secondary event, before pathogenesis occurs; such as 
a second hit mutation, or an inflammation promoting infection.   
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1.6.4. The Origin of LCH Cells 
The cell of origin of LCH is unknown, though the history of LCH 
research points to the Langerhans cell. In the 1940s and 50s, the three 
disease entities eosinophilic granuloma, Hand-Schüller-Christian disease 
and Letterer-Siwe disease (see section 1.5.3, page 41) were united under 
the title Histiocytosis X, due to their concordant histiocytic cell morphology 
(Farber, 1941; Mallory, 1942; Lichtenstein, 1953). Later it was discovered 
that both Langerhans cells and the disease cells in Histiocytosis X 
contained Birbeck granules (Birbeck et al., 1961; Basset and Turiaf, 1965), 
leading to the re-classification of the disease as Langerhans Cell 
Histiocytosis (Nezelof et al., 1973). This definition is further enforced by 
the discovery of the markers Langerin and CD1a on both LC and LCH 
cells (Harrist et al., 1983; Rousseau-Merck et al., 1983; Valladeau et al., 
2000) see Figure 1.15. 
 
 
Figure 1.15. Brief History of Discoveries in LCH 
A. Timeline of major discoveries. Red text indicates potential cells of origin. 
B. Electron microscopy of Birbeck granules in LCH cells. 
C. CD1a immunohistochemistry staining of CD1a on LCH cells. 
D. Langerin immunohistochemistry staining of CD1a on LCH cells. 
Photos B-D courtesy of Marian Malone (Malone, 2014) 
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Recent studies in dendritic cell biology and preliminary cell-specific 
gene expression studies cast doubt on the paradigm of the epidermal 
Langerhans cell as the cell of origin in LCH. These observations include: 
 
i) Immunohistochemistry and gene expression studies show 
substantial differences between LCH cells and native LCs. The 
LCH cells appear more like BM derived immature myeloid DCs than 
the LCs (Geissmann et al., 2001; Pinkus et al., 2002; Annels et al., 
2003; Fleming et al., 2003; Rust et al., 2006; Allen et al., 2010; 
Hutter et al., 2012).  
 
ii) Recent murine data have shown the existence of LC-like Langerin+ 
cells within most non-lymphoid tissues (Ginhoux et al., 2007; Poulin 
et al., 2007), and our own recent work has demonstrated a 
langerin+ CD1a+ DC subset in the skin which is phenotypically and 
functionally distinct from LCs(Bigley et al., 2014). 
iii) LCH can occur in organs usually devoid of LCs such as bone, 
viscera, brain and lungs. 
 
These observations are more consistent with a model that LCH 
cells arise by differentiation of a precursor that acquires some but not all 
the characteristics of epidermal LCs and has the capacity to migrate to 
multiple sites that do not normally contain LCs. It is therefore possible that, 
similarly to normal tissue DCs, LCH cells derive from circulating precursors 
rather than tissue-resident LCs.  
 
It is known that human CD34+ progenitor cells can differentiate into 
cells expressing langerin and CD1a, very similar to LCs (Caux et al., 1992; 
Strobl et al., 1997; Ratzinger et al., 2004; Klechevsky et al., 2008). 
Monocytes can also acquire langerin and CD1a (Geissmann et al., 2001; 
Hutter et al., 2012). Circulating myeloid DCs are increased in LCH 
(Rolland et al., 2005) but have not been shown to express markers typical 
of LCH cells. In addition, several studies have consistently found that 
blood myeloid DCs may express low levels of Langerin in healthy 
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individuals (MacDonald et al., 2002; Haniffa et al., 2012; Harman et al., 
2013).  
 
These in vitro observations suggest that CD34+ progenitors and 
monocytes might have the capacity to form LCH cells(Weitzman and Jaffe, 
2005). A review of studies to date, looking at the LC-like differentiation 
potential of human CD34+ progenitors and monocytes, is given in Table 
1.5, page 64. 
 
The origin of the aberrant cells in LCH and ECD remains obscure 
but the presence of mutated BRAF is a possible means of identifying 
putative precursor cells in the peripheral blood or bone marrow.  Previous 
analysis of blood monocytes and bone marrow did not detect mutated 
BRAF by next generation sequencing or immunohistochemistry, 
respectively (Sahm et al., 2012; Satoh et al., 2012).  A recent study, using 
allele-specific PCR, has reported BRAFV600E in the CD14+ monocytes and 
CD14-CD11c+ fraction of peripheral blood and CD34+ bone marrow 
populations, of children with MS LCH (Berres et al., 2014).  The CD14-
CD11c+ fraction of cells in human peripheral blood includes CD16+ 
monocytes, CD1c+ mDCs, CD141+ mDCs and a residual CD11c+16-1c-
141- population, leaving the exact identity of the cells containing the 
BRAFV600E mutation in this fraction open to further investigation.  A clonal 
disorder of myelopoiesis was also suggested by the detection of 
BRAFV600E in CD34+ bone marrow cells and their in vitro differentiated 
progeny. 
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(Kashihara et al., 1986; Caux et al., 1992; Caux et al., 1996; Strobl et al., 1996; Strunk et al., 1996; Strobl et al., 1997; Geissmann et al., 1998; Caux et al., 1999; Ito et al., 1999; Mohamadzadeh et al., 2001; Guironnet et al., 2002; Arrighi et al., 2003; Chomarat et al., 2003; Mollah et al., 2003a; Mollah et al., 2003b; 
Hoshino et al., 2005; Barbaroux et al., 2006; Shibasaki et al., 2007; Musso et al., 2008; Eljaafari et al., 2009; Bonetti et al., 2011; van de Ven et al., 2012; Yasmin et al., 2013a; Yasmin et al., 2013b; Balan et al., 2014) 
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1.6.5. The Origin of ECD Cells 
The question of the origin of disease cells in ECD is harder to 
approach. The only known marker for the disease is an aberrant 
expression of CD68 in the target organs. The functions of CD68 are not 
entirely clear, though it is thought to have a role in the clearance of debris 
from cells, which would bear an association with the high degree of 
phagocytosis seen in ECD. Unfortunately, CD68 is a fairly ubiquitous 
marker, seen in virtually all peripheral blood cell subsets (Kunz-Schughart 
et al., 2003; Kunisch et al., 2004), so it would be impossible to determine 
the relationship between ECD cells and circulating cells using this marker 
alone. Therefore this thesis will concentrate on using the BRAFV600E 
mutation to attempt to track the precursors of LCH and ECD, and the 
markers Langerin and CD1a to find which circulating cells have the 
potential to become LCH-cell-like.  
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Chapter 2. General Materials and Methods 
 
This chapter covers the general methodology used throughout this thesis. 
 
2.1. Sample Collection 
Informed consent was sought for all human samples used in this project 
in accordance with a favourable ethical opinion from Newcastle & North 
Tyneside 1 Research Ethics Committee (Appendix 8). 
 
2.2. Media and Buffers 
2.2.1. Flow Buffer 
Flow buffer was made up of Dulbecco’s Phosphate Buffered Saline 
(D-PBS) + 2% Heat Inactivated Foetal Calf Serum (HI-FCS) (both from 
PAA; www.paa.com) + 0.4% EDTA (Sigma-Aldrich; 
www.sigmaaldrich.com). 
 
2.2.2. Sort Buffer 
Sort buffer was made up of Dulbecco’s Phosphate Buffered Saline 
(D-PBS) + 0.5% Heat Inactivated Foetal Calf Serum (HI-FCS) (both from 
PAA; www.paa.com) + 0.4% EDTA (Sigma-Aldrich; 
www.sigmaaldrich.com). 
 
2.2.3. RF-10 
RF-10 was made up of RPMI 1640 Media + 10% Heat Inactivated 
Foetal Calf Serum (HI-FCS) + 1% Penicillin-Streptomycin + 2% L-
Glutamine (all from PAA; www.paa.com). 
 
2.2.4. Freezing Solution 
Freezing Solution was made up of 90% Heat Inactivated Foetal Calf 
Serum (HI-FCS) (PAA; www.paa.com) + 10% DMSO (NBS Biologicals; 
www.nbsbio.co.uk). 
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2.2.5. Red Blood Cell (RBC) Lysis Buffer 
A 10x concentration stock of RBC lysis buffer was made up of 
41.4g NH4Cl (Sigma-Aldrich; www.sigmaaldrich.com), 5.0g KHCO3 and 
0.18g EDTA (both from VWR; www.uk.vwr.com) dissolved in 400ml sterile 
water. This stock was pH adjusted to 7.35 by addition of 1M NaOH (Fisher 
Scientific; www.fisher.co.uk) and topped up to 500ml with sterile water. 
The buffer was diluted to 1x concentration with sterile water before use. 
 
2.3. General Cell Processing 
2.3.1. Isolation of Peripheral Blood and Bone Marrow Aspirate Cells 
Mononuclear cells were extracted from fresh peripheral blood (PB) 
and bone marrow (BM) aspirates following standard protocols. Briefly, 
samples of PB or BM were diluted1:2 or 1:4 respectively in Dulbecco's 
Phosphate-Buffered Saline (D-PBS) and then layered on top of a volume 
of LymphoprepTM density-gradient media (Axis-Shield Diagnostics Ltd; 
www.axis-shield.com) equivalent to half the total volume of diluted sample. 
The mononuclear cells were then separated from the rest of the sample by 
room temperature density centrifugation (800g, 15 minutes). The interface 
between the lymphoprep and the supernatant was aspirated (See Figure 
3.1) with a Pasteur pipette and washed twice in D-PBS (500g, 5 minutes 
followed by 200g for 7 minutes to remove platelets). 1-2mls of RBC lysis 
buffer was added to the cell pellet and allowed to incubate in the dark for 5 
minutes before a final wash in D-PBS (500g, 5 minutes). 
 
Figure 2.1.  Diagram of Lymphoprep Separated Sample 
MC = Mononuclear Cells; RBC = Red Blood Cells 
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2.3.2. Isolation of Neutrophils 
Neutrophils are isolated from the pellet formed after PB or BM 
samples are lymphoprepped (Figure 2.1). Briefly; after the mononuclear 
cells were aspirated from the samples, the remaining lymphoprep was 
discarded leaving RBCs and a cellular pellet which is 66-88% composed 
of neutrophils (see section 4.3; pg. 122). RBC lysis buffer was added 
equivalent to the same volume as the RBCs. The sample was vortexed 
and left at room temperature in the dark for 15 minutes before being 
topped up with D-PBS and centrifuged (500g, 5 minutes). Supernatant 
was discarded, leaving a cellular pellet which could be counted. If RBCs 
were still present, the RBC lysis, incubation and washing steps were 
repeated. 
 
2.3.3. Isolation of Cells from Tissue 
LCH lesions and tissues were digested to single cell suspensions 
as previously described (Haniffa et al., 2012).Briefly; the tissue was placed 
into a 24 well plate with 1ml RF-10 media and cut down to ~5mm2 
sections. 1/100 collagenase (1.6mg/ml) was added and the plate was 
incubated at 37°C, 5% CO2 for eight hours. Digested cells were then 
diluted with room temperature PBS and centrifuged at 500g for 5 minutes. 
 
2.3.4. Isolation of Cells from Hip Femoral Head Bone Marrow 
Control BM was collected either from normal donor material excess 
to clinical BM transplantation or from hip femoral heads after hip 
replacement surgery. From femoral heads, BM was carefully extracted 
from the surgical opening using bone clippers while wearing chain mail 
safety gloves. This semi-solid BM was placed into a 100µl nylon cell 
strainer in a 50ml falcon tube and washed with PBS until white. The 
washed cell solution was then layered onto lymphoprep as previously 
described in section 2.3.1.  
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2.3.5. Cell Counting 
Cells were counted at 1:1 with trypan blue exclusion dye 
(Invitrogen; www.invitrogen.com) on an Improved Neubauer 
Haemocytometer (Weber Scientific International; 
www.weberscientific.com). 
 
2.3.6. Cryopreservation and Thawing of Cells 
Cells were frozen at a maximum concentration of 0.5x107 Cells/ml 
of freezing solution in Nunc cryovials (Sigma-Aldrich; 
http://www.sigmaaldrich.com/). Vials were wrapped in bubble-wrap and 
frozen in a -80°C freezer before being transferred to a -140°C freezer 
within 24 hours.  
 
If defrosting of samples was required, vials were removed from the 
freezer and defrosted in a 37°C water bath before quickly transferring to a 
15ml tube of warm RF-10 in a dropwise manner. This tube was then 
centrifuged for 5 minutes at 500g and the cells were resupended in 1ml of 
the appropriate media (e.g. sort buffer/RF-10) before counting (see 2.3.5) 
to ascertain post-thawing count and viability.  
 
2.3.7. Cytospin Slides and May-Grünwald-Giemsa Staining 
Cytospin slides were prepared from sorted cells in 200µl RF-10 
using a Shandon Cytospin 4, with Shandon filter cards and Shandon 
Cytospin coated slides (Thermo Scientific; www.thermoscientific.com) 
spinning at 600rpm for 10 minutes. Slides were left to dry for 30 minutes 
and then fixed in 100% methanol for 2 minutes. Next, the slides were 
stained in May-Grünwald stain (pH 6.8) for 2 minutes, rinsed with water 
and stained in Giemsa stain (pH 6.8) for 2 minutes. Photographs were 
taken on a Zeiss Axioimager Z2 microscope with AxioVision 4.8 software 
at 100 times magnification.  Scales as indicated.  
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2.4. General Flow Cytometry 
2.4.1. Mononuclear Cell Flow Cytometry Phenotyping 
According to standard protocols for flow cytometric analysis, cells 
were diluted/concentrated to 1x106(BM & DC panels) or 0.2x106(Lymph 
panel) in 50μl flow buffer. 3μl anti-mouse IgG (Sigma-Aldrich; 
www.sigmaaldrich.com) was added to each sample tube and allowed to 
incubate for 10 minutes to help prevent non-specific binding. The relevant 
antibodies were then added to the sample tubes (See Table 3.1) and 
allowed to incubate in the dark at 4°C for 30 minutes. Cells were then 
washed in flow buffer (500g, 5 minutes) and finally re-suspended in 250μl 
flow buffer. LSRII and Canto cytometers (Becton Dickinson; 
www.bd.com/uk) were used to perform the flow cytometry and the data 
was analysed on FlowJo software version 7.6.5 (Treestar; 
www.treestar.com).  
 
2.4.2. Flow Cytometry Cell Sorting 
Fluorescence activated cell sorting was performed using a BD 
FACS Aria (custom 100 mW 488 sapphire, 60mW 355 UV, 40 mW 640 
red, 50 mW 407 violet, 70 μm nozzle and 20 psi) or BD FACS Aria-Fusion 
(standard50 mW 488 sapphire, 15mW 355 UV, 100 mW 640 red, 85 mW 
405 violet, 50mw 561 yellow-green, 70 μm nozzle and 20 psi).Cells were 
sorted using the flow cytometry panels described in section 2.6, pg. 76. 
 
Sorted cells were collected into 1.5ml Eppendorf tubes containing 
200µl RF-10.After sorting, collection Eppendorfs were topped up with RF-
10 and kept on ice until processing. For cell culture, Eppendorfs were 
spun at 500g for five minutes and the supernatant was removed. 1ml of 
the relevant cell culture media was added and the Eppendorfs were spun 
again at 500g for five minutes. Finally, the supernatant was replaced with 
the required volume for culture. For DNA extraction, centrifuge spins were 
increased to maximum speed, and supernatants were replaced with water. 
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2.4.3. Stains and Antibodies 
4,6-diamidino-2-phenylindole (DAPI; Partec; www.partec.com) was 
used to exclude dead cells. Details of the antibodies used are displayed in  
Table 2.1. Unless otherwise stated, the term ‘lineage markers’ or 
Lin includes the antibodies for CD3, CD19, CD20 and CD56. 
 
2.4.4. TruCOUNT 
An absolute count of cells in each sample was achieved using 
TruCOUNT™ tubes (Becton Dickinson; www.bd.com/uk) and following the 
manufacturers’ protocols. Briefly, 5μl of each antibody (CD3 APC; CD14 
PE; CD45 APCCy7 and CD34 FITC; See Table 3.1) was added to the 
mesh of the TruCOUNT™ tube followed by50μl whole blood (added by 
reverse pipetting). The tube was vortexed and allowed to incubate in the 
dark at 4°C for 20 minutes before a further vortex. 150µl of RBC lysis 
buffer (see section 2.2.5) was added and the tube was allowed to incubate 
in the dark at room temperature for 15 minutes before a further vortex. An 
LSRII cytometer (Becton Dickinson; www.bd.com/uk) was used to perform 
the flow cytometry and the data was analysed on FlowJo software, version 
7.6.5 (Treestar; www.treestar.com). The absolute count of each cell 
population was discerned using Equation 2.1. 
 
 
Equation 2.1. Absolute Cell Population Counting Equation 
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Antibody Fluorochromes Company Clone Isotype 
CD1a A700 BioLegend HI149 Mouse IgG1,κ 
CD1a BV421 BioLegend HI149 Mouse IgG1, κ 
CD1c APC Miltenyi Biotec AD5-8E7 Mouse, IgG2a, κ 
CD1c PeCy7 BioLegend L161 Mouse IgG1,κ 
CD3 APC BD Biosciences UCHT1 Mouse IgG1,κ 
CD3 FITC BD Biosciences SK7 Mouse IgG1,κ 
CD3 PERCPCy5.5 BD Biosciences SK7 Mouse IgG1,κ 
CD3 V500 BD Biosciences UCHT1 Mouse IgG1, κ 
CD4 PE BD Biosciences SK3 Mouse IgG1,κ 
CD7 FITC BD Biosciences 4H9 Mouse, IgG2a, κ 
CD8 APCCy7 BD Biosciences SK1 Mouse IgG1,κ 
CD10 PE-TR Beckman Coulter ALB1 Mouse IgG1 
CD11b APC BioLegend ICRF44 Mouse IgG1,κ 
CD11c A700 BD Biosciences B-ly6 Mouse IgG1, κ 
CD11c V450 BD Biosciences B-Ly6 Mouse IgG1,κ 
CD14 APCCy7 BD Biosciences MΦP9 Mouse, IgG2b, κ 
CD14 BV650 BioLegend M5E2 Mouse IgG2a, κ 
CD14 ECD Beckman Coulter RMO52 Mouse IgG1,κ 
CD14 FITC BD Biosciences M5E2 Mouse, IgG2a, κ 
CD14 PE BD Biosciences M5E2 Mouse, IgG2a, κ 
CD14 PE-Cy7 BD Biosciences M5E2 Mouse, IgG2a, κ 
CD14 Q655 Invitrogen Tϋk4 Mouse, IgG2a 
CD16 APC-H7 BD Biosciences 3G8 Mouse IgG1,κ 
CD16 FITC BD Biosciences NKP15 (Leu-11a) Mouse IgG1,κ 
CD16 PE BD Biosciences 3G8 Mouse IgG1,κ 
CD16 PeCy7 BD Biosciences B73.1 Mouse IgG1,κ 
CD16 PE-TR Invitrogen 3G8 Mouse IgG1,κ 
CD19 FITC BD Biosciences 4G7 Mouse IgG1,κ 
CD19 PE BD Biosciences HIB19 Mouse IgG1,κ 
CD19 PeCY7 BD Biosciences SJ25C1 Mouse IgG1,κ 
CD20 FITC BD Biosciences L27 Mouse IgG1,κ 
CD25 PECy7 BD Biosciences 2A3 Mouse IgG1,κ 
CD34 APC BD Biosciences 581 Mouse IgG1,κ 
CD34 APCCy7 BioLegend 581 Mouse IgG1,κ 
CD34 FITC BD Biosciences 8G12 Mouse IgG1,κ 
CD34 PE BD Biosciences 8G12 Mouse IgG1,κ 
CD38 PECy7 BD Biosciences HB7 Mouse IgG1,κ 
CD45 APCCy7 BD Biosciences 2D1 Mouse IgG1,κ 
CD45 PE-TR Invitrogen HI30 Mouse IgG1 
CD45 V450 BD Biosciences 2D1 Mouse IgG1,κ 
CD45 V500 BD Biosciences HI30 Mouse IgG1,κ 
CD45RA BV510 BioLegend HI100 Mouse, IgG2b, κ 
CD45RA V500 BD Biosciences HI100 Mouse, IgG2b, κ 
CD56 APC BD Biosciences B159 Mouse IgG1,κ 
CD56 FITC BD Biosciences NCAM16.2 Mouse, IgG2b, κ 
CD83 FITC BD Biosciences HB15e Mouse IgG2b, κ 
CD90 PERCPCy5.5 BioLegend 5E10 Mouse IgG1,κ 
CD110 APC BD Biosciences 1.6.1 Mouse, IgG2b, κ 
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Antibody Fluorochromes Company Clone Isotype 
CD114 APC BioLegend LMM741 Mouse IgG1,κ 
CD123 BV421 BioLegend 6H6 Mouse IgG1,κ 
CD123 PE BD Biosciences 9F5 Mouse IgG1,κ 
CD123 PERCPCy5.5 BD Biosciences 7G3 Mouse, IgG2a, κ 
CD135  
(FLT3) 
PE BD Biosciences 4G8 Mouse IgG1,κ 
CD141 APC Miltenyi Biotec AD5-14H12 Mouse IgG1 
CD172a  
(SIRP-α) 
PE BioLegend SE5A5 Mouse IgG1,κ 
CD207 
(Langerin) 
PE Beckman Coulter DCGM4 Mouse IgG1,κ 
CD235a 
(Glycophorin A) 
PE BD Biosciences GA-R2 (HIR2) Mouse, IgG2b, κ 
CD324  
(E-Cadherin) 
APC BioLegend 67A4 Mouse IgG1, κ 
CD326 
(EpCAM) 
APC BD Biosciences EBA-1 Mouse IgG1, κ 
HLA-DR A700 BD Biosciences L243 (G46-6) Mouse, IgG2a, κ 
HLA-DR V450 BD Biosciences L243 (G46-6) Mouse, IgG2a, κ 
HLA-DR V500 BD Biosciences L243 (G46-6) Mouse, IgG2a, κ 
 
Table 2.1. Antibodies Used Throughout This Thesis 
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2.5. Flow Cytometry Controls 
2.5.1. Fully Stained Controls 
A series of fully stained normal controls were run for all panels, to 
create standard ranges of cell numbers (see section 2.7, pg.81). One fully 
stained normal control was run with each cell sort experiment for 
comparison. 
 
2.5.2. Unstained Controls 
During the setup for each panel, a tube of unstained cells was run 
to rule out any background or cellular autofluorescence.  
 
2.5.3. Single Stain Controls 
During the setup for each panel, a series of single stained tubes of 
‘normal control’ cells were run as positive controls.  
 
2.5.4. CompBead Controls 
A series of unstained and single stained positive and negative 
Compensation Bead (Becton Dickinson; www.bd.com/uk) tubes were run 
for the setup of each panel to give distinct positive and negative stained 
populations to set compensation values and to make adjustments for 
spectral overlap. 
 
2.5.5. Fluorescence Minus One (FMO) & Isotype Controls 
A combined ‘fluorescence minus one’ and isotype system of 
controls was used to confirm true positive staining and to aid in defining 
gating boundaries. Isotype controls were used at the same concentration 
as the corresponding antigen specific antibodies. This is especially 
important as some cells such as macrophages have a high 
autofluorescence, which can result in false positives.  
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2.6. Multiparameter Flow Cytometry Panels 
In order to study the development of DCs in haematological malignancies 
and histiocytic disorders, it was necessary to develop methods to determine 
quantities of these cells in the peripheral blood (absolute counts) and bone 
marrow (relative counts) in the steady state. These methods were built upon 
previous work of the Human Dendritic Cell (HuDC) Lab and developed in this 
thesis. 
 
2.6.1. Antigen Presenting Cells 
A fourteen parameter panel was adapted to enable analysis of the 
antigen presenting cell (APC) compartment, comprising monocytes and 
dendritic cells (DC) in PB and other tissues. The panel can identify 8 
different populations (See Table 2.2). The gating strategy for the panel is 
given in Figure 2.2. 
 
Cell Type Markers 
CD14+ Monocytes CD45+DR+Lin-CD14+CD16- 
CD14+CD16+ Monocytes CD45+DR+Lin-CD14+CD16+ 
CD16+ Monocytes CD45+DR+Lin-CD14-CD16+ 
CD123+Plasmacytoid DC CD45+DR+Lin-CD14-CD16-CD123+CD34- 
CD34+ Circulating Progenitors CD45+DR+Lin-CD14-CD16-CD123-CD34+ 
CD141+ Myeloid DC CD45+DR+Lin-CD14-CD16-CD123-CD34-CD141+ 
CD11c+ Myeloid DC CD45+DR+Lin-CD14-CD16-CD123-CD34-CD11c+ 
CD1c+ Myeloid DC CD45+DR+Lin-CD14-CD16-CD123-CD34-CD11c+CD1c+ 
Table 2.2. Cell Populations Identified by the APC Panel 
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Figure 2.2. Antigen Presenting Cell Panel Gating Strategy 
(A) The cell population was gated on FSC-A and SSC-A, excluding debris. (B) 
Live cells were gated by excluding DAPI positive cells. (C) Singlets were gated 
on SSC-H and SSC-A, excluding doublet cells. (D) Leukocytes were isolated by 
expression of CD45. (E) Monocytes and Antigen Presenting Cells (APCs) were 
isolated by expression of HLA-DR and lack of Lineage markers (CD3, CD19, 
CD20, and CD56). (F) Monocytes were separated by expression of CD14 
and/or CD16. (G) CD16+ monocytes were isolated by their expression of HLA-
DR to exclude any CD16+ NK cell contamination. (H) pDCs were separated by 
expression of CD123 and CD34+ circulating progenitor cells were isolated by 
CD34 expression. (I) pDCs were isolated by their expression of HLA-DR to 
exclude any CD123+ Basophil contamination. (J) CD141+ and CD11c+ mDCs 
were separated from the CD123-CD34- group. (K) The CD11c+ mDC group 
was further divided by expression of CD1c into true CD1c+ mDCs and a 
residual CD1c- fraction. 
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2.6.2. Lymphocytes 
An eight parameter panel was set up to analyse the lymphoid 
compartments in PB and other tissues. The panel can identify 7 different 
populations (See Table 2.3). The gating strategy for the panel is given in 
Figure 2.3. 
 
Cell Type Markers 
T Cells CD3+ 
CD4+ T Cells CD3+CD4+ 
CD8+ T Cells CD3+CD8+ 
CD56+ T Cells CD3+CD56+ 
T Regulatory Cells (Tregs)* CD3+CD19-CD8-CD4+CD25+ 
B Cells HLA-DR+CD19+ 
Natural Killer Cells CD3-CD56+ 
Table 2.3. Cell Populations Identified by the Lymphocyte Panel 
* This fraction may also contain CD4+CD25+ activated T cells. 
 
Figure 2.3. Lymphocyte Panel Gating Strategy on Fresh PBMC 
(A) The cell population was gated on FSC-A and SSC-A, excluding debris. (B) 
Live cells were gated by excluding DAPI positive cells. (C) Singlets were gated 
on SSC-H and SSC-A, excluding doublet cells. (D) Leukocytes were isolated by 
expression of CD45. (E) CD3-CD56+ NK cells and the small CD3+CD56+ T cell 
fraction isolated. (F) B cells identified by expression of CD19 and T cells by 
expression of CD3. (G) T cells split by CD4 and CD8. (H) Tregs isolated from 
CD4+ T cells by expression of CD25. 
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2.6.3. Progenitor Cells 
A thirteen parameter panel was set up to analyse the CD34+ 
progenitor compartment in BM, PB and other tissues. The panel can 
identify 7 different progenitor cell populations (See Table 2.4), according to 
recent descriptions (Manz et al., 2002; Doulatov et al., 2010; Goardon et 
al., 2011), as well as an uncharacterised CD34+38+10-45RA+123high cell 
fraction. The gating strategy for the panel is given in Figure 2.4. 
 
 Cell Type Markers 
Haematopoietic Stem Cells (HSCs) CD34+CD38-CD90+CD45RA- 
Multi-Lymphoid Progenitors (MLP) CD34+CD38-CD90-CD45RA+ 
Multi Potent Progenitors (MPP) CD34+CD38-CD90-CD45RA- 
B cell and NK Progenitors (BNK) CD34+CD38+CD10+ 
Common Myeloid Progenitors (CMP) CD34+CD38+CD10-CD123+CD45RA- 
Megakaryocyte/Erythroid Progenitors (MEP) CD34+CD38+CD10-CD123-CD45RA- 
Granulocyte/Macrophage Progenitors (GMP) CD34+CD38+CD10-CD123+CD45RA+ 
CD123High Fraction (CD123High) CD34+CD38+CD10-CD123highCD45RA+ 
Table 2.4. Cell Populations Identified by the CD34+ Panel 
 
None of the following markers proved to be more efficient than 
CD123 (Interleukin-3 receptor) at splitting the CMP and MEP populations: 
CD11b (Integrin alpha M), CD16 (a low affinity Fc receptor) region 
receptor), CD110 (Thrombopoietin receptor), CD114 (granulocyte colony-
stimulating factor receptor), CD135 (Fms-like tyrosine kinase 3), CD172a 
(Signal regulatory protein α), CD235a (Glycophorin A) (data not shown). 
 
80 
 
 
Figure 2.4. CD34+ Progenitor Panel Gating Strategy on Fresh BM 
 (A) The cell population was gated on FSC-A and SSC-A, excluding debris. (B) 
Live cells were gated by excluding DAPI positive cells. (C) Singlets were gated 
on SSC-H and SSC-A, excluding doublet cells. (D) Progenitor cells where 
isolated by their expression of CD34. (E) Progenitor cells were split by their 
expression of CD38. These gates were arbitrarily but consistently set at 25% for 
CD38+ cells and 17% for CD38- cells. (F) Primitive CD38- Progenitors where 
split by their expression of CD90 and CD45RA into CD90-CD45RA+ MLPs, 
CD90+CD45RA- HSCs and CD90-CD45RA- MPPs. (G) From the more mature 
CD38+ cells, BNKs were isolated by their expression of CD10. (H) CD38-CD10- 
progenitors where split by expression of CD123 and CD45RA into 
CD123+CD45RA- CMPs, CD123+CD45RA+ GMPs, CD123-CD45RA- MEPs 
and an unclassified CD123highCD45RA+ cell fraction. 
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2.7. Normal Ranges 
2.7.1. Peripheral Blood Mononuclear Cell Profile 
In order to create normal ranges for the mononuclear cell types 
present in peripheral blood, samples from 22 healthy adult volunteers (age 
range 25 – 55 years) were analysed using the preceding APC and 
Lymphocyte multi-parameter flow cytometry panels (see sections 2.6.1 
and 2.6.2).  A whole blood TruCOUNTTM tube (see section 2.4.4) was run 
alongside each PBMC sample including the antibodies CD14 and CD3 
which allowed for the determination of the absolute counts of the 
mononuclear cell and lymphoid compartments respectively (Figure 2.5). 
 
 
 
Figure 2.5. Absolute Quantified Normal Ranges of PBMCs 
Standard ranges of mononuclear and lymphocyte cell subsets from 22 healthy 
adult volunteers. Absolute quantifications based on TruCOUNTTM tube analysis. 
Error bars are means with 95% confidence interval (CI). All axes are as cells/µl. 
Monos = Monocytes; pDC = plasmacytoid DC; mDC = myeloid DC; NK = 
Natural Killer Cell. 
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2.7.2. Progenitor Cell Profile (BM and PBMC) 
It is more difficult to create standard ranges of the progenitor cell 
subsets in steady-state bone marrow, as this is rarely extracted from 
healthy volunteers. Therefore normal BM was sourced from two different 
sources (see section 2.3.4) and analysed using the progenitor cell panel 
(see section 2.6.3).  
 
Firstly, donor material was sourced from the Stem Cell 
Transplantation unit at the Royal Victoria Infirmary, but as peripheral blood 
stem cells (PBSCs) are now more regularly used for allogeneic 
transplantation than bone marrow, this source was limited to 6 samples 
(age range 18-33). The remaining samples (n=14) were taken from hip 
femoral head bone marrow post hip replacement surgery (age range 38- 
92), see Figure 2.6. A further set of peripheral blood samples (n=10) was 
taken from healthy adult volunteers (age range 24 – 48) to form a 
comparison of the progenitor cells in the circulating peripheral blood, see 
Figure 2.6. Samples were not G-CSF mobilised. 
 
There were statistical differences between BM and PBMC for all 
progenitor cell subsets, apart from MPP. HSCs were seen to be variable in 
BM, but most frequently represented the largest population (21%), 
whereas in PBMC, very few HSCs were present (3%). MLP were enriched 
in the PBMC (38%), but low in proportion in the BM (8%), whereas B/NK 
were enriched in BM (18%) and reduced in PBMC (2%).  In the myeloid 
pathway; CMP, GMP and MEP were similar in the BM (9-15%), although 
in the PBMC, CMPs were predominant (28%). CD123high cells were low in 
both cell sources but slightly higher in BM than PBMC (4% and 1% 
respectively). 
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Figure 2.6. Normal BM Cell Type Ranges 
HSC = Haematopoietic Stem Cell; MPP = Multi-Potent Progenitor; MLP = Multi-
Lymphoid Progenitor; B/NK = B/NK Cell Progenitor; GMP = 
Granulocyte/Macrophage Progenitor; CMP = Common Myeloid Progenitor; 
MEP = Megakaryocyte/Erythroid Progenitor; CD123high = CD123highCD45RA+ 
undefined progenitor population. Error bars indicate mean with 95% CI. 
A) Standard ranges of BM (n=20) and PBMC (n=10) progenitor cell subsets. 
B) Comparison of the % of CD34+ cells of each progenitor cell type. Statistics 
are two-tailed Mann-Whitney T tests.  
C) Mean proportional percentage of progenitor subsets in the CD34+ gate. 
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2.8. General Molecular Biology 
2.8.1. DNA Extraction 
DNA was extracted using one of two Qiagen kits 
(www.qiagen.com). For less than 1x106cells, a QIAamp DNA Micro Kit 
was used; for cell numbers between 1x106 and 1x107, a QIAamp DNA 
Mini Kit was used, including the optional addition of4µl RNAse A. 
Company protocols were followed, with the modification of increasing all 
centrifugations to full speed for five minutes and repeating the final elution 
step.  
 
2.8.2. NanoDrop DNA Quantification 
DNA was quantified using a NanoDrop model ND1000 
(www.nanodrop.com) as per standard protocol. 
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Chapter 3. Mononuclear Cell Development in Myeloid Malignancies 
3.1. Introduction 
As discussed in the introduction section (section 1.4.5, page 35), data on 
risk markers for AML prognosis and outcome at the time of diagnosis are 
lacking in the literature, therefore this chapter concerns the exploration of 
possible risk markers at diagnosis. This analysis involves comparative flow 
cytometry and ELISA assays of acute myeloid leukaemia (AML) and the pre-
leukaemic conditions sporadic myelodysplastic syndrome (MDS) and dendritic 
cell, monocyte and B and NK cell (DCML) deficiency.  
 
3.1.1. Chapter Aims 
1) To use state of the art multiparameter flow cytometry and enzyme-
linked immuno assays (ELISAs) to evaluate the differences between 
DCML deficiency, MDS and AML patients and their related 
immunodeficiencies.  
 
2) To use the tools developed in this thesis to test the hypothesis that 
acute leukaemia is associated with an ‘extended phenotype’ of cellular 
immunodeficiency.  
 
3) To analyse whether acute leukaemia is variably associated with 
immunodeficiency due to depletion of mononuclear cells, in addition to 
global bone marrow failure, and that this cellular immunodeficiency is 
a risk factor for infection during the initial treatment of leukaemia.   
 
4) To use the tools developed in this thesis to explore new leukaemia 
biology including the correlation of the extended phenotype of 
leukaemia with standard and novel genetic alterations in leukaemia 
and new marker panels for residual disease. 
 
3.1.2. Acute Leukaemia 
Acute leukaemia (AL) is a life-threatening accumulation of abnormal 
haematopoietic cells, which causes bone marrow failure and leads to 
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death in ~50% of patients. Therefore it is crucial to find out more about the 
basic biology of leukaemia, in order to develop a wider range of effective 
treatments and ways to diagnose and monitor the disease. Further details 
of acute leukaemia are given in introduction section 1.4.2, pg. 26. 
 
3.1.1. Classifying Leukaemic Cells by Immunophenotype 
Multi-parameter flow cytometry facilitates complex analysis of 
peripheral blood and stem cell compartments (Autissier et al., 2010; 
Jardine et al., 2013). Recently developed flow cytometry protocols created 
in the Human Dendritic Cell Lab (HuDC) and developed in this thesis are 
capable of resolving 23 distinct components from the peripheral blood 
mononuclear cell and CD34+ progenitor cell compartments (see section 
2.6.3, pg. 79). Using these flow cytometry methods, It may be possible to 
reproduce the AML progenitor phenotypes introduced by Goardon et al, 
2011 (see section1.4.3.1 pg. 32), but also to group AML by the phenotypic 
pattern of mature markers seen on AML blast cells.  
 
3.1.2. The Extended Phenotype of Leukaemia 
Loss or aberrant expansion of specific cell populations during the 
evolution of leukaemia may lead to immunodeficiency.  At presentation, 
the failure of erythropoiesis, granulopoiesis and thrombocytopoiesis are 
paramount but the extent to which mononuclear cell differentiation has 
failed has not been examined. Recent studies show clear relationships 
between leukaemic blasts and normal progenitor compartments (Cox et 
al., 2004; Kong et al., 2008; le Viseur et al., 2008; Goardon et al., 2011) 
and it is likely that different extended phenotypes will be associated with 
each biological type of acute leukaemia. Understanding how defects in 
myelopoiesis affect circulating DC populations, has the potential to 
provide: 1) new insight into the nature of immunodeficiency and the 
attendant clinical problems of bone marrow failure; 2) new information 
about the basic biology of acute myeloid leukaemia; 3) new insights into 
the homeostasis of antigen presenting cells. Further details of this 
hypothesis are given in the introduction section 1.4.6, pg. 35. Multi-
parameter flow cytometry using TruCOUNT tubes is a testable model for 
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this project, as it gives absolute quantification of all of the mononuclear 
cell types present in peripheral blood.  
 
3.1.3. Dendritic Cell, Monocyte and B and NK Lymphoid Deficiency 
The theory of an extended phenotype of leukaemia is supported by 
the recently described Dendritic Cell, Myeloid and B and NK Lymphoid 
(DCML) deficiency, otherwise referred to as MonoMac (Vinh et al., 2010; 
Calvo et al., 2011).DCML deficiency patients have a common patient 
presentation of atypical mycobacterial and viral infections with an 
underlying specific deficiency of DCs, monocytes, B and NK cells, and an 
overall deficiency of the MLP progenitor cell (Bigley and Collin, 2011; 
Calvo et al., 2011). DCML deficiency is caused by mutations in the GATA2 
gene (Dickinson et al., 2011; Hsu et al., 2011) and up to 50% of patients 
develop MDS (Calvo et al., 2011; Hsu et al., 2011; Bodor et al., 2012; 
Holme et al., 2012; Hsu et al., 2013) and may progress further to 
leukaemia (Vinh et al., 2010; Bigley and Collin, 2011). 
 
Although the cellular losses seen in DCML deficiency could imply 
that it is in fact a form of MDS, the specific immunodeficiencies appear to 
be an ‘accessory phenotype’ rather than playing a significant role. In fact, 
many DCML deficiency patients present with clinical problems prior to their 
meeting the standard criteria for MDS, indicating that the cell-intrinsic 
phenotype of the disease directly effects haematopoiesis. Therefore, it is 
not certain how closely DCML can be generalised to sporadic MDS and 
AML. 
 
Mononuclear cytopenia, in particular the loss of DCs, has not been 
systematically investigated in symptomatic GATA2 mutation patients. 
Furthermore, it is not known how distinct the phenotype of DCML 
deficiency is from cytopenias occurring in acquired MDS with wild-type 
GATA2. A more precise understanding of the evolution of cellular 
deficiency and progression of DCML deficiency, in comparison to other 
forms of BMF may further assist the recognition and clinical management 
of these disorders. These data may also be very useful in the prognosis of 
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leukaemia and leukaemia biology itself, due to possible progression of 
DCML deficiency to MDS to AML. 
 
3.1.4. Fms-like Tyrosine Kinase Ligand 
Fms-like Tyrosine Kinase 3 (FLT-3) is a cytokine receptor involved 
in normal haematopoiesis. FLT3 Ligand (FLT3L) may be increased in the 
refractory anaemia form of MDS (Zwierzina et al., 1999), and it has more 
recently been found to be massively elevated in cases of DCML deficiency 
(Bigley et al., 2011). No studies to date have examined serum levels of 
FLT3L in AML, though AML cells express high levels of the FLT3 receptor 
(Birg et al., 1992), and in vitro studies have reported that FLT3 ligand can 
promote AML cell proliferation and survival (Drexler et al., 1999; Meyer 
and Drexler, 1999). It is therefore possible that variable levels of serum 
FLT3 ligand may be used as a simple differentiating biomarker of the 
diseases. 
 
3.1.5. Chapter Hypotheses 
1) Acute leukaemia is variably associated with immunodeficiency due to 
failure of development of mononuclear cells, independently of the 
effect of global bone marrow failure. 
 
2) Distinct patterns of cytopenia are observed with GATA2 mutation, 
sporadic MDS and acute leukaemia.  
 
3) The ‘extended phenotype’ of acute leukaemia is related to the 
immunophenotype of blast cells.  
 
4) The ‘extended phenotype’ of leukaemia correlates with the genotype 
of acute leukaemia. 
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3.2. Materials and Methods for Chapter Three 
3.2.1. Sample Collection 
Blood surplus to diagnostic requirement was collected from GATA2 
mutation and MDS patients. Samples of blood and BM which remained 
after diagnostic requirements were collected from AML patients. Samples 
from all patients were linked with clinical data, including the age and 
gender of the patient, the date of presentation, and the treatment protocol 
used. Laboratory data obtained at the time of diagnosis, including the 
immunophenotype and karyotype of the leukaemic cells, was also 
collected from AML patients. A summary of all patients recruited for this 
study is given in Figure 3.1. Detailed patient characteristics are given in 
Table 5.1. All patient and control samples were acquired with ethical 
approval from the Newcastle and North Tyneside Research Ethics 
Committee (Appendix 8).  Informed consent was obtained in accordance 
with the Declaration of Helsinki. 
 
3.2.1.1. DCML Deficiency (GATA2 Mutation) Patients 
Patients with DCML deficiency carrying GATA2 mutations were 
referred from a wide range of clinicians suspecting a GATA2-related 
disorder. There were no specific inclusion criteria and all patients 
found to have GATA2 mutation by direct sequencing are reported 
(n=18). Sequencing was performed in a separate study (Dickinson et 
al., 2014).  
 
3.2.1.2. Myelodysplastic Syndrome Patients 
Patients with acquired myelodysplasia (MDS; WHO 
classification: refractory cytopenia and multilineage dysplasia) were 
recruited from the FRH ambulatory clinic. Inclusion criteria was for 
those patients who displayed a tri-lineage MDS as defined by BM 
morphology and histology and dysplastic features in the cells of all 
three haematopoietic lineages (myeloid, erythroid and 
megakaryocytic).All MDS patients were symptomatic and some 
required transfusion support but none had received high dose 
90 
 
cytoreductive therapy prior to testing. These patients were seen to 
have no GATA2 mutations in a separate study (Dickinson et al., 2014). 
 
3.2.1.3. Acute Myeloid Leukaemia Patients 
Samples of peripheral blood and bone marrow were gathered 
from acute myeloid leukaemia patients presenting to Haematology at 
Northern Centre for Cancer Care (NCCC), Freeman Hospital (FRH) 
(Figure 5.1). There were no specific recruitment criteria, other than the 
availability of material surplus to diagnostic requirements and the 
ability to consent. A total of 43 AML patients were recruited into the 
study at time of diagnosis. AML was diagnosed by blast percentage of 
20% or higher by qualified diagnostic laboratory staff. 38 patients had 
a diagnosis of de novo AML, consisting of specific diagnosis of AML 
(30), AMML (2), APML (4) and BPDCN (2). 5 patients were 
transformations of AML from MDS. PBMC samples were analysed 
from 38 patients and BM from 15 patients (10 patients with both PBMC 
and BM). The PBMC samples from 2 patients were found to have 
insufficient cell numbers for analysis. 
 
3.2.1.4. Control Peripheral Blood and Bone Marrow 
Normal peripheral blood samples were taken with informed 
consent from voluntary donors. Bone marrow was taken either from 
donations to the bone marrow transplantation service (informed 
consent for research taken by the donor registries) or from patients 
undergoing hip replacement surgery (informed consent at site).  
 
3.2.2. FLT3L Serum Biomarker ELISA Screening 
Serum ELISA was performed with Quantikine Human FLT3/Flk-2 
Ligand Immunoassay, according to manufacturer’s instructions (R&D 
Systems; www.rndsystems.com). All samples were performed in duplicate. 
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3.2.3. Bioinformatics Data Clustering 
Unsupervised hierarchical clustering was performed using a 
Euclidean distance matrix and Ward method agglomeration. These 
analyses were performed using base packages of the 'R' programming 
language (ver. 3.1.1 "Sock it to Me"). 
 
3.2.4. Statistical analysis 
ANOVA with Bonferroni Multiple Comparisons Test were used to 
compare groups in most analyses. Cell count data were obviously skewed 
in DCML deficiency patients and so non-parametric tests were preferred 
(Mann-Whitney or Kruskal-Wallis with Dunn’s Multiple Comparison Test).  
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3.3. Results 
A summary of patient recruitment is given in Figure 3.1, detailed patient 
characteristics are given in Table 3.1.A (DCML deficiency) B (MDS) and C 
(AML). 
 
 
 
 
 
Figure 3.1. Haematological Disorder Patient Recruitment 
AML = Acute Myeloid Leukaemia; AMML = Acute Myelomonocytic Leukaemia; 
APML = Acute Promyelocytic Leukaemia; BPDCN = Blastic Plasmacytoid 
Dendritic Cell Neoplasm; MDS = Myelodysplastic Syndrome; Tri-Lin = Tri-
lineage (Red blood cells, neutrophils and platelets); DCML = Dendritic Cell, 
Monocyte, B and NK Cell Deficiency. 
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Table 3.1. Patient Clinical Characteristics 
A) DCML Deficiency Patients; B) MDS Patients; C) AML Patients (Next Page) 
A review of the common clinical features of the cohort is presented.  
Hb = Haemoglobin; Plt = Platelets; Neut = Neutrophils; FLT3L = Fms-like 
tyrosine kinase 3; GATA2 = The gene which codes for GATA binding protein 2, 
found to be mutated in almost all patients with the DCML deficiency phenotype 
(37/43 to data, unpublished data). PBMC = Peripheral Blood Mononuclear 
Cells; BM = Bone Marrow; WBC = Whole Blood Count; w/RGA = with Recurrent 
Genetic Abnormalities; wMDRC = with Myelodysplasia Related Changes; NOS 
= Not Otherwise Specified. 
FLT3L was measured in Serum/Plasma Samples taken at time of diagnosis. 
Details of the classifications of leukaemia are given in section 1.4.2.1, pg. 28. 
FAB = French American British; WHO = World Health Organisation; 
Cytogenetic Risk Status based on Grimwade et al, 2010.  
A 
B 
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3.3.1. General Clinical Features 
Age of presentation and gender were collected from all patients. 
DCML deficiency patients were diagnosed at a significantly younger age 
than MDS and AML patients (Figure 3.2). No statistical significance was 
seen for patient gender. 
 
Figure 3.2. Patient Age of Diagnosis 
Age of diagnosis of patients with dendritic cell, monocyte, B and NK lymphoid 
deficiency (DCML), myelodysplastic syndrome (MDS) and acute myeloid 
leukaemia (AML). Blue lines are medians. Statistics were Kruskal-Wallis One 
Way ANOVA. **** = <0.0001 
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3.3.2. Diagnostic Laboratory Results 
Data from the diagnostic lab for haemoglobin (Hb), platelets (Plts) 
and neutrophils were collected from DCML deficiency (18/18), tri-lineage 
MDS (13/13) and AML (42/43) patients. 
 
There were significant reductions in all three factors in MDS and 
AML patients compared to DCML deficiency patients. None of the factors 
were significantly different between MDS and AML. 
 
 
Figure 3.3. Automated Diagnostic Blood Counts 
Comparison of automated diagnostic blood counts of patients with DCML 
deficiency (n=18), MDS (n=13) and AML (n=42). Grey line is the standard 
range. Blue lines are medians. Hb = Haemoglobin; Plts = Platelets; Neuts = 
Neutrophils. 
Statistics with Kruskal-Wallis with Dunn’s Multiple Comparison Test. * = <0.05; 
** = <0.01; *** = <0.001.  
 
 
 
 
 
 
97 
 
3.3.3. Mononuclear Cell Profiles 
In order to profile the extent of mononuclear immunodeficiency, 
PBMC samples from DCML deficiency (18/18), tri-lineage MDS (13/13) 
and AML (36/43) patients and 20 normal controls were run on the APC 
and Lymph panels (see section2.6, pg. 76) and TruCOUNT tubes were 
used to extrapolate absolute counts.  
 
As expected, DC, monocyte, B and NK counts were significantly 
reduced in all symptomatic carriers of GATA2 mutation, whereas T cells, 
although appearing reduced in some patients, were maintained. DCML 
deficiency was significantly different from MDS in levels of CD16+ 
Monocytes, CD141+ mDCs and NK Cells (all p=<0.05), and from AML in 
all cell subtypes other than T cells (all p=<0.001). The only subtype 
significantly different between MDS and AML patients was circulating non-
classical CD16+ monocytes, which appeared expanded in AML (p=<0.05). 
There were trends for lower mDCs and B cells in MDS, but these did not 
achieve significance after adjustment for multiple comparisons. NK cells 
were difficult to isolate from blast cells by flow cytometric analysis, so care 
must be taken when interpreting NK cell count data. 
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Figure 3.4. DCML Deficiency, MDS and AML Gating Examples 
Examples of gating strategies for Dendritic Cell, Monocyte and B and NK 
Lymphoid (DCML) Deficiency, Myelodysplastic Syndrome(MDS) and Acute 
Myeloid Leukaemia(AML) patients. Gating strategies were kept as consistent as 
feasibly possible. As seen, AML phenotyping profiles can vary massively. Most 
likely blastic populations are ringed in red in the three AML examples. BPDCN = 
Blastic Plasmacytoid Dendritic Cell Neoplasm, a subset of AML. 
 
Tube One (APC Panel)- Cells gated on FSC-A and SSC-A and gate for live 
(DAPI negative) singlets (not shown); A = CD14+ monocytes; B = CD14+16+ 
monocytes; C = CD16+ monocytes; D = CD123+ pDCs; E = CD34+ circulating 
progenitor cells; F = CD141+ mDCs; G = CD1c+ mDCs. 
 
Tube Two (Lymph Panel) -Cells gated on FSC-A and SSC-A and gate for live 
(DAPI negative) singlets (not shown); H = CD19+ B Cells; I = CD3+ T Cells; J = 
CD56+ NK Cells. BPDCN patient NK cell data not used, due to CD56 positivity 
on BPDCN cells. 
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Figure 3.5. DCML Deficiency, MDS and AML Mononuclear Profiles 
A) Comparison of automated diagnostic blood counts of patients with DCML 
Deficiency (n=18), MDS (n=13) and AML (n=42). Grey line is the standard 
range. Blue lines are medians. 
B) Statistical analysis of the data in figure A. Statistics with Kruskal-Wallis with 
Dunn’s Multiple Comparison Test. * = <0.05; ** = <0.01; *** = <0.001.  
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3.3.4. Fms-like Tyrosine Kinase 3 Ligand (FLT3L) 
In order to see whether FLT3L levels varied in the patients, serum 
from symptomatic DCML deficiency (n=18), tri-lineage MDS (n=12) and 
AML (n=36) patients were analysed for levels of FMS-Like Tyrosine 
Kinase 3 Ligand (FLT3L) using an Enzyme-Linked Immunosorbent Assay 
(ELISA) (Figure 3.6.A). Results indicated significantly elevated FLT3L for 
symptomatic GATA2 mutation, and significantly decreased in AML 
(p=<0.0001 for both vs. normal and each other). In fact 24/36 AML 
patients did not have any detectable FLT3L above the limit of the assay 
(7pg/ml), and 3/8 of the remaining patients were below the normal range 
of 48.30 - 173.8pg/ml. The highest level of FLT3L in an AML patient was 
119.634pg/ml. Both DCML deficiency and AML were also significantly 
different to MDS (p=<0.0001 for both), where there was a wide spread of 
FLT3L levels, some high; others low and one patient had undetectable 
levels, though this was not seen to be significantly different to normal 
controls.  
 
As might be expected, there was a statistically significant 
correlation coefficient between % BM blasts and diagnostic laboratory 
WBC in AML patients (p=0.0152; Figure 3.6.B), therefore levels of FLT3L 
were compared to both of these factors. Neither % BM blasts nor WBC 
had a statistically significant correlation coefficient in comparison with 
FLT3L levels (Figure 3.6.C&D). Detectable or not detectable FLT3L in 
AML patients did not correlate with cytogenetics, FAB or WHO types, 
immunophenotypic types or blast percentage CD34 positivity, however 
CD14+ and CD16+ monocytes were increased in patients with 
undetectable FLT3L (p=<0.05, data not shown). 
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Figure 3.6. FLT3-Ligand Analysis 
A) Comparison of serum levels of Fms-like tyrosine kinase 3 ligand (FLT3L) in 
patients with DCML deficiency (n=18), tri-lineage MDS (n=12), AML (n=36) 
and normal controls (n=10). Error bars indicate medians. For the purposes of 
statistics, readings below the ELISA readable sensitivity were analysed as 
7pg/ml. Statistics were individual T-tests. **** = <0.0001. 24/36 AML patients 
had FLT3L <7pg/ml. 
B) Comparison of diagnostic laboratory WBC readings versus BM blast count 
percentages. The diagnosis for AML is above 20% BM blasts. 
C) Comparison of FLT3L serum levels versus BM Blast count percentage. Grey 
bars indicate normal ranges. 
D) Comparison of FLT3L serum levels versus diagnostic laboratory WBC. Grey 
bars indicate normal ranges. 
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3.3.5. AML Blast Cell Analysis 
In order to see if the results from the Goardon et al paper were 
reproducible, BM from 15 AML patients was analysed using the progenitor 
cell panel described in section2.6.3, pg.79(see Figure 3.7). In both CD34+ 
and CD34- AML patients, gating originated from the CD34+ cells in the 
bone marrow. In CD34- patients, blast cells were also gated for progenitor 
cell markers to confirm the phenotype (see Figure 3.7). Phenotypes 
matched between CD34+ cells and blast cells in all CD34- AML patients 
analysed. Two patients were excluded due to low cell numbers making 
analysis impossible. In the remaining thirteen patients; three 
immunophenotypic groups could be seen. 8/13 patients matched the 
GMP/MLP immunophenotype, 4/13 patients matched CMP/MPP 
immunophenotype. One final patient (A6492) represented a ‘Hybrid’ type, 
where the highest expansions were seen in the CMPs and MLPs, with 
lesser expansions in the GMPs, MPPs and HSCs (see Figure 3.7). 
 
In pursuance of classification of AML patients where BM was 
unavailable, the flow cytometric progenitor cell panel was performed upon 
the PBMCs of 30 of the AML patients. Both BM and PBMC was thus 
analysed from 9 AML patients. For all 10 patients, the phenotypic type of 
leukaemia matched between BM and PBMC (see Table 3.1). Thus, PBMC 
progenitor immunophenotypes were used to further this analysis. Four 
patients were excluded due to low cell numbers making analysis 
impossible. From the PBMC results; 19/26 patients were GMP/MLP type, 
6/26 patients were CMP/MPP type. The BPDCN patient with progenitor 
immunophenotyping data (A2577) had a GMP/MLP phenotype.  
 
Comparative graphs of the different progenitor fractions in the two 
main immunophenotypes are given in Figure 3.8. HSCs, and MEPs were 
proportionally and statistically increased in CMP/MPP patients. 
Interestingly, all but one CMP/MPP patients were completely deficient in 
CD123high cells.  
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Figure 3.7. AML Progenitor Gating Examples 
AML BM progenitor gating examples. In cases where blasts were CD34-, the 
blasts were gated using the same strategy as the CD34+ cells, in order to 
confirm the phenotype. A = Haematopoietic Stem Cells; B = Multi-Potent 
Progenitors; C = Multi-Lymphoid Progenitors; D = B/NK Cell Progenitors; E = 
Common Myeloid Progenitors; F = Megakaryocyte/Erythroid Progenitors; G = 
Granulocyte/Macrophage Progenitors; H = CD123high unclassified fraction. 
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Figure 3.8. AML Patient PBMC CD34+ Cell Phenotyping Results 
A. Percentage composition of CD34+38+ cells by GMP and CMP and of 
CD38- cells by MLP and MPP as used in the detection of phenotypic blast 
type. 
B. Percentage composition of CD34+38- cells by HSCs and CD38+ cells by 
B/NKs, MEPs and CD123high cells.  
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Blue error bars indicate medians. Grey bars are standard ranges derived from 
10 normal PBMC samples. Statistics are Mann Whitney t tests. 
3.3.6. Mononuclear Subset Comparison by Phenotypic Blast Type 
In order to see whether the different phenotypic types of AML had 
varying effects on the normal mononuclear cell content of the peripheral 
blood, the previously derived data on circulating mononuclear cell subsets 
were re-analysed from 30 AML patients where phenotypic typing results 
were available (Figure 3.9). 
 
Results varied for all cell types. The GMP/MLP group had a 
significantly higher median level of CD14+ monocytes and CD1c+ mDCs 
than the CMP/MPP group. The CMP/MPP group had a significant 
decrease in B cells, whereas the median of the GMP/MLP was within the 
normal range. The GMP/MLP group appeared to have higher levels of 
CD16+ monocytes, and in the CMP/MPP group DCs appeared reduced, 
however these results were not statistically significant.  
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Figure 3.9. ‘Goardon’ Type Mononuclear Cell Analysis 
Comparison of controls (n=21, grey bars, indicating 95% CI) and patients with 
GMP/MLP type blasts (n=20) and CMP/MPP type blasts (n=8) by TruCOUNT 
analysis. Analysis was performed as previously described. pDC: plasmacytoid 
Dendritic Cell; mDC myeloid Dendritic Cell. Error bars show medians. Statistical 
analysis was Mann Whitney t tests.* p=<0.05; ** p=<0.01. 
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3.3.7. AML Blast DC Marker Clustering Analysis 
To examine the expression of DC related markers on the blastic 
cells of AML, and to see if these expressions could be used to group AML 
subtypes, blast cells were isolated. The majority of blast cells appeared to 
fall into two groups visually. These were Lineage-DR- blasts or Lineage-
DR+CD14-16-34+ blasts. No blast cells were seen which were positive for 
CD16, CD141 or CD1c. 
 
After the blast cells were isolated, the Mean Fluorescence Intensity 
(MFI) of each marker on the cells could be collected (n=29). This included 
MFIs for HLA-DR, Lineage (CD3,19,20,56), CD14, CD16, CD123, CD34, 
CD141, CD11c, CD141 and CD1c. These data were then clustered using 
the statistical software ‘R’.  
 
Clustering analysis showed that the AML patients could be split into 
5 groups by DC marker MFIs (Figure 3.10.A). Cluster 1 and 2 patients look 
very similar visually, though CD34 expression was higher and CD14 
expression lower in cluster 1.The third cluster of patients had a ‘null’ 
phenotype, negative for all DC panel markers. Cluster 4 patients had 
Lineage-DRlowCD14-16-123low11c-141-1c- blasts, which could be either 
CD34 positive or negative. Finally cluster 5 was specific for a single 
BPDCN patient, where the blasts were Lineage-DR+CD16-123low34-11c-
141-1c-. Flow cytometric examples and representations of each clustering 
type are given in Figure 3.10.B. 
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Figure 3.10. AML DC Marker MFI Clustering Analysis 
A) Cluster dendrogram of AML patient (n=29) based on mean fluorescence 
intensity (MFI) of DC related flow cytometry markers. 
B) Flow cytometry examples of each clustered AML type. Red dots are blast 
cells, black dots are normally differentiated cells. 
C) Illustrative examples of the markers identifying each clustered AML type. 
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3.3.8. AML Comparison Summary Tables 
Where available, data from the previous analyses were cross-
compared in order to see if the progenitor and mature marker 
immunophenotypes were related, and to correlate with cytogenetics (Table 
3.2).  
 
Patients with the GMP/MLP progenitor immunophenotype had a 
wide range of mature immunophenotypes and cytogenetics. Only one 
GMP/MLP patient had the ‘null’ phenotype of cluster 3. Nine patients had 
normal cytogenetics and 4 patients had complex abnormalities. The 
BPDCN patient had a normal karyotype, though due to the nature of 
BPDCN, this patient had an adverse phenotype. There were no blast 
phenotyping data available from the final patient with complex 
abnormalities. 
 
All five CMP/MPP patients were seen to have the mature 
phenotype of cluster 3, where all mature cell markers are negative. Three 
of these patients had a normal karyotype, and two had 15;17 
translocations. Of the three CMP/MPP not shown, two had a normal 
karyotype and one carried a Deletion 5Q mutation. No 15;17 
translocations or 5Q deletions were seen in any of the GMP/MLP type 
leukaemias.  
 
Similarly, only AML patients with blasts of mature phenotype cluster 
3 appeared to have an association with WHO or FAB type, being exclusive 
to AML with recurrent genetic abnormalities or AML not otherwise 
specified in the WHO classification system and to the M0 and M3 FAB 
type AMLs (see Table 3.2).  
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Table 3.2. Comparison of phenotypic and clustered blast types. 
Summary of cytogenetics, phenotypic blast type and cluster blast type (where 
known). Cytogenetic risk groups based on Grimwade et al, 2010. 
❶ =Cluster 1; ❷ = Cluster 2; ❸ = Cluster 3; ❹ = Cluster 4; ❺ = Cluster 5. 
BPDCN = Blastic Plasmacytoid Dendritic Cell Neoplasm  
 
* Complex cytogenetics given below; indicated by superscript numbers: 
Complex 1:47,XY,t(1;12)(q25;q24),del(4)(q31),del(5)(q1?3),add(15)(p11.1),-
18,-22,-22,+4mar [7] /46,XY [3] (not shown in table) 
Complex 2:46,XX,del(5)(q22q35), del(12)(p1?)[11] flt3- npm1- 
Complex 3:45,XY,der(3)add(3)(p1?3) 
add(3)(q27),7,add(12)(1?2),add(12)(p13),-13,+mar [6] FISH: MECOM 
REARRANGED [99/100] 
Complex 4:45~47,XY,inv(3)(q21q26),-7,+8[cp6], FISH:MECOM NOT 
rearranged [100] 
Complex 5:45~46,XY,dic(2;?)(q37;?),add(3)(p2?),add(3)(q2?),5,-12,-
12,del(17)(p1?),-22, -22,+5~7mar[5] 
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Figure 3.11. Comparison of Blast Types and WHO/FAB Classifications 
Summary of WHO/FAB AML types, cytogenetics, phenotypic blast type and 
cluster blast type (where known).  
❶ =Cluster 1; ❷ = Cluster 2; ❸ = Cluster 3; ❹ = Cluster 4; ❺ = Cluster 5. 
WHO = World Health Organisation AML Classification System 
FAB = French-American-British AML Classification 
For details of classification systems, see section 1.4.2.1, page 28. 
BPDCN = Blastic Plasmacytoid Dendritic Cell Neoplasm  
* Complex cytogenetics given on previous page 
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3.4. Discussions for Chapter Three 
This chapter describes the comparative analysis of DCML deficiency, 
MDS and AML patients in terms of; major diagnostic parameters, cell profiling of 
normal mononuclear cell fractions and levels of FLT3L in serum. Also more 
detailed analysis was performed on the blast cells of AML patients in terms of 
phenotypic markers (related to progenitor cells and mature cells) and 
cytogenetics. 
 
3.4.1. Comparative Phenotyping of DCML Deficiency and MDS 
Although GATA2 mutation is a constitutive genetic risk for 
developing MDS (Hahn et al., 2011; Hsu et al., 2011; Holme et al., 2012; 
Kazenwadel et al., 2012; Pasquet et al., 2013), patients with GATA2 
mutation may be distinguished from those with acquired MDS and AML on 
several grounds. GATA2 mutation is associated with a much younger age 
of presentation, better preserved haemoglobin, neutrophils and platelets 
and much more severe defects of DCs, monocytes, and lymphoid cells 
than patients with MDS and AML. The observation that control MDS 
patients did not have GATA2 mutations is consistent with a recent large 
cohort study showing an incidence of mutation in only 4 of 603 MDS 
patients (Papaemmanuil et al., 2013). 
 
Overall, it was seen that GATA2 mutation causes a specific 
mononuclear cell loss prior to the development of leukaemia. This is 
distinct from sporadic MDS, where there is a less severe and more 
generalised tri-lineage failure of haematopoiesis. Now that I know that the 
profile of cell loss differs between GATA2 mutation and MDS, it would be 
interesting to explore if the cells in both diseases are lost due to different 
mechanisms. 
 
3.4.2. Immune Dysfunction in Acute Leukaemia 
Leukaemia is a known cause of bone marrow failure (BMF); 
however the specific order of failure has not previously been explored. The 
hypothesis proposed in this thesis was that leukaemia has an ‘extended 
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phenotype’ of cellular immunodeficiency relating to the progenitor 
compartment from which it arises. 
 
In a small cohort of patients (n=30), it was seen that variable 
patterns of normal cell loss can be seen in de novo AML, however the 
majority of patients had an unexpectedly intact level of immune cell 
differentiation even at high levels of BM blasts and/or circulating WBCs. 
This finding is surprising as it has been assumed that the normal progeny 
of a stem cell compartment will contract when displaced by leukaemic 
clones, owing to impaired differentiation. The next stage of this line of 
research would be to define whether these circulating ‘normal’ 
mononuclear cells are indeed normal, or are in fact part of the AML clone. 
 
Although large degrees of variation were seen, some patients with 
expanded subsets and others with specific deficiencies, the only subset 
significantly altered in MDS or AML was B cells in MDS patients which 
were reduced from normal. Interestingly, some AML patients had 
expansions of DC numbers, while others were completely deficient in all 
three DC subtypes. Also, patients with acquired MDS also had mild 
mononuclear cytopenias of pDCs, and both classical and non-classical 
monocytes.  
 
The theory of an extended phenotype of acute leukaemia assumes 
a model of haematopoiesis based on the most recently published data 
with the caveat that certain features (e.g. the possible LMPP/MLP split in 
the murine haematopoietic system, see section 1.1.4, pg. 7), are disputed. 
These are just the closest approximations; it is likely that models of 
haematopoiesis will change significantly in the coming years. 
 
3.4.3. Serum FLT3-Ligand in Haematological Disorders 
FLT3L levels were significantly increased in symptomatic DCML 
deficiency patients seen in this study, whereas DCML deficiency patients 
who progress to MDS have normal levels of FLT3L (Dickinson et al., 
2014), similar to the levels seen in the control tri-lineage MDS patients. 
These results suggest a biphasic relationship, that FLT3L becomes 
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progressively elevated in cases of DCML deficiency but then declines as 
MDS develops. Levels of serum FLT3L in sporadic MDS patients were not 
significantly different from normal. In a study by Zwierzina et al, there was 
a correlation seen between WHO MDS types and serum FLT3L levels 
(Zwierzina et al., 1999). Unfortunately data on WHO/FAB types were 
unavailable for the MDS patients in this thesis. 
 
In previous studies, high rates of mutation in the FLT3 gene, which 
encodes the receptor for FLT3L have been seen in AML (Yamamoto et al., 
2001). FLT3L is vital for the production of DCs in the steady-state 
(Shortman and Naik, 2007; Rahman and Aloman, 2013). Mice deficient in 
FLT3L have been seen to have reduced DC numbers (McKenna et al., 
2000), whereas administration of FLT3L to mice or healthy humans has 
been shown to substantially increase DC numbers (Maraskovsky et al., 
1996; Maraskovsky et al., 2000). It is unclear which cell types produce the 
FLT3L required for DC maturation, though some suggestions are T cells 
(Saito et al., 2013) or bone marrow endothelial cells (Solanilla et al., 
2000). In this thesis, AML patients were seen to have significantly 
decreased levels of FLT3L at diagnosis, quite often lower than the 
detectable range of the ELISA assay. Also, the blast cells of the AML 
patients in this study were seen to bear little or no mature myeloid cell 
markers. These two observations could suggest that the deficiency of 
FLT3L in the AML patients could lead to an inhibition of maturation of the 
blastic cells.  
 
3.4.4. AML Blast Cell Progenitor Phenotype 
The study by Goardon et al, involved phenotyping the blast cells of 
CD34+ (>5%) AML patients using progenitor cell markers (Goardon et al., 
2011). In that study, two immunophenotypic patterns of AML were 
observed; 87.8% of patients were GMP/MLP type and 13.8% of patients, 
were CMP/MPP type.  
 
In this thesis, it was possible to reproduce the AML typing data 
seen in the Goardon et al paper, using both BM and PBMC samples. It 
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was seen in nine patients that the progenitor immunophenotypic pattern of 
blasts in the BM, was reproduced in the blasts of the PBMCs, therefore 
the pattern observed in either sample type can be used in this analysis.  
 
In the paper by Goardon et al, patients were excluded when blasts 
were less than 5% positive for CD34. In this thesis I was able to include 
CD34- AML patients in the analysis by first analysing the progenitor profile 
of the CD34+ fractions of cells, and then comparing to the phenotypic 
profile of the actual blastic cells using the same gating strategy.  In all 
eight CD34- AMLs analysed in this study, the phenotypic bias seen in the 
CD34+ progenitor cells was matched within the phenotypic profile of the 
blastic cells.  
 
This analysis of both CD34+ and CD34- AML patients led to a 
disparity in the proportion of blast cell progenitor immunophenotypic 
patterns, with a slightly higher rate of CMP/MPP patients (63% GMP/MLP; 
24% CMP/MPP). In this thesis it was seen that nearly all GMP/MLP 
patients had a CD34 expression greater than 5% (14/15) whereas the 
majority CMP/MPP patients had a CD34 expression of less than 5% (6/8). 
This was in fact a statistically significant difference between the two AML 
types (p=0.0023).  
 
In terms of extended phenotyping, it was seen that patients with the 
GMP/MLP phenotype had a better preserved mononuclear cell profile, 
including DC and lymph levels averaging on normal and expanded levels 
of monocytes. 
 
Interestingly, a third blast cell progenitor immunophenotypic pattern 
was observed in one patient (A6492). In this patient there were clear 
expansions of the CMP and MLP progenitor groups, although there were 
also lesser expansions of GMPs, MPPs and HSCs, while B/NK and MEP 
progenitors were almost completely absent. This patient had an extremely 
high level of CD34 positivity (91%), and appeared to have normal levels of 
T and B cells, with slightly increased monocyte, pDC and CD141+ mDC 
fractions. NK cells looked to be greatly increased whereas CD1c+ mDCs 
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were completely absent (data not shown). It would be interesting to gather 
more data on this patient to observe possible differences from the two 
main patterns. 
 
3.4.5. AML Blast Cell Mature Immunophenotypic Type 
Secondary to the progenitor-marker immunophenotypic patterns 
discussed above, AML patients were also bioinformatically clustered 
according the MFIs of DC-related markers upon the blast cells, the ‘mature 
immunophenotype’. This is a form of analysis not attempted before in 
AML, and may give important information about the relationship between 
AML blasts and DC lineages. FSC-A and SSC-A MFIs were added in an 
additional analysis, but these were found to confound the data, most likely 
due to the high levels of variability of these measurements (data not 
shown). In this analysis it was seen that the AML patients (n=29) could be 
clustered into 5 distinct groups.  
 
Interestingly, it was seen that 5/5 of the CMP/MLP patients with 
clustering data available, fell into cluster 3, which had a ‘null’ phenotype, 
with no obvious expression of any DC related markers. The GMP/MLP 
patients fell into all five clusters, 4/18 in cluster 1; 6/18 in cluster 2; 1/18 in 
cluster 3, 5/18 in cluster 4. One BPDCN patient, who also displayed a 
GMP/MLP phenotype was included in the analysis and clustered 
separately from all other patients (cluster 5), which is characterised by 
HLA-DR positivity and CD34 negativity.  
 
3.4.6. Genetic Abnormalities and the Extended Phenotype of AML 
In the Goardon et al study, no correlations were found between 
morphology or cytogenetics and Blast Cell Immunophenotypic Patterns. 
However, in this thesis, I have seen that the CMP/MPP pattern correlates 
with both clustering analysis as a mature marker ‘null’ phenotype, as well 
as cytogenetics, notably 15:17 translocations and normal karyotype. 
These correlations were likely missed by the Goardon et al group due to 
the exclusion of CD34- patients, which overall account for ~32-55% of 
AML patients (Del Poeta et al., 1994; Krasinskas et al., 1998; Legrand et 
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al., 2000; Thalhammer-Scherrer et al., 2002). As patients with normal 
cytogenetics were found in both immunophenotypic types, there is a 
possibility that these patients could be grouped and observed for any 
outcome differences, potentially splitting the intermediate risk group.  
 
3.4.7. Summary 
Using techniques established earlier in this thesis, I have 
successfully derived peripheral blood and bone marrow phenotypic 
profiles in DCML deficiency, MDS and AML. I have seen that both DCML 
deficiency and MDS have deficiencies in mononuclear cells, though the 
reduction is less severe in MDS, while in AML, mononuclear differentiation 
is remarkably well preserved.  
 
Secondly, I have seen that serum levels of FLT3L are vastly 
increased in DCML deficiency patients, and almost completely abated in 
AML patients. FLT3is a gene with a high frequency of mutation in AML 
patients (Yamamoto et al., 2001), so this is an interesting finding, and may 
be exploitable in a clinical setting. 
 
Also, I have reported in AML that the phenotypic profiles of the 
blastic cells can be used to group different types by both the previously 
described progenitor cell phenotyping analysis or by clustering analysis of 
the DC-related markers. These groups, particularly the CMP/MPP, cluster 
3 types showed correlations to normal and translocation 15;17 cytogenetic 
groups, which may be able to be exploited in the future.  
 
The final aims of this chapter were to attempt to correlate the 
extended phenotype of AML patients with FAB/WHO types, rates of 
infection and extra-medullary disease. Unfortunately, due to the low 
numbers of patients recruited into the study, and the unavailability of data 
on FAB/WHO types, these analyses were not performed. 
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Chapter 4. BRAFV600E Mutation Detection Assay Setup 
 
4.1. Introduction 
This chapter describes the development of methods to analyse the BRAFV600E 
mutational allele levels of sorted cell types using real-time PCR (RT-PCR).  
4.1.1. Chapter Aims 
1) To develop polymerase chain reaction (PCR) protocols to detect 
BRAFV600E in lesions and sorted peripheral blood and bone marrow 
fractions. 
4.2. Methods of Detection of BRAFV600E 
As technology is expanding at an exponential rate, new and 
modified methods of mutation detection arise each year. The following is a 
brief summary of the current methods available for the detection of 
BRAFV600E. For a full summary of the sequencing, mass spectrometry and 
melting curve analysis techniques, plus 454 Pyrosequencing and Cobas 
4800 BRAF test, see (Curry et al., 2012). 
 
 
4.2.1. First Generation Sequencing - Sanger Sequencing 
Sanger sequencing, pioneered in the 1970s (Sanger and Coulson, 
1975; Smith et al., 1986), involves DNA polymerase controlled selective 
incorporation of chain-terminating dideoxynucleotides during DNA 
replication.  This technique has been largely supplanted by next-
generation sequencing for large scale genome work, but is still often used 
for single gene confirmationary studies, including for BRAFV600E in 
Histiocytic disorders  (Go et al., 2014). 
 
4.2.2. Sequenom (Mass Spectrometry) 
The company Sequenom provides a mass-spectrometry based 
method for diagnostic laboratoryBRAFV600E testing in lesions, and is 
typically used for Formalin Fixed Paraffin Embedded (FFPE) samples. The 
Sequenom protocol has a sensitivity of 10%, however, the diagnostic 
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laboratory warns of the possibility of false negatives under 30% 
(NewGene, 2014; Sherwood et al., 2014).  
 
4.2.3. Melting Curve Analysis 
PCR product double stranded DNA has specific melting 
temperatures dependant on the sequence of bases in the strand. Melting 
curve analysis depends on these slight differences to tell between PCR 
products containing the series of bases specific to wild-type BRAF 
compared to mutated BRAF (Ansevin et al., 1976; Ririe et al., 1997). This 
method has a high sensitivity to detect mutations, however as it only 
shows a melting point difference compared to normal, it is not possible to 
tell whether the mutation detected is BRAFV600E or another mutation.  
 
4.2.4. Next Generation Sequencing - Pyrosequencing 
Pyrosequencing is a form of next-generation sequencing which 
differs from Sanger sequencing, in that instead of detecting chain-
terminating dideoxynucleotides, it detects the release of pyrophosphates 
when certain nucleotides are incorporated (Ronaghi et al., 1996; Ronaghi 
et al., 1998). The benefit of pyrosequencing is that it has a much greater 
sensitivity than Sanger sequencing, it is able to detect the BRAFV600E 
mutation down to a percentage of 2%, rather than the limit of detection of 
20% of Sanger sequencing (Tan et al., 2008). Recently, pyrosequencing 
was used on whole blood (23 patients) and CD14+ monocytes (7 patients) 
of LCH patients, with no positivity in either group, with a limit of detection 
of 1-2% (Satoh et al., 2012). 
 
4.2.5. VE1 Antibody 
Recently, a BRAFV600E specific antibody has been developed which 
can differentiate between wild-type and V600E mutated BRAF (Andrulis et 
al., 2012), and has been used for detection of lesional BRAFV600E in LCH 
(Sahm et al., 2012). Although this antibody is chiefly used for FFPE 
samples, it may be useful in this study for detection of the mutation on 
cytospins of cellular fractions which are in too small a quantity for allele-
specific PCR. However several studies have noted that the VE1 antibody 
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has a low sensitivity (71%) and specificity (74%) and can have non-
specific nuclear staining (Kuan et al.; Adackapara et al., 2013). Indeed in 
personal experience I have seen that the VE1 antibody can have low-level 
non-specific staining of macrophages in healthy controls (data not shown). 
Therefore much care must be taken when interpreting these results, 
strong staining is likely to be true positive, but weak staining may be low or 
false positive. 
 
4.2.6. Allele Specific PCR 
Allele-specific PCR can be used as a direct detection method for 
Single Nucleotide Polymorphisms (SNPs), by enzymatic amplification of 
the specific DNA sequence to be studied by oligonucleotide primers. The 
primers are specific for the mutation or wild-type and produce different size 
products, so a difference can be observed when running the products out 
on polyacrylamide gel. Recently, allele specific Mutation Detection RT-
PCR Assays have been produced by several companies which can detect 
both wild type and SNP from a sample, and give a result of quantity based 
on fluorescent probes, removing the need for gel analysis. These 
techniques can have specificity down to 0.1%, and were therefore chosen 
for this analysis. Recently the techniques have been used to show that 
BRAFV600E can be found in the peripheral blood of LCH patients,  
specifically in the CD14+ and CD11c+ cells (Berres et al., 2014).  
 
Allele specific PCR is the method of choice for this thesis due to its 
high levels of sensitivity and specificity, cost-effectiveness and lower DNA 
input requirements and current expertise in the lab. It was therefore 
necessary to optimise methods of cellular subset sorting, DNA extraction 
and quantification specific for this study, and the best allele specific PCR 
assay to use. 
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4.3. Cellular Composition of the ‘Neutrophil Cell Pellet’ 
Monocyte, DC and lymphocyte subsets were sorted from lymphoprepped 
PBMCs by the methods described previously (see section 2.4.2, pg. 71). 
However, due to the higher density of neutrophils, they cannot be isolated from 
peripheral blood in the same way. Therefore it was important to determine the 
exact cellular composition of the ‘neutrophil pellet’ after lymphoprepping 
samples, to ensure that this could be defined as a pure neutrophil fraction in 
further experiments in this thesis.  
 
As described in section 2.3.1 (pg. 68), neutrophils were instead isolated 
from the cell pellet formed at the bottom of the tube during lymphoprepping of 
samples (Figure 4.1.A). As this isolation is based only on density centrifugation, 
it was important to ascertain the true cellular content of the cell pellet. This was 
achieved by running 6 ‘neutrophil cell pellets’ from fresh LCH patient samples 
on the DC profile panel discussed insection2.6.1, pg. 76. 
 
Neutrophils were distinguished by their high SSC-A, medium FSC-A and 
positivity for CD11c (Figure 4.1.B). The majority (66-88%) of events were 
neutrophils, there was also 9-20% debris and <2% ‘other cells’ (Figure 4.1.C). 
From the 2% ‘other cells’, 40-85% (0.8-1.7% of total events) were T cells, and 
11-44% (0.2-0.9% of total events) were HLA-DR-Lineage- cells (Figure 4.1.D). 
All other cell types constituted <4% of the ‘other cell’ fraction, <0.08% of the 
total.  
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Figure 4.1. Cellular Composition of the ‘Neutrophil Cell Pellet’ 
A. Diagrammatic representation of a sample post lymphoprep. Showing 
density based separation of plasma, PBMCs, lymphoprep solution, RBCs 
and the ‘neutrophil cell pellet’. 
B. Flow cytometry schematic of neutrophil isolation from the ‘neutrophil cell 
pellet’. Neutrophils are identified from all events by high SSC-A and 
medium FSC-A (1) and then by positive expression of CD11c (4). 
Contaminates include debris (2) and ‘other’ cells (3). 
C. Percentage of total events which are debris, neutrophils or ‘other’ cells of 
the fresh ‘neutrophil cell pellets’ of six LCH patients. Showing the majority 
of events (66-88%) to be true neutrophils. 
D. Composition of the ‘other’ cell gate of (3) by percentage of cell types (see 
section Figure 2.2, pg.  77for gating strategy) 40-85% (0.8-1.7% of total 
events) was T cells, and 11-44% (0.2-0.9% of total events) was HLA-DR-
Lineage- cells. 
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4.4. DNA Recovery Optimisation 
The processes involved in sample preparation for the allele specific PCR 
assay are complex, including sample density centrifugation, cell staining and 
sorting, DNA extraction and finally PCR. There are several variable options to 
use during this processing, so the outcomes of certain variables were compared 
to optimise the results.  
 
4.4.1. Pre-Amplification 
One option to allow for a greater sensitivity of mutation detection 
would be to amplify the DNA pre-PCR. This would allow for small numbers 
of cells >1,000 per well to be analysed. For this study, pre-amplification 
was not employed, as it reduces the potential sensitivity of the assay. I.e. if 
less than 1,000 cells are used per well, it is impossible to say with certainty 
that the mutation can be detected down to 0.1%. 
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4.4.2. NanoDrop Readings 
A total of 2-20ng DNA is recommended for use in the different allele 
specific PCR kits. In order to keep input DNA consistent, at the outset of 
testing a NanoDrop (www.nanodrop.com) was used to quantify DNA in the 
samples. However, the sensitivity of the NanoDrop analyser at the low 
concentrations of DNA expected from patient samples is unknown. 
 
In order to test the sensitivity of the NanoDrop at low DNA 
concentrations three separate serial dilutions were created from normal 
PBMCs from three different donors, originally quantified by viCell analysis. 
These dilutions were at the following cell numbers: 100k, 50k, 10k, 1k, 
100, 10, 1 and a further 10x dilution which would theoretically equate to 
0.1 cells. DNA was extracted from these preparations using Qiagen DNA 
micro kits and the quantity of DNA was measured on the NanoDrop 
analyser. The average DNA content of mononuclear cells is 6pg(Baechtel, 
1989), therefore an expected curve could be created of the maximum DNA 
quantity possible to extract from each set number of cells.  
 
As can be seen in Figure 4.2.A, samples with a DNA concentration 
of less than ~10ng/µl, may have falsely high NanoDrop analyser 
concentration readings. Figure 4.2.B shows the NanoDrop analysed 
260/280 and 260/230 ratios of DNA purity. As can be seen, there appears 
to be correlations between low DNA concentrations and less pure 
samples. This could be due to incorrect NanoDrop analysis at low DNA 
concentration, or there could be a link between low DNA concentration 
and higher levels of contaminates from the DNA extraction process. 
 
As this study involves samples with small numbers of cells, and to 
make sure enough DNA was used in the PCR assay, it was decided to 
base the volume of DNA used on the original cell count prior to DNA 
extraction, instead of potentially inaccurate NanoDrop DNA concentration 
readings.  
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Figure 4.2. Known Cell Number NanoDrop Sensitivity Testing 
A) NanoDrop readings (ng/µl) in samples of DNA extracted from set numbers of 
cells and eluted into 20µl. Black line indicates the expected maximum 
quantity of DNA extractable, based on 6pg DNA per cell. Coloured lines 
indicate 3 replicates of the sample preparation and DNA extraction.  
B) NanoDrop 260/280 and 260/230 readings from samples with differing 
expected concentrations of DNA. DNA samples with 260/280 ratios of ~1.8 
and 260:230 ratios of 2.0-2.2 are considered pure. 
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4.5. Available Mutation Detection RT-PCR Assays 
There are currently three BRAFV600E specific mutation detection PCR 
assays available from; Qiagen (www.qiagen.com); Life Technologies 
(www.lifetechnologies.com) and GeneFirst (www.genefirst.com). The following 
section of this chapter covers a comparison of the available assays, in order to 
ensure that the most reliable and cost-efficient assay was used. 
 
4.5.1. Qiagen Assay 
The assay from Qiagen is a ‘qBiomarker Somatic Mutation PCR 
Assay’ which employs Amplification Refractory Mutation System (ARMS®) 
primer-based allele discrimination and Hydrolysis Probe-based 
quantitative real-time PCR technology. 
 
ARMS® technology, otherwise known as allele-specific PCR can be 
used to detect single base pair mutations. First described by Newton et al, 
(Newton et al., 1989), the system works by splitting 5-10ng of DNA 
between two PCR wells; one containing a mutation primer specific for 
BRAFV600E, the other containing a reference primer specific for a non-
variable region of the BRAF gene (Figure 4.3). Taq polymerase is then 
able to discriminate between a match and a mismatch at the 3’ prime end 
of the PCR primer. 
 
Post RT-PCR, the threshold cycle (CT) values of each well are 
compared to get the delta CT (dCT). The reference primer specific well 
gives a quantification of the total number of the alleles in the well, and the 
mutation primer specific well gives the percentage of alleles which contain 
the BRAFV600E mutation. The CT value (CTMut) from the mutation specific 
assay is inversely correlated to the abundance of mutant DNA in the 
sample (Equation 4.1). 
 
Delta CTTest = CtMut – CtRef 
Equation 4.1. Calculation of Delta CT (dCT) of the Test 
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The QIAGEN assay uses HotStart DNA Polymerase to prevent non-
specific amplification during the set up process, before a 95°C, 10 minute 
activation step and a ROX passive reference dye to compensate for non-
PCR related variations in fluorescence detection. 
 
4.5.2. Life Technologies Assay 
The assay from Life Technologies is a ‘TaqMan® Mutation 
Detection Assay’. This works in the same way as the Qiagen, although it 
has two additional benefits; Competitive Allele-Specific TaqMan® PCR 
(castPCR), and optional Internal Positive Controls. CastPCR, developed 
by Life Technologies combines the mutation allele specific TaqMan® 
quantitative PCR (qPCR) with MGB oligonucleotide blockers which are 
specific for the wild-type allele, thus blocking any wild-type background 
amplification and allowing higher specificity and sensitivity than normal 
qPCRs (Figure 4.3). Life Technologies have performed spiking 
experiments which demonstrate that the assay sensitivity is below 0.1%.  
 
The optional Internal Positive Control (IPC) can be duplexed with 
any TaqMan® Mutation Detection Assay, using an exogenous non-human 
DNA target and probe for a robust PCR-positive signal. This allows 
detection of low copies or target DNA while providing a distinction between 
a mutation target negative result and a PCR fail result. 
 
4.5.3. GeneFirst Assay 
In January 2011, a new molecular diagnostics company named 
GeneFirst was founded by Guoliang Fu from Oxford University. This 
company now offers a further BRAFV600Emutation detection assay using 
Multiplex Mutation Detection (MMD) PCR. The benefit of this type of PCR, 
is that only one well is required which contains a mutation primer 
(HEX/FAM signal), and an endogenous control (ROX signal), thus less 
DNA is required. This assay has a stated sensitivity of 1% (1.5-3ng DNA) 
or 0.1% (15-30ng DNA). Although this assay was not used in this study, 
comparative assessment of this assay versus the used Life Technologies 
assay may be beneficial to future work.  
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Figure 4.3. Mutation Detection RT-PCR Assay Figures 
A. For both the Qiagen and Life Technologies assays, DNA is split between two PCR 
wells; well one contains a mutation primer specific for BRAFV600E, well two contains 
a reference primer specific for a non-variable region of the BRAF gene. 
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B. The Life Technologies assay also contains a wild-type allele specific blocker within 
well one, which suppresses wild-type alleles, preventing non-specific amplification. 
C. The TaqMan® Mutation Detection IPC Reagent Kit is a set of optional internal 
positive control reagents that can be duplexed with any TaqMan® Mutation 
Detection assay to provide a positive PCR control result. The IPC reagents can 
distinguish a mutation target negative result from a PCR failure result.(Applied 
Biosystems Assay Manual, 2012). 
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4.5.4. Assay Comparison 
For relative comparisons of the two different assays available at the 
start of this thesis, three separate standard curves were prepared (see 
section 4.6, page 137), with 10,000 cells at concentrations of BRAFV600E of 
0%, 0.001%, 0.01%, 0.1%, 1%, 10% and 100%. Each standard curve 
preparation was performed on both assays on the same day (Figure 4.4). 
As can be seen from the graphs, the Life Technologies assay had lower 
CTs for both positive mutation and reference assays, higher background 
CTs for mutation assays <0.1% and  more consistent CTs overall. Also, 
the CTmut of the QIAGEN assay was between 1.5 and 2.2 CTs lower than 
the CTref. This indicates that the mutation primer is working more efficiently 
than the reference primer in this assay.  
 
The averages of the 3 observed dCT replicates for each assay 
were also compared to the expected dCT for each BRAFV600E positive 
concentration (Figure 4.4.B). The expected dCT was derived from 
Equation 4.2. It can be seen that the Life Technologies assay provided 
dCTs which were almost exactly the same as the expected dCT curve, to 
a limit of 0.1% BRAFV600E in 10,000 cells. The QIAGEN assay dCTs were 
not as ideal and appeared to be less stable. 
 
𝑪𝑻𝑴𝒖𝒕
𝑪𝑻𝑹𝒆𝒇
=
𝟏
𝒏
          𝒏 = 𝟐𝒙          ∴ 𝒙 =
𝒍𝒐𝒈 𝒏
𝒍𝒐𝒈 𝟐
𝒙 = 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐝𝐂𝐓  
 
E.g. 12% BRAFV600E+ 
 
𝟏𝟐
𝟏𝟎𝟎
=
𝟏
𝟖. 𝟑
          𝟖. 𝟑 = 𝟐𝒙          ∴ 𝒙 =
𝒍𝒐𝒈 𝟖. 𝟑
𝒍𝒐𝒈 𝟐
𝒙 = 𝟐. 𝟖𝟖 
 
Equation 4.2. Expected dCT of the Assays 
 
Further details of differences between the two assays are given in 
Table 4.1. The Qiagen assay costs £10/well, whereas the Life 
Technologies assay costs more at £11.63/well, plus £0.27/well if using the 
optional IPC reagent. This extra cost of the Life Technologies assay is 
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somewhat balanced by several benefits; this assay has a lower stated 
sensitivity at <0.1% compared to 1%, increased specificity due to the 
castPCR system, optional IPC, does not need technical replicates, and in 
our hands has fewer problems with bubbles in the reaction mix. For all of 
the above stated reasons, the Life Technologies assay was chosen for this 
project. 
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Figure 4.4. BRAFV600E Mutation Allele PCR Assay Comparison 
A. Comparison of three different standard curve preparations of 10,000 cells 
at 0%, 0.001%, 0.01%, 0.1%, 1%, 10% and 100% BRAFV600E positivity run 
on both assays on the same day. 
B. Comparison of the averages of the dCTs of the above standard curves for 
each assay, compared with the expected dCTs derived from Equation 4.2. 
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Factor  Qiagen Life Technologies 
Total Cost  £10/well  £11.63/well 
Stated 
Sensitivity  
1%  <0.1%  
Specificity  No background blockers.  Increased due to castPCR 
blockers  
Recommended 
DNA  
5-10ng  2-20ng (2ng for 1% detection, 
20ng for 0.1% detection)  
Cycling 
Conditions  
a) 10 mins, 95°C, 1 cycle 
b) 15 sec, 95°C then 
c) 1 min, 60°C, 40 cycles 
a) 10 mins, 95°C, 1 cycle 
b) 15 sec, 92°C then 
c) 1 min, 58°C, 5 cycles 
d) 15 sec, 92°C then 
e) 1 min, 60°C, 5 cycles 
Replicates  Triplicates Recommended Technical replicates not 
required  
Bubbles  Bubbles more frequent Less bubbles, possible due to 
less H2O in the reaction 
Other  Cannot purchase individual 
components of kit  
IPC Kit sold separately 
(£0.27/well) 
Mutation Detection Software 
available 
Table 4.1. BRAFV600E Mutation Allele PCR Assay Comparison 
A comparative summary of the two allele specific PCR assays is provided. 
CastPCR = Competitive Allele-Specific TaqMan® PCR. 
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4.5.1. Optimal Starting Cell Numbers 
As the level of DNA was to be based on starting cell number rather 
than NanoDrop DNA concentration readings, it was important to assess 
the optimal and minimum number of cells to begin DNA preparation from. 
Triplicate standard curves of three separate serial dilutions were created 
from normal PBMCs from three different donors, originally quantified by 
viCell analysis. These dilutions were at the following cell numbers: 40k, 4k, 
400, 40, 4 and a further dilution equivalent to 0.4 cells. DNA was extracted 
from each dilution using QIAGEN micro DNA extraction kits and eluted in 
20µl H2O. 5µl of the elute was run on the PCR using the reference primer 
so therefore CTref values for input of DNA equivalent to the extraction of 
10k, 1k, 100, 10, 1 and 0.1 could be plotted (Figure 4.5).  
 
As seen from the graph, the average CTrefs from these DNA 
preparations were almost exactly equivalent to the average CTrefs from the 
6 replicate standard curves (see section 4.6), indicating that DNA 
extraction was similarly efficient for these 10k cell extractions as the 
1x10^6 cell extractions for the standard curves. The highest CTref seen for 
wells containing DNA equivalent to 1000 cells was 27.63, so a CTref of 27 
was chosen as the limit for analysis down to 0.1%. Likewise the 10k CTrefs 
were fairly consistent at ~21, so this could be used as a theoretical limit of 
0.01% mutation.  
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Figure 4.5. Determining Optimal Starting Cell Numbers 
CTReference in samples of DNA extracted from set numbers of cells and eluted 
into 20µl. Dashed line indicates the average CTReference of 6 replicate standard 
curves of 10k cells. 
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4.6. Standard Curves 
In order to have a reliable system of determining percentage 
positivity of samples from PCR results, standard curves were created 
using BRAFV600E+ cell line A375, from the American Type Culture 
Collection (ATCC; www.lgcstandards-atcc.org) and a BRAFV600E- Epstein-
Barr virus transformed lymphoblastoid cell line (see section 4.7 for details 
of cell line preparation and culture). 
 
Three replicate standard curves were created from preparations at 
various concentrations of cells (1,000/5µl, 10,000/5µl 50,000/5µl) in order 
to explore the ideal concentrations of cells to use in the assay (See Figure 
4.6.A). As seen in the graph, the 1k curve gave reasonable dCTs down to 
a sensitivity of 1% (10/1000 positive cells), after this point results become 
less reliable. The results for the 10k and 50k curves are remarkably 
similar, indicating that there was no need to add DNA equivalent to more 
than 10k cells into the assay.  
 
Therefore, a series of 6 replicate standard curves were created 
from separate DNA preparations, to extrapolate % positivity of test 
samples. Briefly, cells from each cell line were carefully counted using a 
viCell analyser (Beckman Coulter; www.beckmancoulter.com; 731050). 
DNA was extracted from aliquots of 1x107 cells using Qiagen QIAamp 
DNA Mini Kits (using RNAase as directed) and eluted into 100µl H2O. The 
final volume of DNA prepared from each aliquot was diluted to 5ml in H2O 
to give the equivalent of 10,000 cells/5µl. DNA concentration was 
measured with a NanoDrop  Analyser (Thermo Scientific; 
www.nanodrop.com) and the DNA concentration from the A375 cell line  
was adjusted to match that of the control DNA (approximately 1.5-fold 
dilution). This step is crucial due to the hypotriploid (n=62) nature of the 
A375 cell line. Serial 10-fold dilutions of A375 DNA into control DNA were 
prepared as follows: 100% mutated; 10%, 1%; 0.1%; 0.01% and 0% 
(100% control DNA). 5µl of each dilution was used for reference and 
mutation PCR assays. Aliquots of 12.5µl of each dilution were stored for 
use as internal controls (see section 4.8).  
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The final standard curve was constructed from the dCT means of 
the six 10,000 cell/5µl replicates using GraphPad Prism, plotting mean 
dCT (CTmut-CTref) on the y axis and log %BRAFV600E on the x axis. This 
standard curve was used to interpolate all experimental sample values. 
 
Results with a dCT below 10 (equivalent to the stated sensitivity of 
0.1% BRAFV600E+) were considered positive. Results with dCTs between 
10 and 15 were below the stated sensitivity of the assay, though as no 
control BRAFwt samples (n=15 PBMC, n=30 LCL) had a dCT below 18, 
these results were considered positive outside of the quantitative range 
(POQR), giving a theoretical sensitivity of ~0.05%. Results with a dCT 
above 15 were considered negative to ensure no false positives were 
reported.  
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Figure 4.6. Standard Curve 
Standard curves created using BRAFV600E+ cell line A375 and a BRAFV600E- 
Epstein-Barr virus (EBV) transformed lymphoblastoid cell line (LCLs).  
A) Comparison of standard curves using 1k, 10k, or 50k cell DNA equivalent 
per well. Each curve is the average of 3 technical replicates. 
B) Final standard curve using 10k cell DNA equivalent per well. The curve is 
the averages of 5 technical replicates. The error bars represent SD. 
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4.7. Cell Lines 
4.7.1. A375 BRAFV600E+ Cell Line 
The BRAFV600E+ cell line A375 was acquired from the American 
Type Culture Collection (ATCC; www.lgcstandards-atcc.org) and grown in 
high glucose DMEM (Lonza; www.lonza.com; 4.5g/L Glucose w/ L-
Glutamine 500ml) + 10% heat-inactivated foetal bovine serum (Life 
Technologies; http://www.lifetechnologies.com; 10270-106). 
 
 This cell line was used rather than other BRAFV600E+ cell lines (e.g. 
MV522 or HCC344) as it was available in-house and the mutation has 
previously been validated by our colleagues (Armstrong et al., 2011) using 
Custom Taqman SNP genotyping assays (Applera Europe BV; now 
Applied Biosystems; www.appliedbiosystems.com).  
 
A375 is hypotriploid (n=62) and homozygous for BRAFV600E. In 
order to ascertain the karyotype of the A375 cell line, particularly for 
details of chromosome 7, where the BRAF gene is located, 5 metaphases 
were analysed for cytogenetics. The cell line had the basic standard 
cytogenetic processing for adherent cells. Briefly, the cells were 
exposured for 18hrs with colcemid/BrDU followed by hypotonic treatment 
and trypsin release of cells.  Cells were then harvested using standard 
cytogenetic process (Rooney and Czepulkowski., 1992). Metaphase 
preparations were banded using trypsin & Leishman stain to produce G-
bands (GTL technique) and chromosome abnormalities identified were 
described using ISCN 2013: International System for Human 
Chromosome Nomenclature (Shaffer et al., 2013).   
 
There was very little heterogeneity between the 5 metaphases; 
Trisomy 7 and the three marker chromosomes were present in every cell. 
The overall karyotype was 56~60,XX,add(1)(p1?),+del(1)(q3?2),+3,+4,+5,-
6,+7,+add(11)(p1?),+13,+15,+17,+3mar[cp5](Figure 4.7).  
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Figure 4.7 A375 Cell Line Karyotype 
One of five metaphases analysed for the karyotype of the A375 cell line. There 
was very little heterogeneity between the metaphases, all cells had Trisomy 7 
and the three marker chromosomes. 
 
4.7.2. BRAFV600E-LCL Cell Line 
A BRAFV600E- Epstein Barr Virus (EBV) immortalised 
Lymphoblastoid Cell Line (LCL) was created for use as a negative control. 
Briefly; 1x107 PBMCs were re-suspended per 1ml RF-10 media with an 
equivalent volume of EBV supernatant and incubated for 2 hours at 37oC 
in a CO2 incubator. Cyclosporin A was added to a concentration of 1ug/ml 
incubated overnight as above. The cell suspension was transferred to a 
24-well plate at approximately 0.6ml per well, a further 1ml 1ug/ml 
Cyclosporin A was added and the plate was incubated for 1 week as 
above. 1ml supernatant from each well was removed and replaced with 
1ml fresh 1ug/ml Cyclosporin A, and the plate was incubated for 1 week 
as above. When the cells had started to grow, they were transferred to a 
25cm2 flask in 7ml RF-10 and passaged as appropriate. 
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4.7.3. A375 and LCL Cell Line Morphology 
May-Grünwald-Giemsa staining of the A375 and LCL cell lines 
can be seen in Figure 4.8. The majority of both cell types were large 
cells, up to 40µm in diameter. The A375 cell line is often described as 
epithelial-like (ATCC, 2014). In the cultures used in this thesis, the 
A375 cells appeared with large, thick dendrites and a high amount of 
cytoplasm containing some small vacuoles. The nuclei were irregular 
with one or more large nucleoli. The LCL cells used in this study were 
generally slightly smaller, with very fine dendrites and a lower 
cytoplasm:nucleus ratio. Cytoplasm often contained a high number of 
medium sized vacuoles. Nuclei were round or irregular with several 
medium sized nucleoli.  
 
 
Figure 4.8 A375 and LCL Cell Line Morphologies 
Cytospin slides where prepared from cells freshly taken from culture and 
stained with May-Grünwald-Giemsa (pH 6.8) on a Sysmex SP-1000i. 
Photographs were taken on a Zeiss Axioimager Z2 microscope with AxioVision 
4.8 software at 100 times magnification. Scale as indicated. 
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4.8. Internal Controls 
As well as using the IPCs provided by Life Technologies, which allow for 
a determination between a negative BRAFV600E result and a failed PCR 
reaction, a series of in-house IPCs were created to ensure that the mutation 
and reference primers used in the assay were working efficiently throughout the 
project. These IPCs were created alongside each replicate standard curve (see 
section 4.6), in order to ensure accuracy. Therefore controls of 10,000 cell 
equivalent DNA at 0%, 0.1% and 10% BRAFV600Epositivity, as well as a no 
template control (NTC) were run on each plate used to test BRAFV600E in patient 
samples. These controls were used to control for false negative results, as well 
as to monitor the sensitivity of the assay over time (Figure 4.9). 
 
Over the period of this study, the controls from two preparations were 
used as internal controls. As can be seen from Figure 4.9.A, the CTref levels of 
both control sets used were reasonably consistent throughout, indicating that all 
of the controls had equivalent levels of total DNA. However some variation was 
seen in CTmuts in control set 1. As control set 2 had remarkably stable CTref 
levels in 0.1% and 10% mutation samples, it can be assumed that the variances 
seen in control set 1 are due to incorrect sample preparation (possibly inefficient 
mixing before aliquoting), rather than fluctuations in the PCR analyser. Also, at 
no point during PCR testing did the CTmut of the 0% control (lowest CTmut = 
39.81) crossover with the 0.1% control (highest CTmut = 38.01), see Figure 
4.9.B. Therefore a sensitivity of 0.1% can be stated with confidence, and it was 
not necessary to normalise any patient results. 
 
As seen in Figure 4.9.C, there was also no overlap of dCTs between 0% 
and 0.1% controls. Interestingly, the average dCTs of the 0.1% and 10% 
controls were higher than the original levels set by the standard curve averages, 
whereas the mean of the 0% dCTs is almost exactly the same. Standard curves 
were run fresh, but controls had been frozen and defrosted, so these 
discrepancies could indicate that BRAFV600E DNA may be more fragile than 
BRAFWT and thus more easily degraded during the freeze/thaw process.  
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4.8.1. BRAFWT Control PBMCs 
In order to determine the average background activity of the 
mutation primer, a total of fifteen samples of 50k BRAFWT PBMCs were 
run with the BRAFMutation and BRAFReference assays, either to 40 or 50 
cycles. None of these samples, or the 10k 0% BRAFV600E control samples 
had a CTmut below 40 cycles (see Figure 4.9.D), indicating that results for 
CTmut below 40 can be treated as true positive results. The lowest dCT of 
the control PBMC samples was 13.57 when run to 40 cycles and 19.47 
when run to 50 cycles (data not shown). This indicates that the ability to 
distinguish positive from false-positive results is greatly increased when 
running to 50 cycles. 
 
4.8.2. PCR Amplification Curve Visual Control 
After each PCR experiment, the amplification curves were 
examined for credibility. In order to be accepted as accurate, the curves 
had to be distinct with a linear amplification phase. 
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Figure 4.9 Internal Positive Controls 
A) In-house internal positive control CTmut and CTref results as run on each PCR 
plate over a period of one and a half years. Vertical black lines indicate the 
transition between control sets. The limit of the test was CT 50 as indicated 
by the wide dashed horizontal line. 
B) Separate graphs of CTmut and CTref as above. Error bars are means with SD. 
C) dCTs (CTmut - CTref) of all in-house controls. Horizontal dotted lines indicate 
the average dCTs of 6 replicate serial dilution standard curves from which the 
control samples were derived. Error bars are means with SD.   
D) CTmut results of thirty in-house 10k 0% BRAFV600E controls and fifteen 50k 
BRAFwt PBMC samples. At no point does the dCT result for these samples 
drop below 18 (Lowest CTmut level was 40). 
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4.9. Discussions for Chapter Four 
Allele-specific PCR for BRAFV600E was adapted to analyse fractions 
of peripheral blood and bone marrow mononuclear cells in a quantitative 
fashion. The PCR detection protocol was developed using a TaqMan® 
Mutation Detection Assay (www.invitrogen.com), which was found to be 
the most sensitive and reproducible of the two assays available at the start 
of this thesis. This assay involved splitting the DNA between two PCR 
wells, one containing a mutation primer specific for BRAFV600E, the other 
containing a reference primer specific for a non-variable region of the 
BRAF gene. The mutation detection well also contained a Competitive 
Allele-Specific TaqMan PCR assay which acts as a blocker of the wild-
type allele at the location of BRAFV600E, reducing non-specific 
amplification. 
 
Due to the lack of necessary sensitivity of available DNA 
quantification equipment (NanoDrop), DNA was estimated on original 
number of input cells.  In order to maximize sensitivity, 10,000 nuclear 
equivalents of DNA (approximately 60ng) were amplified in each assay.  A 
detection limit of 0.1% (10/10,000 cells) was confirmed by titration of the 
BRAFV600E mutated melanoma cell line A375 into BRAF wild-type EBV-
transformed B cells from healthy volunteers. The DNA levels of the 
BRAFV600Epositive cell A375 line were diluted down to the levels of the 
LCL line due to hypotriploid cytogenetics in A375. 
 
The assay has a sensitivity of 0.1% (dCT <10, CTref cut-off 27), 
although it was possible to define a region of the curve that was positive 
outside the linear quantitative range (POQR) corresponding to 0.05-0.1% 
positivity (dCT 10-15, CTref cut-off 21) but for the current purpose, results 
in this range were treated as negative. PCR assays were run to 50 cycles, 
though a CTmut above 40 was considered negative and CTref above 27 
were considered fails. Life technologies IPC kits, in-house controls (10,000 
cells, 0%, 0.1%, 10% mutation) and visual examination of all PCR curves 
were used to ensure validity of results. 
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Chapter 5. Tracking BRAFV600E in Histiocytic Disorders 
 
5.1. Introduction 
In Chapter 3, I examined a known bone marrow haematopoietic disorder 
(AML) and its implications on the dendritic cell/monocyte system. In this chapter 
I will relate a known dendritic cell/monocyte system disorder (Histiocytosis) to 
the bone marrow haematopoietic system. 
 
The work in this chapter concerns comparative flow cytometry of the 
histiocytic disorder, Langerhans cell histiocytosis (LCH) and Erdheim Chester 
disease (ECD), as well as hairy cell leukaemia (HCL). Also, allele-specific PCR 
assays are used to determine cells which contain the BRAFV600E mutation, and 
which may potentially be precursors of the diseases. 
 
5.1.1. Chapter Aims 
1) To compare the distribution of BRAFV600E in peripheral blood 
mononuclear cells (PBMC) of LCH, ECD and HCL. 
 
2) To test whether BRAFV600E is present in the bone marrow (BM) 
haematopoietic stem cell. 
 
5.1.2. Langerhans Cell Histiocytosis and Erdheim Chester Disease 
Langerhans Cell Histiocytosis (LCH) and Erdheim Chester Disease 
(ECD) are rare histiocytic disorders with highly distinct pathological and 
clinical features.  LCH cells express langerin, CD1a and Birbeck granules 
and cause granulomatous lesions predominantly in the bone, epithelia and 
haematopoietic organs (Nezelof et al., 1973; Allen et al., 2010).  ECD 
lesions show abundant CD68+ foamy macrophages and affect the distal 
long bones, skin (xanthelasmata) and cardiovascular tissue (Haroche et 
al., 2012b). LCH is found in both children and adults while ECD is 
predominantly found in adults. Both diseases can lead to organ 
impairment, disability and death. 
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5.1.3. The Origin of LCH/ECD Cells 
LCH cells have a number of similarities with epidermal Langerhans 
Cells (LCs) including Birbeck Granules, Langerin and CD1a 
expression(Nezelof et al., 1973), but the relationship between LCH cells 
and LCs or LC precursors remains undefined.  LCH cells have a different 
gene expression pattern to LCs (Allen et al., 2010; Hutter et al., 2012), 
also mouse studies have shown that langerin is not specific to LCs 
(Ginhoux et al., 2007) and indeed langerin and CD1a can be expressed by 
other subsets of human DCs(Bigley et al., 2014). It has been shown that 
LC-like cells can be formed from CD34+ BM progenitor cells (Caux et al., 
1992; Strobl et al., 1997; Ratzinger et al., 2004; Klechevsky et al., 2008) 
and circulating monocytes(Geissmann et al., 2001; Hutter et al., 2012), so 
it is possible that LCH cells may originate in the bone marrow or from 
circulating myeloid cells.  
 
As ECD cells have a macrophage-like appearance, they are 
thought to be derived from circulating myeloid cells, though as both LCH 
and ECD can coexist in individual patients (Hervier et al., 2014), another 
possibility would be that both diseases may originate from an early stem 
cell with the ability to produce both cell types.  
 
5.1.4. Genetic Mutations in Histiocytosis 
Recent observations indicate that the histiocytes in both diseases 
harbour single monoallelic mutations of BRAF, MEK, RAS or other 
regulatory/survival pathway members that presumably prevent the 
resolution of inflammation and allow a progressive accumulation of 
abnormal cells. 50-70% of LCH and ECD lesions harbour BRAFV600E 
mutations (Badalian-Very et al., 2010; Haroche et al., 2012b). Two BRAF 
wild-type ECD patients have since been shown to express the 
NRASQ61Rmutation (Aitken et al., 2014; Emile et al., 2014). The ability to 
detect pathogenic mutations at high sensitivity allows several important 
questions to be addressed: 
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5.1.5. Chapter Hypotheses 
1) Allele specific PCR of the BRAFV600E mutation in peripheral blood and 
bone marrow will identify potential precursor cells of the histiocytic 
disorders LCH and ECD.  
 
2) The distribution of BRAFV600E alleles will correlate with the type of 
histiocytosis and other clinical variables.   
 
3) Allele specific PCR of the BRAFV600E mutation will be useful for 
diagnosis and/or disease monitoring of patients with LCH and ECD.  
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5.2. Materials and Methods for Chapter Five 
5.2.1. Patient Samples and Clinical Data 
Blood, skin, bone marrow and surplus biopsy material was obtained 
from LCH, ECD and HCL patients.  Blood and skin was obtained from 
healthy volunteers or patients undergoing plastic surgery.  All samples 
were acquired with ethical approval from the Newcastle and North 
Tyneside Research Ethics Committee (Appendix 8).  Patients with 
histiocytosis were referred to a local clinic and gave consent for ethically 
approved use of their clinical data.  Disease activity was assessed by 
biopsy at diagnosis or subsequently by physical and radiological 
examination including magnetic resonance imaging and positron emission 
tomography.  See Figure 5.1 for patient recruitment and Table 5.1 for 
detailed patient clinical characteristics. 
 
 
Figure 5.1. Patient Recruitment 
LCH = Langerhans Cell Histiocytosis; ECD = Erdheim Chester Disease; HCL = 
Hairy Cell Leukaemia; SS = Single-System; MS = Multi-System; MF = Multi-
Focal; BM = Bone Marrow; RP = Retroperitoneum; CNS = Central Nervous 
System. 
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5.2.1. Lesional BRAFV600E testing 
Genomic DNA from formalin-fixed paraffin embedded LCH lesions 
was extracted using Promega Maxwell Tissue DNA Purification Kits 
(Promega; www.promega.co.uk) and the region flanking codon 
600amplified by PCR.  Amplicons were purified and genotyped by primer 
extension for the c.1799T>A, p.Val600Glu (V600E) mutation using the 
Sequenom iPlex protocol (Sequenom; www.sequenom.com).  The 
extension products were detected by MALDI-TOF Sequenom mass 
spectroscopy using a Sequenom Typer 4.0. 
 
5.2.2. BRAFV600E allele-specific PCR 
Peripheral blood and bone marrow cell subsets were sorted as 
previously described (see section2.4.2, pg. 71). Genomic DNA from sorted 
cells and neutrophil pellets (see section2.3.2, pg. 69), LCH lesion cells or 
control cell lines was extracted using Qiagen micro-kits (Qiagen; 
www.qiagen.com). BRAF mutation and reference qPCR was performed 
with competitive allele-specific TaqMan® mutation detection assays: 
Mutation Allele Assay: BRAF_476_mu 4465804 Hs00000111_mu; Gene 
Reference Assay - BRAF_rf - 4465807 Hs00000172_rf, according to the 
manufacturer’s instructions (Life Technologies; www.lifetechnologies.com). 
A standard curve was derived from 6 serial dilutions of genomic DNA from 
BRAFV600E melanoma cell line A375and EBV-transformed LCLs. 0%, 0.1% 
and 10% V600E mutation controls were performed with every run. The 
percentage of BRAFV600Emutation was determined from the dCT 
(CTreference-CTmutant) using the standard curve. Graphs were plotted with 
Prism Version 5.0 (GraphPad Software, Inc.).For further details of this 
methodology, see Chapter 4. 
 
5.2.3. Sanger Sequencing 
Genomic DNA was amplified from the pellets of 90-3,600 sorted 
cells using the REPLI-g Mini Kit (Qiagen; www.qiagen.com) according to 
manufacturers’ instructions.  The amplified DNA was then diluted 1:20 and 
3 µl of the diluted DNA was then used as a template in the PCR reaction.  
All reactions were performed on a 2720Thermal Cycler (Applied 
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Biosystems; www.appliedbiosystems.com). The cycling conditions were as 
follows: initial denaturation for 15 min at 95 C, followed by 35 cycles of: 
30 secs at 95 C, 30 secs at annealing temperature of 55 C and 1 min at 
72 C with a final extension for 10 min at 72 C. The reaction volume of 30 
µl contained DNA, 1 PCR Buffer containing 1.5mM MgCl2 (Qiagen), 0.25 
mM dNTPs, 0.5 µM each primer and 1U HotStar Taq DNA Polymerase 
(Qiagen).  The nucleotide sequences of the primers used for PCR 
amplification of the NRASQ61R mutation were the following: NRAS Forward 
5’- GTGGTAACCTCATTTCCCCA-3’ and NRAS Reverse 5’- 
GGGACAAACCAGATAGGCAG with a specific product size of around 400 
bp.  PCR products were visualised on a 2% (w/v) agarose gel with added 
ethidium bromide and then prepared for sequencing.  The clean-up 
reaction contained 15 µl of PCR product, 30 U Exonuclease I (Thermo 
Scientific; www.thermoscientific.com) and 3 U FastAP Thermosensitive 
Alkaline Phosphatase (Thermo Scientific).  The reactions were then 
incubated at 37 C for 30 mins.  The reactions were stopped by heating 
the mixture at 85 C for 15 mins.  This clean-up reaction removes 
unincorporated primers and degrades unincorporated nucleotides.  The 
resulting PCR products were then ready to use for sequencing without 
additional purification.  Around 80 ng (20 µl) of purified PCR product was 
sent to SourceBioscience (www.sourcebioscience.com) for Sanger 
Sequencing along with 100 µl of NRAS forward and reverse primer at 3.2 
µM concentration.  The sequencing traces were analysed using Chromas 
Lite v2.1 software (www.chromas-
lite.software.informer.com).Chromatogram peaks were then measured and 
the relative peak height percentage was calculated using the peak height 
of one allele divided by the sum of the peak heights of both alleles.                  
 
5.2.4. Statistical methods 
Kruskal-Wallis non-parametric tests (not assuming Gaussian 
distributions) with Dunns’ multiple column comparison post-tests and/or 
Fisher’s exact tests were performed using GraphPad Prism 5.0 software. 
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5.3. Results 
All analysis was performed after some patients had received 
cytoreductive therapy but no patients were on active treatment.  No statistical 
differences were seen in treated or untreated patients. 
 
5.3.1. Langerhans Cell Histiocytosis Patients 
Over the period 2011-2013, 13 cases of adult LCH were referred to 
the Northern Centre for Cancer Care (NCCC), Newcastle, UK. Five 
patients had BRAFV600E+ lesions, 3 with multi-system (MS) LCH and 2 with 
single system (SS) LCH bone disease.  One of the BRAFV600E+MS 
patients was subsequently found to have advanced aortitis due to co-
existent ECD (A2712). 
 
In agreement with the BRAF status defined by primer extension 
assays (Table 5.1), allele specific PCR confirmed the presence of 
BRAFV600E in lesions from 2 of the 3 multisystem LCH patients. 
Unfractionated PBMC contained mutated BRAF at 0.33 and 3.29% in 
A2712 and A2951, respectively. 
 
The third MS LCH patient with quiescent disease on maintenance 
chemotherapy had no detectable mutated BRAF in the blood; 2 other 
patients withBRAFV600E+ SS LCH, 1 active at the time of evaluation, were 
also BRAFV600E negative in blood.  BRAFV600E mutation was not detected 
in the blood of the 8 patients with BRAFV600E negative lesions.  The 
association between positive BRAFV600E in peripheral blood and active MS 
LCH in this small sample did not reach significance (p= 0.067 by Fisher’s 
exact test). 
 
LCH cells and lymphocytes from a skin lesion of patient A2712 
were sorted and tested for BRAFV600E. Results showed 46.24% mutational 
alleles in the LCH cells, and only 0.51% in the T Cells, which translate as 
at least 92.5% positivity of LCH cells and <1% BRAFV600E in lymphocytes.  
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Figure 5.2. Lesional Cell Sorting in LCH Patient A2712 
Gating strategy for cells in the LCH lesion of patient A2712. Leukocytes were 
isolated by expression of CD45. Antigen presenting cells were gated by 
expression of HLA-DR and T cells were sorted by low SSC-A and lack of HLA-
DR expression (A). Macrophages were excluded by autofluorescence. LC/LCH 
cells were sorted by high expression of both CD1a and Langerin (B). 
 
 
5.3.2. Erdheim Chester Disease Patients 
Over the period 2013-2014, samples were taken from 7 cases of 
ECD who were patients at the Memorial Sloan Kettering Cancer Centre 
(MSKCC), New York, USA. One further patient was referred to the NCCC, 
presenting with skeletal ECD and was found to have pathological evidence 
of LCH confined to bone (A2867).   
 
Seven patients, including the patient with co-existent LCH had 
BRAFV600E+ lesions, 5 with multi-system (MS) ECD and 2 with single 
system (SS) skin or bone disease. The lesion BRAFV600E-patient was 
previously shown to be positive for an NRASQ61R mutation, by the group at 
MSKCC (Emile et al., 2014). 
 
BRAFV600E mutation was detected in the whole PBMC of 5/7 
lesionBRAFV600E+ECD patients, however two of these patients (A7343 and 
A7349) were positive outside of the quantitative range (POQR). In these 
two patients, the mutation was detected above the limit of detection of 
0.1% when subsets were enriched. The SS ECD patient with co-existent 
LCH was negative for BRAFV600Ein the PBMC. The final patient, who had 
ECD restricted to the central nervous system (CNS) and orbits, was 
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negative for BRAFV600Ein the PBMC, and enriched fractions did not reach 
levels above POQR (highest level in Lineage-DR- cells; 0.03%).See 
Figure 5.1 for patient recruitment and Table 5.1 for detailed patient clinical 
characteristics. 
 
5.3.3. Hairy Cell Leukaemia Patients 
Over the period 2013-2014, 5 cases of HCL and 1 HCL variant 
were referred to a clinic in the North of England. Four patients had 
BRAFV600E+ cells in the peripheral blood, one patient who had previously 
had cladribine treatment and the HCL variant patient were both BRAFV600E 
negative. See Figure 5.1 for patient recruitment and Table 5.1 for detailed 
patient clinical characteristics. 
  
 
5.3.4. Peripheral Blood Diagnostic Full Blood Count (FBC) Profiles 
In order to ascertain whether there were any abnormal expansions 
or deficiencies in blood cell counts, Full Blood Count (FBC) results from 
each patient at the time of peripheral blood sample collection for this 
project, were gathered from the diagnostic laboratories. The LCH patients 
showed heterogeneity in terms of white blood cell counts (WBC) as well as 
in neutrophil counts. The two multi-system LCH patients showed an 
obvious increase in total WBC and monocyte fractions and a slight or 
severe thrombocytopenia. The majority of LCH patients were within the 
95% CI for total lymphocyte counts, whereas all of the ECD patients were 
low or below the 95% CI. All of the ECD patients were also within the 95% 
CI for platelets. HCL patients were variable for all cell types, with general 
decreases in monocytes and platelets. Haemoglobin levels were low for 
nearly all patients of all groups, the ECD and HCL means being slightly 
lower than the LCH means. 
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Figure 5.3. Peripheral Blood Diagnostic Full Blood Count Profiles 
Comparison of automated diagnostic blood counts of patients with LCH (n=13), 
ECD (n=7) and HCL (n=6). Grey line is the standard range. Analysis was 
performed as previously described. WBC = White Blood Cells; Hb = 
Haemoglobin. Error bars show medians. Statistical analysis with Kruskal-Wallis 
non-parametric tests and Dunns’ multiple column comparison post-tests. * p 
<0.05; ** p <0.01. 
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5.3.5. Peripheral Blood Mononuclear Cell Phenotypes 
The FBC analysis given in section 5.3.4, page 156 gives 
comparative results on bulk cell types such as lymphocytes and 
monocytes, however, I have previously shown in this thesis that these cell 
types can be subdivided into several subsets. Therefore, flow cytometric 
profiling of the subsets was performed to analyse whether any specific 
subset expansions or deficiencies were present which were potentially 
masked in the bulk cell profiling. 
 
Absolute counts of CD14+  and CD14+16+ monocytes and total 
CD11c+ mDCs were increased in some patients with LCH, compared with 
healthy controls, notably those with active disease, whereas CD16+ 
monocytes appeared relatively depressed. Conversely in ECD, CD16+ 
monocytes were more often within the 95% Confidence Interval (CI) of the 
normal range and CD14+ monocytes were relatively diminished. 
 
CD141+ mDCs and CD123+ pDCs were not substantially increased 
in either LCH or ECD patients although CD123+ pDC levels were 
heterogeneous. CD141+ mDC levels appeared to be deficient in the ECD 
patients, however patient numbers with data for this cell fraction were 
more limited. As expected, HCL patients had an almost total deficiency in 
all myeloid subsets. 
 
Lymphocyte counts were more heterogeneous than myeloid counts 
in the patient groups. In LCH; T, B and NK cells were not increased. In 
HCL, lymph counts varied considerably and were increased in some 
cases. In ECD, lymphocyte counts were decreased in all of the 
BRAFV600Epatients, but relatively normal in the NRASQ61R patient. Patient 
A2712 was B cell deficient but had received prior therapy with cladribine. 
 
All analyses were performed when patients were not receiving 
active therapy although some had previously received cytotoxic drugs.  
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Figure 5.4. Peripheral Blood Mononuclear Cell Phenotype Profile 
Comparison of controls (n=21, grey bars, indicating 95% CI) and patients with 
LCH (n=13), ECD (n=7) and HCL (n=6) by TruCOUNT analysis. Analysis was 
performed as previously described. pDC: plasmacytoid Dendritic Cell; mDC 
myeloid Dendritic Cell. Error bars show medians. Statistical analysis with 
Kruskal-Wallis non-parametric tests and Dunns’ multiple column comparison 
post-tests.   * p=<0.05; ** p=<0.01. CD123+ pDCs in HCL and T cells in ECD 
were statistically reduced from normal (p=<0.05 for both). 
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5.3.6. Peripheral Blood Cell BRAFV600E Mutation Profiling 
Having demonstrated mutated BRAF in the peripheral blood 
(section 5.2.2, page 152), I sought to map these alleles to a specific 
cellular compartment.  Peripheral blood was separated into mononuclear 
fractions and granulocytes.  Mononuclear cells were further divided into 
CD3+ T cells, CD19+ B cells and HLA-DR+ Lineage- cells, the last 
composed of monocytes and dendritic cells, (Figure 5.5.A).  There was no 
evidence of abnormal populations of mononuclear cells in these patients 
and no cells bearing LCH markers CD1a and Langerin or HCL marker 
CD103 (Figure 5.5.B-C) 
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Figure 5.5. Peripheral Blood Gating Strategies 
A. Mononuclear cell profiling of BRAFV600E MS LCH patients compared with 
control.  Lineage contained CD3/CD19/CD20/CD56.  The CD3 vs. CD19 plot 
was derived from a separate tube.  Populations: A: CD14+ monocytes; B: 
CD14+16+ monocytes; C: CD16+ monocytes; D: CD123+ pDCs; E: CD34+ 
progenitors; F: CD141+ mDCs; G: CD11c+ mDCs; H: CD1c+ mDCs; I: residual 
CD11c+ cells; J: CD19+ B cells; K: CD3+ T cells; *: HCL cells. 
B. Absence of circulating Langerin+ or CD1a+ cells in patients with MS LCH.  
Lesional cells from the skin and PBMC of patient A2712 shown for comparison. 
C. Absence of HCL cells in LCH/ECD patients. CD19+20+ B cell-like cells of 
HCL patient A7264 and ECD patient A7343 shown for comparison. 
162 
 
5.3.6.1. Comparative Gating Strategies 
A recent study found mutated BRAF in CD14+ and CD14- 
fractions of CD11c+ cells (Berres et al., 2014).  As these populations 
are heterogeneous, I sought to resolve the fractions in more detail, to 
find the exact cell types harbouring the mutation. The CD11+CD14+ 
component contains classical and intermediate monocytes while the 
CD11c+14- population comprises CD16+ monocytes, CD1c+ DCs and 
residual CD1c- CD11c+ cells (often counted with CD1c+ DCs as 
‘CD11c+ mDCs’).  The gating strategy used in the aforementioned 
study, and the gating strategy used in this thesis is compared in Figure 
5.6.   
 
 
 
 
 
Figure 5.6. Comparative Analysis of Berres et al Gating Strategy 
Comparison of the gating strategy used in this thesis with the study of Berres et 
al (Berres et al., 2014).  When HLA-DR+ Lineage- cells are displayed as a 2D 
plot of CD11c vs. CD14, CD11c+ CD14+ cells contain two subsets of 
monocytes: (A) CD14+ classical monocytes; and (B) CD14+CD16+ 
intermediate monocytes. CD14- cells contain CD11c+ myeloid cells (C) and 
CD123+ pDCs (D).  The CD11c+ myeloid cells from this gate may be divided 
into three further subsets, the CD16+ non-classical monocyte (E) residual 
CD11c+ mDCs (F) and CD1c+ mDCs (G). 
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5.3.1. Peripheral Blood May-Grünwald-Giemsa Stain Morphology 
In order to evaluate if there were any circulating cells with abnormal 
morphology in the disease types, cytospins of each sorted mononuclear 
cell subtype were made and stained with May-Grünwald-Giemsa. Normal 
samples were processed in a quicker time than disease patients due to 
constraints between clinic times and flow cytometry sorter availability (Max 
6 hours for normal, 18 hours for LCH and HCL), and ECD cytospins were 
from frozen material received from another site.  
 
Evaluation of the cytospins showed no evidence of abnormal 
populations in either LCH or ECD patients (Figure 5.7). HCL also showed 
no abnormalities in the morphology of the normal cell subtypes. This 
absence of abnormal cells suggested that mutated BRAF was harboured 
by leukocytes with a normal phenotype. There may however be 
differences in cellular size, the LCH patient’s monocytes and mDCs, 
particularly the CD16+ monocytes appeared to be larger than the normal 
cells, and both the ECD and HCL cells appeared to be smaller and more 
activated. The small cell sizes in the ECD patient could be an artefact of 
the freeze/thaw process. These observations are only exploratory; many 
more patients would have to be assessed to determine if these are 
common morphologies. 
 
HCL cells were sorted from patient A7264 by positivity staining for 
CD19, 20, 11c and 103. The majority of these cells were medium sized 
and had cytoplasmic projections with a characteristic hair-like appearance. 
The cells had irregular cell membranes containing a moderate amount of 
cytoplasm and round or oval shaped nuclei with well-defined borders and 
overly large nucleoli. A smaller fraction of cells were round in appearance, 
lacking projections and containing several large vacuoles in the cytoplasm. 
 
LCH cells were sorted from a skin lesion of patient A2712 by 
expression of CD1a and langerin. There was heterogeneity in these cells 
for staining intensity and cellular size. The majority of cells were large in 
comparison to circulating DCs, with no or varied amounts of cytoplasmic 
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projections which could be fine like mature DCs, or thicker, similar to the 
BRAFV600E+ cell line A375 (Figure 4.8, pg. 142), or possibly veiled like 
immature DCs. Although large in comparison with normal cells, the nuclei 
of the LCH cells were small in comparison with their size, and were 
irregularly shaped with prominent nucleoli. The cells tended to contain a 
large amount of cytoplasm containing several small vacuoles. 
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Figure 5.7. Cytology of Sorted Mononuclear Fractions 
Cytospin slides were prepared from sorted cells and stained with May-
Grünwald-Giemsa (pH 6.8) on a Sysmex SP-1000i. Photographs were taken on 
a Zeiss Axioimager Z2 microscope with AxioVision 4.8 software at 100 times 
magnification.  Scale as indicated.  
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5.3.2. Peripheral Blood Mononuclear Cell BRAFV600E Profiles 
The cellular subsets from all patients displaying BRAFV600E positivity 
in the PBMCs, were flow cytometrically sorted as in Figure 5.4, and tested 
for BRAFV600E by the PCR methods developed in Chapter 4 in order to 
ascertain the specific identity of the cells containing the mutation. 
 
As was expected, in HCL the majority of mutated alleles were seen 
in the CD11c+CD103+ HCL cells, with some positivity seen in the CD11c-
103- B Cells and NK cells of some patients (Figure 5.8). 
 
In both MS LCH patients BRAFV600E was greatly enriched in all 
fractions of monocytes and CD1c+ mDCs.  Neutrophils and T cells were 
negative but pDCs and B cells were also low positive in A2951.  Although 
some positivity was seen in the CD14+ monocytes, the greatest 
enrichment of mutated BRAF was found in CD16+ and CD14+CD16+ 
monocytes even though these were minor populations relative to CD14+ 
monocytes (Figure 5.8). Residual CD1c- CD11c+ cells were also positive 
in A2951, but at a lower level than CD1c+ DCs. 
 
T cells were negative for the mutation in all patients, and pDCs, B 
cells and NKs were negative or positive to a very low level in all the LCH 
and ECD patients. Surprisingly, no BRAFV600E was seen in ECD patients in 
any of the subsets corresponding to those which were BRAFV600E+ in 
either LCH or HCL. 
 
To gain further insight into the potential of monocytes or mDCs to 
contribute to peripheral LCH cells, the product of BRAFV600E allele 
frequencies and the abundance of each cell fraction were calculated.  This 
demonstrated that 95-98% of the mutated BRAF signal was contained in 
CD14+, CD14+CD16+ and CD16+ monocytes.  The total BRAFV600E 
contribution of CD1c+ mDCs was <2%. 
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Figure 5.8. Peripheral Blood HLA-DR+Lineage- Subsets % Mutation 
The % distribution of BRAFV600Eamong peripheral blood cell subsets.  
nt = not tested (due to low cell numbers); n/a = not applicable.  
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5.3.3. Peripheral Blood Lineage/DR Fractions BRAFV600E Profiles 
In order to exclude any BRAFV600E positive but unidentified 
mononuclear progenitors, the distribution of BRAFV600E was analysed 
across the entire mononuclear population according to four quadrants 
defined by the HLA-DR vs. lineage plot (Figure 5.14).   
 
As expected, in HCL patients the majority of mutated alleles (68-
99%) were localised within the HLA-DR+Lineage+ fraction, which is mostly 
composed of B Cells. The remaining mutated alleles were located in the 
HLA-DR-Lineage+ fraction, and are most likely HCL cells which have 
leaked into this fraction. 
 
In multisystem LCH, BRAFV600E was primarily localised to 
monocytes and CD11c+ mDCs.   Overall, 78-94% of all BRAFV600E alleles 
were found in HLA-DR+, lineage- cells. Only a few percent of BRAFV600E 
signal was recovered in the HLA-DR- lineage- gate or lineage+ fractions, 
indicating that monocytes and DCs were the major carriers. 
 
In contrast, in ECD, BRAFV600E was undetectable in monocytes and 
80-82% of mutated alleles were recovered from the HLA-DR- lineage- 
quadrant.  Further analysis localised these alleles to CD33+ early myeloid 
cells. Thus differences in disease phenotype were reflected in distinct 
patterns of involvement of mononuclear cells. 
 
The HLA-DR-Lineage- fraction of two further ECD patients was 
analysed (see Figure 4.8 for gating strategy) revealing the presence of 
most BRAFV600E alleles in a population of CD33+ early myeloid cells 
(Figure 5.8). Low levels of positivity were seen in other Lin-DR- subsets 
including eosinophils and cells which bore the appearance of innate lymph 
cells. 
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Figure 5.9. Peripheral Blood Lineage/HLA-DR Subsets % Mutation 
The distribution BRAFV600E in sorted HLA-DR-Lineage- PBMC of LCH, ECD and 
HCL patients. Pie chart colours relate directly to Lineage/DR plot inset (control 
sample); Green = Lineage-DR+; Blue = Lineage+DR+; Red = Lineage+DR-; 
Purple = Lineage-DR-. 
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Figure 5.10. Peripheral Blood HLA-DR-Lineage- Subset Sort Gating 
Gating strategy for subsets of the HLA-DR-Lineage- fraction from two ECD 
patients compared with a control. The HLA-DR-Lineage- fraction of live cells is 
gated and split by expression of CD33 and CD123 into three subsets: CD33+ 
Myeloid (A); CD123+ Basophils (B) and a double negative fraction which is 
thought to be comprised mostly of innate lymph cells. This double negative 
fraction was further split by CD16 and CD7 into four sub-fractions (C-F). The 
HLA-DR+Lineage- fraction was split between CD14-CD16- dendritic cells (H) 
and a combined gate of CD14+ and CD16+ monocytes (G). 
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Figure 5.11. Peripheral Blood HLA-DR-Lineage- Subset Results 
A. Cytospin slides were prepared from HLA-DR-Lineage- fractions of patient 
A7349 and stained with May-Grünwald-Giemsa (pH 6.8) on a Sysmex SP-
1000i. Photographs were taken on a Zeiss Axioimager Z2 microscope with 
AxioVision 4.8 software at 100 times magnification.  Scale as indicated.  
B. The % distribution of BRAFV600E mutation among HLA-DR-Lineage- peripheral 
blood cell subsets. Monos = CD14+ & CD16+ Monocytes; DCs = Dendritic 
cells, i.e. All HLA-DR+Lineage-CD14-CD16- cells. 
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5.3.4. Bone Marrow Progenitor Phenotypic Profiling 
In order to evaluate the presence or absence of LCH cells in patient 
bone marrow, and the levels of normal progenitor cells, samples of this 
tissue were run on the bone marrow progenitor cell flow cytometric 
profiling protocols developed earlier in this thesis (section 2.6.3, page 79), 
with the additional inclusion of CD1a and Langerin antibodies to test for 
aberrant LCH cells. 
 
In keeping with pathological examination (data not shown), bone 
marrow specimens of the MS LCH patients contained CD1a+ Langerin+ 
LCH cells by flow cytometry.  Notably, these and any CD14+ cells that 
might contain BRAFV600E were localised exclusively to the CD34- fraction 
of bone marrow mononuclear cells (Figure 5.12.A).  The CD34+ BM 
progenitor population was divided into CD38 high and low fractions and 
subsequently analysed according to expression of CD10, CD45RA, 
CD123 and CD90 to capture hematopoietic stem cells (HSC) and 
committed progenitor fractions (Figure 5.12.B).   
 
The frequency of CD34+ cells was not increased in the MS LCH 
patients, but there was a relative expansion of the HSC and the myeloid 
fractions; common myeloid progenitors (CMP) and granulocyte 
macrophage progenitors (GMP) megakaryocyte/erythroid progenitors 
(MEP) and the uncharacterised CD123high fraction (Figure 5.13).  At the 
time of analysis, both patients had received prior cytoreductive 
chemotherapy.  Multi-lymphoid progenitors (MLP) were decreased in the 
older patient (A2951) and B/NK progenitors were markedly decreased in 
the patient lacking peripheral B cells who had previously received 
cladribine (A2712). 
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Figure 5.12. Bone Marrow Progenitor Cell Profile of LCH Patients 
A. Langerin+CD1a+ LCH cells were detected by flow cytometry in both patients 
with active MS LCH (left panels).  These cells were excluded from the CD34+ 
gates used to analyse progenitors (right panels). 
B. Phenotype of BM from BRAFV600E/NRASQ61Rpatients compared with healthy 
control.  Populations: A: Hematopoietic stem cells (HSC); B: Multi-lymphoid 
progenitors (MLP); C: B/NK cell progenitors (B/NK); D: common myeloid 
progenitors (CMP); E: granulocyte/macrophage progenitors (GMP); F: 
megakaryocyte/erythroid progenitors (MEP); G: CD123high population. 
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Figure 5.13. Bone Marrow Progenitor Cell Profile of LCH Patients 
BM CD34+ progenitor profiles in four patients; two BRAFV600E+ MS LCH, one 
NRASQ61R+ ECD and one BRAFV600E+ HCL. Grey error bars demonstrate the 
median and normal range in healthy controls (n=21) for comparison. CD34+ 
cells are expressed as % of total live cells, all other cell types are expressed as 
% of CD34+ cells. BM aspirate was obtained in parallel with the peripheral 
blood shown previously. 
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5.3.5. Bone Marrow Progenitor BRAFV600E Profile 
To explore the existence of long lived BRAFV600E + progenitors that 
could differentiate into monocytes with BRAFV600E mutation, bone marrow 
CD34+ cells from the two MS LCH patients were sorted and analysed by 
PCR for mutated BRAF. BRAFV600E was present in HSC, CMP and GMP.  
MLPs which have lymphoid, monocyte and DC potential in vitro contained 
a low level of 0.2% BRAFV600E in A2951. 
 
BM was available from one of the HCL patients, but there were very 
few CD34+ cells present. The HCL patient had decreased levels of BNK, 
GMP, MEP and the uncharacterised CD123high fraction, with relative 
increases in HSCs and MLP (Figure 5.13), though the only subset in high 
enough numbers forBRAFV600E mutation testing was the HSCs, which 
were found to be positive to 0.57%.  
 
5.3.5.1. NRASQ61R Mutations in ECD 
Unfortunately no BM was available from any of the BRAFV600E+ 
ECD patients, however BM from the ECD patient with an NRASQ61R 
mutation was analysed. This patient had a relatively low level of BM 
CD34+ cells, with reduced numbers of MPP and BNK and relatively 
increased levels of CMPs, GMPs and MEPs. The CD123high fraction 
was within the normal range. 
 
In this patient, the BM progenitor subtypes were sorted and 
DNA extracted as previously described, then was amplified and 
analysed by Sanger Sequencing for the NRASQ61R mutation. The 
results from the sequencing showed a similar profile to the BRAFV600E+ 
profile in LCH, with positivity in the HSCs, CMPs and GMPs (Figure 
5.14), however the population with the highest degree of mutation was 
the GMPs rather than the CMPs as was seen in LCH. 
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Figure 5.14. Peripheral Blood Subset % Mutation 
A. The % distribution of BRAFV600Eamong bone marrow progenitor cell subsets. 
nt = not tested (due to low cell numbers); n/a = not applicable. BM aspirate 
was obtained in parallel with the peripheral blood shown previously. 
B. Detection of NRASQ61R by Sanger sequencing. Red circles indicate positivity, 
blue circles indicate negativity.  
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5.4. Discussions for Chapter Five 
This chapter describes a high resolution mapping of the BRAFV600E+ 
haematopoietic clonal disease cells in adult patients with LCH, ECD or HCL 
using the techniques established in Chapter 4, alongside multi-parameter flow 
cytometric peripheral blood and bone marrow phenotyping. 
 
5.4.1. Phenotyping 
Consistent with previous reports, no CD1a+ or Langerin+ cells were 
detected in the peripheral blood (Rolland et al., 2005; Senechal et al., 
2007; Satoh et al., 2012; Berres et al., 2014). Likewise, the LCH and ECD 
patients did not have any detectable circulating CD11c+103+ HCL cells. 
 
Patients with MS LCH had relatively expanded myelopoiesis with a 
reactive phenotype, but cytological examination of the blood and bone 
marrow excluded any evidence of leukemic transformation.  Expansion of 
blood CD11c+ mDCs in LCH has been previously but not uniformly 
reported (Rolland et al., 2005; Senechal et al., 2007). Possible differences 
were seen between the LCH and ECD patients, in general the 
BRAFV600E+ECD patients had less expanded myelopoiesis, with possible 
deficiencies in CD141+ mDCs and lymphoid cell types, whereas the 
NRASQ61R+patient was more in keeping with the MS LCH, with expanded 
monocytes and CD11c+ mDCs, and relatively normal or slightly expanded 
lymphoid cell numbers. As expected in HCL, the majority of patients had 
reductions in all myeloid cell types, with variable numbers and increases in 
B and NK cells. Unfortunately due to the low number of recruited patients, 
it is hard to draw any further conclusions from the PBMC phenotyping 
results. 
 
Similarly, few BM samples were available for the study. BM from 
the two PBMC BRAFV600E+ MS patients showed normal levels of CD34+ 
progenitors, but with a myeloid skewed phenotype including CMP, GMP, 
MEP and the uncharacterised CD123high fraction. The older patient who 
had previously had cytoreductive cladribine treatment had decreased 
levels of BNK progenitors. BM from the NRASQ61R patient showed reduced 
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CD34+ and MPP progenitor numbers, but a similar profile of increased 
myeloid progenitors CMP, GMP and MEP, but with normal numbers of 
CD123high cells. Due to the fact that the BM from HCL patients is 
characteristically fibrotic (Burke, 1978), only one sample was available for 
analysis. This patient had extremely low levels of CD34+ progenitors, 
mostly comprised of HSC, with low levels of myeloid progenitors and 
complete absence of CD123high cells. 
 
5.4.2. PBMC BRAFV600E 
Due to the increased numbers of circulating monocytes and CD1c+ 
myeloid DCs in the MS LCH patients, it could be inferred that they might 
contribute to the pathogenesis of LCH, however this requires more than 
phenotypic correlation. I therefore looked to patients with detectable BRAF 
mutation in their peripheral blood to determine whether CD11c myeloid 
DCs or monocytes were part of the abnormal clonal myelopoiesis and 
might therefore contribute to LCH pathology.  
 
A number of previous reports did not find mutated BRAF in the 
peripheral blood or bone marrow of patients with LCH (Sahm et al., 2012; 
Satoh et al., 2012).  One reason may be that this appears restricted to MS 
patients with active disease, which are a relatively small subset of patients 
particularly among adults (Berres et al., 2014).  Another factor is that 
sufficiently sensitive techniques must be used such as allele-specific PCR, 
rather than primer extension or next generation sequencing, to detect 
mutated alleles below 1% abundance (Satoh et al., 2012).   
 
Data on BRAFV600E in ECD lesions and peripheral blood are even 
more controversial, possibly dependant on the specificity of techniques 
used. One study puts the percentage positivity of ECD lesions at 54% with 
pyrosequencing (Haroche et al., 2012b).However a later study shows that 
67% of patients are positive by pyrosequencing but 100% using the 
immunohistochemistry antibody VE1, followed by detecting the mutation in 
100% of patient’s PBMC by droplet delay PCR (ddPCR) or 
pyrosequencing coupled to locked nucleic acid PCR (LNA-PCR) (Cangi et 
179 
 
al., 2014). In my hands I have seen the VE1 antibody to have non-specific, 
granular staining in cells such as lymph node macrophages and 
sebaceous gland cells (data not shown), and is therefore not useful for the 
specific identification of LCH or ECD cells. 
 
In order to deal with these potential problems, I used a 
commercially available mutation detection PCR assay, modifying the 
amount of input DNA to ensure that sufficient genome equivalents were 
analysed to detect as few as 0.1% mutated alleles.  
 
In keeping with a recent report in children(Berres et al., 2014),  
BRAFV600E was only detected in the peripheral blood of LCH patients with 
active MS or ‘high risk disease’ involving liver, spleen or bone marrow. 
Therefore I would speculate that there is a correlation between MS LCH 
and circulating BRAFV600E, though due to limitations in patient numbers I 
cannot say that this is a certainty. If this is the case though, it could go 
some way to explaining the differences between MS and SS disease, the 
former arising from the BM via a circulating precursor, the latter arising 
from a localised tissue precursor.  
 
BRAFV600E mutation was detected in the PBMC of 2/3 patients with 
multi-system (MS) LCH, 5/8 ECD patients and 4/6 HCL patients. Of the 
two negative HCL patients, one has variant HCL, which is known to be 
BRAFWT in all cases (Tiacci et al., 2011), the other patient was clinically 
well (WBC 4.0x109/L) and had received cytotoxic cladribine treatment two 
months previously. Patients with single system LCH or BRAF wild-type 
lesions did not have detectable BRAFV600Ein their peripheral blood. 
 
In the study by Berres et al, mutant BRAF was found in both CD14+ 
and CD14-CD11c+ populations in childhood LCH (Berres et al., 2014). In 
this thesis, similar results were obtained in adults showing that CD14+ 
monocytes are a substantial reservoir of BRAFV600E.  It was also possible 
to resolve the distribution of BRAFV600E within CD14-CD11c+ cells in more 
detail. Results here indicate that the major mutated component in LCH is 
contained in non-classical CD16+ monocytes.  CD1c+ mDCs, although 
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BRAFV600E+, are relatively rare and contributed less than 2% of 
BRAFV600Esignal detectable in the HLA-DR+Lineage- population. The cell 
types seen to contain the BRAFV600E mutation all have a phagocytic 
capacity, so a false positive result may have arisen from phagocytosis of 
aberrant LCH cells. However, I have seen that the peripheral blood 
contains no evidence of LCH cells, so this is unlikely. 
 
In ECD, the major mutated component was a CD33+ early myeloid 
cell and in HCL the majority of mutation was seen in the CD103+11c+ 
HCL cells or CD103-11c- normal B cells. The HLA-DR-Lineage- quadrant 
is the least characterised fraction of cells; it will be well worth studying this 
quadrant in ECD to learn more about the difference between LCH and 
ECD. 
 
The occurrence of mutated BRAF in multiple lineages in 
multisystem LCH is anticipated on the grounds that, in order to sustain 
clonal myelopoiesis, the mutation must occur in a sufficiently primitive 
population to be self-renewing. BRAF mutations that occur in non-self-
renewing hematopoietic compartments may only be transiently detectable 
in the peripheral blood or in an isolated lesion, which is self-healing, as 
others have observed (Satoh et al., 2012; Kansal et al., 2013). In the lung, 
presence or absence of mutated BRAF has recently been used to indicate 
the clonality of LCH in this site (Yousem et al., 2013). The level of BRAF 
mutation in PBMC was low. This is in keeping with abnormal 
haematopoiesis occurring in parallel with physiological haematopoiesis 
and suggests that LCH lesions form because the few percent of mutated 
precursor cells have enhanced survival mechanisms in tissues.  
 
The fact that in ECD the mutated BRAF is most restricted to what 
appears to be an early myeloid cell, suggests that the cells in ECD may be 
arrested at an earlier differentiation time point than those in LCH and more 
driven towards a macrophage like phenotype. It would be interesting to 
explore whether any BRAFV600E can be seen in the HLA-DR-CD33+ of MS 
LCH patients, although if this is the case, the population is likely to be very 
small in comparison to the BRAFV600E+ cells in the HLA-DR+Lineage- 
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fraction, as the mutation levels in the HLA-DR-Lineage- fraction of LCH 
accounted for only 1-2% of the total mutation load. It would also be 
interesting to explore the HLA-DR-CD33+ fraction of ECD patients in 
greater detail, to see if they already express, or can be induced to express 
CD68 like the infiltrating macrophage-like cells in ECD. 
 
5.4.3. BM BRAFV600E 
The consistent finding of BRAFV600E in the peripheral blood of both 
MS LCH patients at several time points implies the existence of self-
renewing myeloid progenitors with mutated BRAF. Although the bone 
marrow contained cells with LCH phenotype and CD14+ cells carrying 
mutated BRAF, it was possible to exclude these and to demonstrate that 
BRAFV600E was present in early myeloid progenitors including the GMP, 
CMP and HSC, with a bias towards the CMP fraction.  These findings add 
further support to recent data showing that unfractionated CD34+ 
progenitors carrying the BRAF mutation from children with MS LCH may 
be expanded in vitro into myeloid DC and monocyte colonies. In this study 
it was proposed that MS LCH arises from self-renewing BM progenitors 
that produce circulating precursor cells but SS LCH evolves by mutation of 
myeloid progenitors in the periphery (Berres et al., 2014). Unfortunately 
colony forming unit assays could not be repeated in this thesis due to low 
progenitor cell numbers. It is difficult to exclude low level BM and blood 
involvement in SS disease, but the threshold of detection afforded by 
allele-specific PCR appears to yield a distinction that correlates well with 
clinical observations. 
 
Bone marrow from BRAFV600E+ ECD patients was not available, 
though BM from an ECD patient carrying the NRASQ61R mutation revealed 
a similar profile of positivity to LCH, with the mutation detected in HSCs, 
CMPs and GMPs, with a skewing towards the GMPs. Similarly in HCL, 
one patient showed BRAFV600E mutation in the CD34+38-45RA-90+ 
haematopoietic stem cells (HSCs), echoing recent data showing 
BRAFV600E positivity in the HSCs of five HCL patients (Chung et al., 2014). 
These results indicate that at least some subtypes of each disease could 
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have origins as early as the haematopoietic stem cell. It would certainly be 
interesting to examine the other BM progenitor subsets in HCL to see 
whether the profile is different to LCH and ECD.  
 
5.4.4. Lesional BRAFV600E 
Analysis of the skin lesion in LCH patient A2712 confirmed previous 
results that close to 100% of cells with characteristic LCH phenotype are 
mutated (Badalian-Very et al., 2010; Sahm et al., 2012; Satoh et al., 2012; 
Berres et al., 2014). The relatively low and stable abundance of BRAFV600E 
in blood and bone marrow subsets is perhaps surprising given the context 
of a multi-system disease.  Comparison with the 100% frequency in 
lesional LCH cells implies that BRAFV600E does not confer a selective 
advantage within the progenitor or precursor compartments, but rather 
operates to promote myeloid cell recruitment, proliferation or survival by 
pathways that are only activated at an inflammatory nidus in the periphery.  
From this perspective, MS LCH is unlike a leukemic process in which 
driver mutations invariably cause clonal dominance of haematopoiesis and 
tissue infiltration is a relatively rare secondary phenomenon. 
 
Lesions in LCH are made up of an admixed selection of LCH cells, 
T cells, eosinophils, macrophages and dendritic cells. Unfortunately, in this 
study there was limited availability of lesional material to sort, and 
therefore only the LCH and T cells of one patient were tested for the 
mutation. The previous study by Berres et al stated that the eosinophils In 
the lesion were not positive for the mutation (Berres et al., 2014) and it is 
interesting to note that eosinophils have not been seen in mouse LCH 
(Steiner et al., 2008).Therefore it seems possible that eosinophils in LCH 
are a skin-specific immune response rather than a direct contributor to 
pathobiology, unlike in Hodgkin’s lymphoma, where eosinophils are known 
to play an important role (Pinto et al., 1997). 
 
5.4.5. Summary 
Using techniques established earlier in this thesis, I have 
successfully derived peripheral blood and bone marrow phenotypic 
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profiles and clonal lineages of the histiocytic disorders Langerhans Cell 
Histiocytosis and Erdheim Chester Disease, as well as reproducing results 
seen previously in Hairy Cell Leukaemia. However, as several subsets 
were seen to express the BRAFV600E mutation, the exact identity of 
possible LCH and ECD precursor cells is yet to be discovered. Also, I 
cannot say with certainty that any of the BRAFV600E+ circulating subsets 
directly contribute to the development of the disease cells.  
 
Prospective studies are now required to test whether therapeutic 
decisions can be made according to BRAFV600E testing in the peripheral 
blood.  Adults with high risk MS LCH are rare and may be difficult to treat 
but the results here illustrate the biological features in common with MS 
LCH in children.  The presence of BRAFV600E in hematopoietic stem cells 
and poor outcome with myelosuppressive chemotherapy suggest that 
targeted therapy may be beneficial.  The patients described in this study 
did not access clinical trials of BRAF inhibitors owing to exclusion due to 
performance status or personal preference.   The two patients with PBMC 
BRAFV600E+ MS LCH had aggressive disease with only partial responses 
to chemotherapy. BRAFV600E levels were monitored throughout treatment 
and remained detectable in the peripheral blood throughout with 
substantial burdens in the PBMC and BM shortly before death (data not 
shown). Taken together, the results obtained in patients of all ages 
suggest that the BRAF status of an LCH or ECD lesion and testing for 
BRAFV600E in the blood and BM may assist the delivery of optimal therapy 
for LCH and ECD. 
 
Faced with several possible myeloid precursor populations, in vitro 
differentiation models may help to define the potential of different 
BRAFV600E+cells to form LCH or ECD cells.  Langerin expression may be 
induced in vitro on both CD14+ monocytes and CD34+ progenitor 
fractions (Caux et al., 1992; Strobl et al., 1996; Geissmann et al., 1998; 
Ratzinger et al., 2004; Klechevsky et al., 2008; Bauer et al., 2012; Hutter 
et al., 2012).  It is unclear whether or not CD34+ progenitors transition 
through a monocyte differentiation stage during this process.  GM-CSF, IL-
4, TNF-α and TGF-β, factors that induce langerin in vitro, have all been 
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reported in LCH lesions (Annels et al., 2003; Fleming et al., 2003).  
However, several studies have confirmed the role of cell signalling through 
CD40, Notch and other receptors that are less often studied in in vitro 
models of LC differentiation (Egeler et al., 2000; Hoshino et al., 2005; 
Hutter et al., 2012).  These models are consistent with the potential of 
CD14+ monocytes to form LCH-like cells but also demonstrate that 
Langerin expression is not an exclusive property.  
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Chapter 6. Peripheral Blood DC Langerhans Cell Potential 
 
6.1. Introduction 
The work in this chapter involves the in vitro culture of flow cytometry 
sorted mononuclear subsets from control peripheral blood (PB), in an attempt to 
determine which, if any, subsets can be induced to bear a phenotype similar to 
Langerhans cells, and thus, also similar to the pathologic cells in Langerhans 
Cell Histiocytosis (LCH).  
 
6.1.1. Chapter Aims 
1) To analyse negative and positive methods of DC and monocyte 
isolation, to ascertain the true composition of the isolated cells. 
 
2) To find if it is possible to stimulate CD1c+ mDCs or other DCs and 
monocytes of the blood to bear the features of Langerhans cells in 
vitro. 
 
6.1.2. On the Origin of LCH Cells 
The key markers of LCH cells are surface expression of langerin 
and CD1a and internal presence of Birbeck granules (BGs). These 
pathologic cells are thought to be related to the Langerhans cells (LCs) 
resident in the epidermis, which also bear all three markers  (Birbeck et al., 
1961; Nezelof et al., 1973; Harrist et al., 1983; Rousseau-Merck et al., 
1983; Schuler et al., 1983; Valladeau et al., 2000). However, the definitive 
origin of the LCH cells is still unclear.  
 
Although murine LCs are self-renewing in the steady state (Merad 
et al., 2002), during inflammation, they are replaced by recruited cells that 
differentiate and express Langerin and CD1a following inflammation 
(Ginhoux et al., 2006; Nagao et al., 2012; Seré et al., 2012).Observations 
in humans also confirm that LCs can be self-maintained (Czernielewski 
and Demarchez, 1987; Bigley et al., 2011; Kanitakis et al., 2011) or 
replaced by bone marrow-derived cells in the context of transplantation 
and inflammation (Perreault et al., 1985; Collin et al., 2006; Kanitakis et 
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al., 2011; Mielcarek et al., 2014). The nature of bone marrow derived LC 
precursors that repopulate the epidermis following inflammation is 
incompletely defined.  Experiments in mice with clodronate depletion and 
bead-labelling suggest a monocyte origin but do not completely exclude 
other precursors (Ginhoux et al., 2006).  It was therefore highly relevant to 
explore in more detail the capacity of blood borne cells to become LCs, 
since dysregulated differentiation in this pathway might explain the origin 
of LCH. 
 
The experiments in this chapter were prompted by three recent 
observations. Firstly the discovery of the BRAFV600E mutation in the 
peripheral blood CD14+ monocytes and CD14-CD11c+ cells and bone 
marrow myeloid progenitors of multi-system Langerhans cell histiocytosis 
(LCH) patients(Berres et al., 2014), which may be precursors of the classic 
LCH disease cells. Secondly the serendipitous observation that langerin 
was induced on mononuclear cells isolated from blood bank leukocyte 
filters held at room temperature overnight. These in vitro observations 
suggest that CD34+ progenitors, monocytes and/or mDCs have the 
capacity to form LCH-like cells. Finally, the observation that CD1c+ mDCs 
in tissues express a low level of langerin and that blood CD1c+ mDCs 
contain langerin mRNA (Bigley et al., 2014). Therefore, it may be possible 
that LCH cells have an origin in circulating monocytes or CD1c+ mDCs or 
even further back in the haematopoietic system in BM progenitor cells. 
 
In humans, langerin+ cells can be made in vitro from monocytes 
(Geissmann et al., 1998; Hoshino et al., 2005; Hutter et al., 2012), 
suggesting a potential precursor role. However, experiments with CD34+ 
progenitors also demonstrate the existence of an LC-differentiation 
pathway that appears independent of CD14+ monocytes (Caux et al., 
1996; Strunk et al., 1996).  More recent studies with murine models have 
shown that expression of BRAFV600E in myeloid haematopoietic 
progenitors drives a disease phenotype similar to low-risk LCH, whereas 
expression in differentiated myeloid cells recapitulated severe high-risk 
LCH. 
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Another report suggested the existence of CD3/7/14/16/19 negative 
LC precursors in human blood, and although noted to express CD1c, 
these were incorrectly described as expressing CD1a (Ito et al., 1999; 
Mason. D et al., 2000; MacDonald et al., 2002).  For a summary of 
historical langerin induction experiments (See Table 1.5, page 64). A 
previous study has shown an increase in CD11c+ cells in the PB of LCH 
patients (Rolland et al., 2005), although this finding is disputed in a study 
showing no increases (Senechal et al., 2007). Previously in this thesis it 
was seen that CD11c+ cells, and specifically the CD11c+1c+ mDCs were 
increased in LCH patients, particularly those with multi-system disease. 
 
More recent observations in mice lacking LCs due to Id2 knockout 
or conditional ablation show that LC repopulation occurs in two waves 
(Nagao et al., 2012; Seré et al., 2012).  The epidermis is initially infiltrated 
by a short term precursor with low langerin expression and features in 
common with monocytes, followed by a long term precursor that acquires 
the full phenotype of LCs, including self-renewal capacity (Nagao et al., 
2012; Seré et al., 2012). It is therefore possible that more than one type of 
circulating myeloid cell could be the originators of LCH cells. 
 
Historical reports where LCs, containing Birbeck granules have 
been derived from monocytes, used CD3,7,19,45RA,56 negative selection 
from PBMC with the now discontinued Monocyte Isolation Kit I from 
Miltenyi Biotec (http://www.miltenyibiotec.com) (Geissmann et al., 1998; 
Mohamadzadeh et al., 2001; Guironnet et al., 2002). In the HuDC lab, 
methods of positive selection are employed which have the ability to 
distinguish two/three different monocyte subsets and at least two different 
DC subsets. It is therefore important to find how relatable these methods 
are, and what is truly isolated by each technique.  
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6.1.3. Chapter Hypotheses 
1) Previous reports demonstrating LC-like cell differentiation from 
monocytes, may have been contaminated by non-monocyte circulating 
dendritic cells. 
 
2) Monocytes and CD1c+ DCs both form Langerin+ cells in response to 
defined in vitro stimuli. 
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6.2. Materials and Methods for Chapter Six 
6.2.1. Cell Culture 
CD14+ monocytes, CD16+ monocytes, CD1c+ myeloid DCs 
(mDCs) and CD123+ plasmacytoid DCs (pDCs) were sorted from PBMC 
(see section 2.4.2, pg. 71) obtained from healthy volunteers under local 
ethical approval (Appendix 8). Sorting was performed with an ARIA Fusion 
(Becton Dickinson; B-D) using previously described protocols. 10,000 cells 
were cultured in RPMI with 10% FBS or X-Vivo in 100µl.  Supplements 
were added at the following concentrations:  GM-CSF: 50ng/ml; TGFβ: 
10ng/ml; BMP7: 200ng/ml.  Cultures were maintained for 3-14 days and 
supplemented with fresh cytokines on day 4, 8 and 12. 
 
6.2.2. Langerhans Cell Isolation 
Normal skin was obtained from mammoplasty and breast 
reconstruction surgery, obtained from healthy volunteers under local 
ethical approval (Appendix 8).  Fresh Langerhans cells were isolated as 
previously described (Haniffa et al., 2012). LCs were isolated from 
epidermal sheets separated from whole skin keratome sections with 
dispase (Invitrogen) 1mg/ml incubated at 37oC for 90 minutes in RPMI and 
subsequently digested with collagenase (Worthington Type IV) 1.6 mg/ml 
incubated for 12 hours at 37oC in RPMI with 10% foetal bovine serum 
(FBS).  Viability was >90% by DAPI exclusion (Sigma). Langerhans cells 
were FACS sorted by lack of autofluorescence and expression of 
CD45+HLA-DR+CD1ahighLangerinhigh. 
 
6.2.3. Electron Microscopy 
Cells were fixed for electron microscopy (EM) according to standard 
protocols in 2% glutaraldehyde, then pelleted, dehydrated and fixed in 
resin (reagents from TAAB Lab, Aldermarston, UK).  Ultrathin sections 
were cut with a diamond knife RMC MT-XL ultramicrotome and examined 
with a Philips CM 100 Compustage (FEI) Transmission Electron 
Microscope.   Images were collected with an AMT CCD camera (Deben). 
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6.3. Results 
6.3.1. Spontaneous Langerin Induction 
The experiments in this chapter were prompted by the 
serendipitous observation that langerin was spontaneously induced on 
mononuclear cells isolated from blood bank leukocyte filters held at room 
temperature overnight (Figure 6.1). It was therefore decided to see which 
particular cells were undergoing this spontaneous induction. 
 
 
Figure 6.1. Spontaneous Langerin Induction in PBMCs 
Examples of spontaneous langerin induction: 
A. Peripheral blood mononuclear cells (PBMCs), 24hours after density 
centrifugation separation. 
B. Blood bank leukocyte filters (Cone) held at room temperature overnight.  
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6.3.2. Comparative Flow Cytometry 
Previous studies on the production of LC-like cells from circulating 
cell subset have used a variety of initial isolation methods (See Table 1.5, 
page 64). The use of negative selection techniques may not enrich a truly 
heterogeneous cell population, which could lead to the identification of LC-
precursors which are in fact contaminants in the original preparation. 
Therefore I sought to determine which subsets have been isolated by 
negative isolation methods in previous studies.  
 
In order to compare the exact cell types isolated by negative and 
positive monocyte and DC isolation methods currently in use; three 
replicate samples were stained with either negative ‘untouched monocyte’ 
selection markers CD3,7,19,45RA,56 or HuDC lineage markers 
CD3,19,20,56. Monocyte and DC markers CD14,16,123,11c,1c were 
stained in separate channels to give a downstream gating strategy of the 
cells isolated. 
 
As seen in Figure 6.2, the cells negatively selected with the 
‘untouched monocyte’ method contain not just classical CD14+ monocytes 
(~90% of isolated cells), but also CD16+ non-classical monocytes (~5%), 
CD11c+1c+ myeloid DCs (mDCs; ~3%) and CD123+ plasmacytoid DCs 
(pDCs; <1%). 
 
192 
 
 
Figure 6.2. Comparative Gating Strategies 
A. PBMC were sorted into fractions indicated using the sequential gating shown. 
A: CD14+ monocytes; B: CD16+ monocytes; C: CD123+ pDCs; D: CD1c+ 
mDCs.  
B.  Illustrative gating of PBMCs using a lineage cocktail as described in an 
‘untouched’ monocyte isolation kit, containing CD3,7,19,45RA,56.  CD123+ 
pDCs are relatively depleted by the inclusion of CD7 and CD45RA but CD1c+ 
mDCs remain. 
C. Frequency of monocyte and DC subsets as in A) above compared with the 
frequency of each subset present in PBMCs analysed with a standard lineage 
cocktail of CD3,19,20,56.  Mean of three experiments +/- SEM is shown.  
CD1c+ mDCs are not significantly depleted by the protocol (Wilcoxon Rank 
Sum test p = 1.00).  
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6.3.3. TGF-β AND Bone Morphogenetic Protein 7 
Prompted by a previous observation that CD1c+ mDCs in tissues 
express a low level of langerin and that blood CD1c+ mDCs contain 
langerin mRNA (Bigley et al., 2014), DC and monocyte fractions of human 
PBMC were cultured in conditions that induce langerin in progenitor cells, 
including TGF AND BMP7. This induced a rapid up-regulation of langerin 
and CD1a dual expression by CD1c+ mDCs, peaking within 3 days 
(Figure 6.3, Figure 6.4).  Langerin+ cells also appeared in CD14+ and 
CD16+ monocytes but the level of expression was lower and did not 
increase further by day 7.   
 
From 10,000 sorted CD1c+ mDCs (counted by the sorter) 5,000-
7,000 cells were recovered the next day and 2,000-3,000 at the end of the 
culture period (6,000-7,000 of monocytes at day 7) (Figure 6.5.A).  There 
was no increase in cell numbers in any culture. Induction of a CD1a+ 
langerinhigh population was restricted to CD1c+ DCs treated with TGFβ, 
BMP7 or both (Figure 6.5.B).  No significant synergy was observed 
between TGFβ and BMP7. No langerin induction was seen in medium with 
serum alone, but serum-free medium with supplements also failed to 
induce any expression. Exhaustive testing of different serum free media 
was not conducted. 
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Figure 6.3. Raw Flow Data from 3 Day Cultures 
Sorted cells cultured for 3 days in conditions as indicated showing expression of 
CD1a and extracellular langerin.  The experiment was repeated five times 
except for the panels with X-Vivo which were repeated three times.  Four 
subsets of cells were collected from one donor, different in each experiment.  
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Figure 6.4. Expression of Langerin and CD1a by Monocytes and 
DCs 
A. Time course of expression of CD1a and langerin double-positive cells. 
Showing a rapid upregulation of langerin and CD1a in CD1c+ mDCs and 
CD14+ and CD16+ monocytes within 72h, peaking at 3 days and a gradual 
decline in the percentage of positive cells up to 7 days of culture. In CD1c+ 
mDC cultures with TGFβ or BMP7 a langerin high, EpCam+ fraction was 
observed, which was unseen in any of the other cell subsets. Mean +/- SEM 
of five experiments with different donors. 
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Figure 6.5. Day 7 Cell Recovery and Langerin/CD1a Dual Positivity 
 
A. Recovery of viable cells under each condition at 7 days of culture, estimated 
by the total number of DAPI-negative cells recorded when the culture was 
analysed and run to dryness on the cytometer.  10,000 cells were added to 
each well as counted by the sorter but typically resulting in 6,000-8,000 viable 
cells at the start of the culture.   There were no statistically significant 
differences between each condition for a given subset of cells. 
B. Percentage of langerin+ cells derived from GM-CSF+TGF (red bars), GM-
CSF+BMP7 (blue bars) and GM-CSF+TGF and BMP7 (green bars) after 3 
days of culture (upper plot).  Percentage of langerinhigh cells derived from GM-
CSF+TGF (red bars), GM-CSF+BMP7 (blue bars) and GM-CSF+TGF and 
BMP7 (green bars) after 3 days of culture (lower plot).  Mean +/- SEM of five 
experiments with different donors.  Gating of langerin+ and langerinhigh cells is 
illustrated using CD1c+ mDCs incubated with GM-CSF and BMP7 as an 
example.  There were no statistically significant differences between each 
condition for a given subset of cells. p = <0.01 compared with corresponding 
CD14+ monocyte culture.  Differences in langerin induction between 
monocyte subsets and pDCs for a given culture condition, were not 
significant. 
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6.3.4. May-Grünwald-Giemsa Stain Morphology 
As the general morphology of LCs is quite different to circulating 
monocytes and DCs, representative examples of each cultured cell type 
were cytospun and stained with May-Grünwald-Giemsa stain at days 0, 1, 
3 and 7, to examine any morphological changes (Figure 6.6.A). 
Cytological development did not differ substantially between subsets of 
monocytes and CD1c+ mDCs, although CD1c+ mDCs developed a higher 
nucleus to cytoplasmic ratio and CD16+ monocytes remained smaller. 
 
Lower resolution images of groups of cells on the cytospins were 
taken of 7 day cultures to represent an overview of cell morphology 
variation, and for comparison with freshly isolated Langerhans cells 
(Figure 6.6.B). CD1c+ mDCs were large after in vitro culture but 
developed pale pink perinuclear staining and vacuole, similar to primary 
LCs. 
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Figure 6.6. May-Grünwald-Giemsa Stain Morphology 
A. Representative examples of Giemsa-stained cell fractions at intervals in cell 
culture (From GM-CSF + BMP7 culture). 
B. Giemsa-stained fields of cells showing freshly isolated epidermal Langerhans 
cells, compared with 7 day cultures of CD1c+ mDCs and CD14+ monocytes 
in GM-CSF, TGF and BMP7.  CD1c+ mDCs were large after in vitro culture 
but developed pale pink perinuclear staining and vacuoles, similar to primary 
LCs. 
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6.3.5. Cell Surface Marker Characterisation 
In order to determine the presence or absence of LC-associated 
markers CD1a, Langerin, EpCAM and E-Cadherin on the cultured cells, 
flow cytometry was performed on days 0 and 7 of CD1c+ mDC cultures. 
Expression of HLA-DR and CD83 were also assessed to determine the 
levels of maturation in the cells. 
 
This showed induction of EpCAM, E-Cadherin and low expression 
of CD11b, similar to primary LCs.  Langerin+CD1c+ mDCs remained 
immature, with lower expression of HLA-DR and CD83 compared to 
freshly isolated LCs (Figure 6.7.A). The expression of EpCAM was highest 
on langerinhigh cells derived from CD1c+ mDCs; in contrast, langerin+ cells 
derived from CD14+ monocytes had low EpCAM and higher CD11b 
expression (Figure 6.7.B). There was no expression of CD83 on the 
CD1c+ mDC cultures, showing that they are still less mature than the 
CD83+ LCs.  
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Figure 6.7. Cell Surface Marker Characterisation of LC-Like Cells 
A. Cell surface marker characterisation of LC-like cells obtained after 7 days of 
culture. Shaded histograms: isotype controls: grey line CD1a and Langerin 
double negative cells; black line CD1a+ Langerin+ cells.  Similar results were 
obtained with GM-CSF and TGF, BMP7 or both together in three different 
donors; one of three experiments performed with GM-CSF, TGF and BMP7 
is shown. 
B. Comparison of Langerin, EpCAM and CD11b expression in CD1c+ mDCs 
and CD14+ monocytes.  Light grey: isotype; mid grey CD1a+ Langerin low 
cells; black: CD1a+ Langerin high cells.  One of three experiments performed 
with GM-CSF, TGF and BMP7 is shown. 
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6.3.6. Birbeck Granules 
LCs are most typically identified by their expression of Langerin and 
CD1a, but the most defining feature is the presence of Birbeck granules 
(BGs). Therefore, day 3 cultures of all cell subsets treated with GM-CSF 
and TGFβ/BMP7 were harvested for EM (all cells), in order to determine 
the presence or absence of BGs. No BGs were seen in ultrathin sections 
of any culture (>50 cells viewed). Day 7, 10 and 14 cultures of CD1c+ 
mDCs, CD14+ monocytes and CD16+ monocytes treated with GM-CSF 
and BMP7 were harvested for EM (all cells). At day 7, BGs were observed 
in 12/20 ultrathin sections of CD1c+ mDCs with many sections containing 
more than 10 granules. At day 10, only 1/20 ultrathin sections of CD1c+ 
mDCs contained BGs (six BGs in total), and by day 14, no BGs were 
seen.  In contrast, BGs were rarely found in cultures of CD14+ monocytes 
(a single granule in 20 cell sections at day 7), and none were seen in 
cultures of CD16+ monocytes (Figure 6.8). 
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Figure 6.8. Formation of Birbeck granules in cultures of CD1c+ 
mDCs 
A. EM images of Birbeck granules in CD1c+ mDCs cultured for 7 days showing 
classical tennis-racket morphology, pentalaminar structure and formation by 
endocytosis.  Insets in the top left panel are displayed beneath and to the 
right.  The experiment was performed twice with 2 different donors with GM-
CSF and BMP7.  The entire culture was processed for EM. 
B. Comparison of the number of Birbeck granules per cell section between 
CD14+ monocytes and CD1c+ mDC cultures on day 7. * p = <0.01.  
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6.3.7. Electron Microscopy – ‘Thumbprint’ Organelles 
During the EM evaluation of the presence of BGs, other atypical 
granules were observed in almost 100% of the CD1c+ mDCs at day 7, 
hereafter named ‘thumbprint’ organelles due to their characteristic 
thumbprint appearance on day 7. When re-viewing the other time 
points, it was seen that these atypical thumbprint organelles could be 
tracked in size throughout the days of culture (Figure 6.9). On day 2, 
the thumbprint organelles were roughly circular, approximately 100-
200nm in diameter, with irregularly spaced circular internal 
striations/lamellar. Between days 4 and 10, the thumbprint organelles 
became more irregular in shape, but with a larger number of more 
regularly spaced internal striations/lamellar, sometimes with a central 
area of clear cytoplasm. On day 14, no thumbprint organelles were 
visible, though larger organelles were apparent which were split into 
long, coiled lines, which resembled BGs in that they had a central 
linear density, but were much longer than a characteristic BG. Cell 
numbers at day 14 were greatly reduced; however, the expanded 
thumbprint organelles were seen in all remaining cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
204 
 
 
 
 
Figure 6.9. Unidentified ‘Thumbprint’ Organelles 
EM images of unidentified ‘thumbprint’ organelles in CD1c+ mDCs cultured for 
2-14 days in RF-10 with GM-CSF and BMP7. Organelles had a pentalaminar 
structure and appeared to grow in size between day 2 and day 14. The 
experiment was performed twice with 2 different donors with GM-CSF and 
BMP7.  The entire culture was processed for EM. 
 
 
205 
 
6.4. Discussions for Chapter Six 
The results in this chapter indicate that there are several possible 
pathways to the generation of langerin+ cells in humans and that CD1c+ mDCs 
but not CD14+ monocytes, generate a high yield of langerinhigh CD1a+ EpCAM+ 
cells with Birbeck granules under the conditions examined.  Results also show 
that BMP7 can affect LC-like differentiation with equal efficiency to TGFβ. 
 
GM-CSF, TGFβ and BMP7 are found in epithelial tissues in vivo where 
similar differentiation may occur (Greter et al., 2012; Yasmin et al., 2013a).  
Previous experiments on CD34+ progenitors have highlighted the difference 
between a TGFβ-dependent pathway of LC generation from CD1a+ 
intermediates versus the TGFβ-independent generation of monocyte-derived 
DCs that are unable to express langerin(Caux et al., 1992; Strobl et al., 1996; 
Ratzinger et al., 2004; Klechevsky et al., 2008; Yasmin et al., 2013a).  It is likely 
that this dichotomy anticipated the differential ability of CD1c+ mDCs and 
monocytes to generate LCs with high langerin, CD1a and EpCAM expression 
and Birbeck granules that I now observe.  
 
Recent data in mice describing two waves of repopulation of the LC 
compartment show an early monocyte-like EpCAM- langerinlow wave succeeded 
by a myeloid precursor of unknown origin(Nagao et al., 2012; Seré et al., 2012).  
In situ studies also show that LC repopulation after inflammation occurs with 
similar kinetics in humans(Kaplan et al., 1987).  CD1c+ mDCs have properties 
that make them candidates for the second-wave LC precursor (such as high 
numbers of epidermal sheet dendrites, high expression of langerin, EpCAM and 
CD1a, and low expression of CD11b).  The nearest homologue to the CD1c+ 
blood DC in mice is the circulating pre-cDC (Naik et al., 2006; Liu et al., 2009).  
It will be interesting to determine whether this fraction contains the long term 
precursor of murine LCs. 
 
These are in vitro experiments, using serum, as in recent publications 
describing DC differentiation (Balan et al., 2014; Martinez-Cingolani et al., 
2014). There is a possibility that serum can be involved in the differentiation. 
For this reason, experiments were also performed without serum, using X-vivo 
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instead of RPMI with 10% bovine serum.  After sorting, viability was 
approximately 50% lower in serum-free medium and I did not observe any 
Langerin induction and only low level CD1a expression. 
 
These data help to explain two puzzling claims from other publications in 
this field. Firstly, that LCs with BGs can be produced from CD14+ monocytes 
(Geissmann et al., 1998; Mohamadzadeh et al., 2001; Guironnet et al., 2002), 
may be contaminated with up to 3% CD1c+ mDCs when using the ‘untouched 
monocyte’ method of cell isolation. These contaminating cells may therefore 
contribute to the high expression of Langerin and Birbeck granules reported.  
Where monocytes have been isolated by positive selection using CD14 
antibodies, there is lower langerin expression as described here (Hutter et al., 
2012). 
 
Secondly, the finding that there are CD1a+ ‘LC precursors’ in human 
blood (Ito et al., 1999).  Blood DCs were reported to express CD1a due to 
incorrect assignment of clone BB5 as a CD1a specific antibody.  It is now 
known that BB5 recognises CD1b/c and not CD1a (Mason. D et al., 2000; 
MacDonald et al., 2002).  The non-monocyte cells in human blood that give rise 
to LCs in response to TGFβ and BMP7 in vitro are now clearly shown to be 
CD1c+ mDCs. 
 
This is the first time that the thumbprint organelles have been followed 
during their development within cells, although it is important to note that the 
link between the organelles seen at each stage cannot be guaranteed.  These 
organelles have in fact been seen previously in similar experiments, for 
example in a study by Grassi et al., similar organelles were seen in 11-36% of 
monocyte-derived DCs when ficoll-derived, adherent monocytes were cultured 
in RF-10 with GM-CSF and IL-4 for 6-7 days, though no BGs were seen (Grassi 
et al., 1998). Incidentally, these organelles have been noted as being 
pathognomonic for the congenital, self-healing form of LCH; Hashimoto-Pritzker 
disease (Hashimoto and Pritzker, 1973; Hicks, 2002; Hicks and Flaitz, 2005). 
 
Later in a study by Guironnet et al., cells were derived from PBMC with 
the ‘untouched monocyte’ isolation method, cultured in ‘complete media’, 
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supplemented with combinations of GM-CSF, IL-4, TGFβ. In cultures with GM-
CSF and IL-4, ring shaped organelles similar to the expanded thumbprint 
organelles seen at day 14 of culture, were seen in ~15% of cells. In cultures 
with GM-CSF and TGFβ, BGs were seen in 15/101 cells, compared to 4/73 
cells with the further addition of IL-4 (Guironnet et al., 2002). In accordance with 
our data showing the lack of BG formation in CD14+ monocytes, and the 
presence of CD1c+ mDCs in the ‘untouched monocyte’ isolation method (see 
6.3.1), it is likely that the 15% of the cells cultured with TGFβ which did display 
BGs in this paper, are actually CD1c+ mDCs not CD14+ monocytes.  
 
More recently, in a study by Bonetti et al, CD133+ primitive myeloid 
progenitor cells were MACS separated from cord blood samples and cultured in 
RF-10 for 7 days with GM-CSF, TNFα, IL-4, TPO, FLT3L, SCF and TGFβ, and 
then until day 18 without TPO, FLT3L, SCF, but with increased TGFβ. At days 7 
and at later time points, thumbprint organelles were seen (Bonetti et al., 2011). 
No Birbeck granules were seen but a small proportion of the cells had dual 
expression of CD1a and langerin.  
 
The data in this chapter show that, while monocytes are able to express 
langerin, when cultured with soluble ligands GM-CSF, TGFβ and BMP7, CD1c+ 
dendritic cells become much more LC-like with high Langerin, Birbeck granules, 
EpCAM and E-cadherin expression, under the same conditions.  Previous 
observations have shown that blood CD1c+ mDCs contain langerin mRNA and 
that tissue CD1c+ mDCs express a low level of langerin (Bigley et al., 2014). 
These data highlight the potential precursor function of CD1c+ mDCs and 
demonstrate an alternative pathway of Langerhans cell differentiation that may 
have relevance in vivo.   
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Chapter 7. General Discussions and Conclusions 
 
This work explores the development of dendritic cells (DCs) in various 
haematological disorders including malignancies, immunodeficiencies and 
histiocytoses. During this thesis I have been able to relate haematopoietic 
disorders (AML, MDS and DCML deficiency) to the DC system, and DC 
disorders (histiocytosis) to the haematopoietic system. 
 
7.1. Mononuclear Cell Development in Myeloid Malignancies 
7.1.1. Mononuclear Cell Profiles in Myeloid Malignancies 
Multiparameter flow cytometry panels were developed to allow in-
depth analysis of the profiles of the mononuclear cell compartment of 
peripheral blood, bone marrow and other (disease) tissues. This analysis 
was used to uncover new information about the relationships between DC 
and monocyte development in pathological states. 
 
Flow cytometry revealed several differences in mononuclear cell 
development between different types of bone marrow failure including DC, 
monocyte, B and NK lymphoid (DCML) deficiency, sporadic 
myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML). 
DCML deficiency has almost complete losses of specific cell subsets, 
MDS has a more generalised and less severe cellular deficiency, and AML 
has a remarkably preserved mononuclear differentiation, even at high 
levels of blasts.  
 
7.1.2. Comparative Phenotyping of AML Blast Cells 
One of the problems with trying to isolate distinct haematopoietic 
progenitor populations by cell markers is that in actuality, the expression of 
several markers on these fractions appear more as a continuous 
spectrum, rather than obviously positive and negative. This is possibly 
related to differentiation. This problem is exacerbated by the fact that 
these populations are most often comprised of very low cell numbers. A 
particular example is the differentiation of MEPs and CMPs. CMPs are 
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known to be able to differentiate into both GMPs and MEPs (Manz et al., 
2002). GMPs are easily distinguished by expression of CD45RA, though 
CMPs and MEPs, although showing different progenitor capacity (Akashi 
et al., 2000; Manz et al., 2002; Na Nakorn et al., 2002; Goardon et al., 
2011), are difficult to isolate by flow cytometry markers. Several markers 
were assessed in this study for the ability to split CMP and MEP more 
effectively, though none were more reliable than CD123.  
 
Also, the identification of blast cells and separation from normal 
mononuclear compartments can be difficult. Only ~45-68% of AML are 
CD34+ (Del Poeta et al., 1994; Krasinskas et al., 1998; Legrand et al., 
2000; Thalhammer-Scherrer et al., 2002), and it is quite often the case 
that the blastic cells obscure a large portion of the flow plots due to sheer 
quantity, and are therefore difficult to isolate by any method. Isolation of 
the blastic cells could have been improved by using the markers CD33, 
which is positive in ~64-98% of AMLs (Del Poeta et al., 1994; Khalidi et al., 
1998; Krasinskas et al., 1998; Legrand et al., 2000; Thalhammer-Scherrer 
et al., 2002)and CD45, which is reported to be helpful in identifying blasts 
(Jennings and Foon, 1997; Panoskaltsis et al., 2003). However, by adding 
these extra markers, other markers for the identification of mononuclear 
cell types would need to have been excluded, thus lowering the 
usefulness of the data. 
 
Although further exploration of the entire haematopoietic system in 
BM is needed, work in this thesis has been effective at dissecting AML 
types by immunophenotypic analysis of progenitor cell markers, as seen in 
Figure 7.1, or by clustering analysis of DC-related markers. 
 
Previous results reported by Goardon et al, 2011 are reproducible, 
showing that AML can be split into two major immunophenotypic groups 
(GMP/MLP type and CMP/MPP type, see Figure 7.1) based on progenitor 
cell markers. AML blasts can also be grouped by the DC-related 
immunophenotype of the blastic cells by bioinformatics. Five clusters are 
seen; clusters 1, 2 and 4 relate to the GMP/MLP type leukaemia and are 
the most heterogeneous. Cluster 5 specifically relates to blastic 
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plasmacytoid dendritic cell neoplasm (BPDCN), which also appears to be 
a GMP/MLP type leukaemia. Finally Cluster 3 relates to a leukaemia type 
with a ‘null’ phenotype for DC-related markers and correlates with the 
CMP/MPP type leukaemia (5/5 with available data).  
 
Correlations were seen between the CMP/MPP; Cluster 3 type 
leukaemia in regards to cytogenetics; specifically 15:17 translocations and 
normal karyotype, although normal karyotype patients are found in both 
immunophenotypic types. 
 
 
Figure 7.1. Models of Immunophenotypic AML Types 
Diagrammatic representations of each immunophenotypic type of leukaemia 
identified in this study. Enlarged cells in the diagrams represent the expanded 
progenitor cell compartment. Numbers indicate the number of each type of AML 
patient identified by profiling in the BM and PBMC.  
 
HSC = Haematopoietic Stem Cell; MPP = Multi-Potent Progenitor; MLP = Multi-
Lymphoid Progenitor; B/NK = B/NK Cell Progenitor; CMP = Common Myeloid 
Progenitor; MEP = Megakaryocyte/Erythroid Progenitor; GMP = Granulocyte 
Macrophage Progenitor. 
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Even though AML patients could be grouped by the Goardon et al 
methods, or by clustering analysis, there was widespread heterogeneity in 
the phenotypes of the AML samples, particularly for Lineage MFIs 
(CD3,19,20,56) and FSC and SSC values. Also, heterogeneity was seen 
in the levels of the major and minor clones in the AML types. These 
differences may be due to specific molecular differences between the 
patients, or because of differences in the blast cell/normal progenitor cell 
composition of the expanded types. The differences seen in the lineage 
MFIs are interesting as these are lymphoid markers, which could imply 
differences in lymphoid cell potential in the blastic cells, or possibly that 
some of the AML patients have bi-phenotypic features of both AML and 
ALL. Detailed analysis of lymphoid markers may be able to further subtype 
the blast clusters.  
 
Overall, it is seen that the AML immunophenotype are essentially 
divided by CD45RA positivity (GMP/MLP) or negativity (CMP/MPP). It is 
therefore clear that the addition of CD45RA into the antigen presenting cell 
flow cytometric panel may be very useful in the analysis of AML. CD45RA 
is positive on naïve and effector T cells (Sallusto et al., 2004), though the 
role of CD45RA in myeloid cells is unclear.  
 
I originally hypothesised that AML patients would have severe 
cytopenias at diagnosis due to disruption of normal haematopoiesis by the 
blastic cells, however the analysis in this thesis has shown that 
haematopoiesis in AML is surprisingly conserved. Nonetheless, data in 
this thesis suggests that different types of AML may have differences in 
the functional levels of immune cells, or specific immunodeficiencies, 
which may increase the risk of severe sepsis or fungal infection, 
responsible for the majority of AML induction therapy related deaths 
(Lech-Maranda et al., 2010). It is therefore possible that the progenitor cell 
immunophenotype of leukaemia may correlate with infection and outcome. 
This is an important issue as induction death is now an equivalent risk to 
relapse death in the best risk patient groups (Lech-Maranda et al., 2010).  
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Infection is the primary cause of death in low-risk MDS patients 
(30%), followed by transformation into AML (15%) and haemorrhage 
(13%) (Dayyani et al., 2010), while high-risk MDS patients are more prone 
to infection (Toma et al., 2012). AML patients have a lower rate of 
infection-related death at around 14.5% of patients (Lech-Maranda et al., 
2010). As seen in this thesis, although not statistically significant, there 
were trends for patients with MDS to have reduced immune cell numbers 
compared to normal controls, and to AML patients, where haematopoiesis 
is relatively conserved. These immune cell reductions could indicate why a 
higher percentage of MDS patients have an infection-related mortality than 
AML patients. Standard primary treatments for AML involve 
myeloreductive (rather than myeloablative) therapy, as such it is likely that 
some normal myeloid cells are present after treatment. Therefore it could 
be clinically significant to ascertain the extended phenotype of AML 
patients post-chemotherapy. Patients whose haematopoiesis remains 
mostly intact even after chemotherapy may have a much lower risk of 
infection than those who have an abolished haematopoiesis at diagnosis 
or post-chemotherapy. Patients who progress from MDS to AML are 
thought to do so due to the development of multiple secondary genetic 
mutations in the malignant clone (Walter et al., 2012). One interesting 
angle for future studies would be to see if the extended phenotype and 
specific cytopenias in MDS patients correlate with which patients progress 
from MDS to AML.   
 
7.1.3. Minimal Residual Disease Testing 
Survival rates in acute leukaemias are improving all the time, due to 
new and more effective methods of diagnosis and treatment. The median 
survival of adult patients in 1966 was just 40 days(Medical Research 
Council, 1966), whereas now 50% of patients achieve a five-year survival 
(CancerResearchUK, 2014b). Although rates of complete remission (CR; ≤ 
5% leukaemic blasts in the BM) are high (50-80%, dependant on age and 
gender), relapse occurs in the majority of patients within 5 years after 
treatment (Paietta, 2012). These relapses are likely due to the presence of 
minimal residual disease (MRD), the low numbers of leukaemic cells which 
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remain in the patient during or after therapy which are undetectable by 
current methods. 
 
The most commonly used MRD testing methods include DNA and 
RNA based tests for cytogenetic abnormalities and multiparameter flow 
cytometry for abnormal cellular markers, otherwise known as Leukaemia-
associated immunophenotypes (LAPs or LAIPs). DNA and RNA methods 
are less useful in AML than other leukaemia types, as ~40% of AML 
patients have normal cytogenetics (Grimwade et al., 2010), though direct 
comparisons have shown that these methods have equivalent 
effectiveness (Perea et al., 2006; Rossi et al., 2012) and the general 
sensitivity level of multiparameter flow cytometry MRD is thought to be 
able to reach 0.01%, which is equivalent to RT-PCR (Paietta, 2012). 
 
Evidence that multiparameter flow cytometry LAP MRD testing 
determined therapy leads to an improvement in AML prognosis is limited, 
though recent assessments have shown that multiparameter flow 
cytometry MRD testing is useful for overall outcome predictions and 
effects of maintenance strategies in patients with AML (Kern et al., 2008; 
Buccisano et al., 2012) and other leukocyte cancers such as multiple 
myeloma (Rawstron et al., 2013). In order to be optimal for clinical use, 
methods of MRD testing must have the ability to be consistently and 
objectively applied, and to be extremely sensitive. A survey of the 
multiparameter flow cytometry MRD testing used for multiple myeloma 
revealed major heterogeneity in analysis criteria and sensitivity between 
centres (Flanders et al., 2013). It is therefore crucial that criteria is 
normalised between centres with highly accurate and sensitive methods. 
 
The reasoning behind the markers used in most LAP studies is that 
they are absent or found very infrequently in normal blood or BM (Feller et 
al., 2013). These markers have been chosen by empirical methods of trial 
and error, whereas the methods of immunophenotyping performed in this 
thesis have been developed using a more rational approach, using a 
limited range of antigens and a classifying system based on the mature 
phenotypes seen in normal mononuclear cells.  
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The methodology described in this thesis could potentially be used 
for MRD testing in a complementary combination with cytogenetic 
analysis. The multiparameter flow cytometry panels can be used to give a 
high sensitivity of quantifying leukaemic cells with an abnormal phenotype, 
which can then be FACs sorted and tested for the particular cytogenetics 
seen in the patients. This would greatly increase the sensitivity of the 
cytogenetic analysis by specifically testing possibly leukaemic cells rather 
than the entire leukocyte fraction. With the development of tools to 
visualise high-dimensional flow cytometry onto two-dimensional plots, 
such as viSNE (Van der Maaten, 2008; Amir et al., 2013), it may be 
possible to use the immunophenotyping methods developed in this thesis 
as a universal method of MRD testing in AML patients, similar to that 
which has recently been described in B-ALL (DiGiuseppe et al., 2015). 
 
7.1.4. The Unclassified CD123high Fraction of CD34+ Bone Marrow 
An interesting observation in the BM of patients relates to the 
CD123highfraction of CD34+ cells. To date these cells have not been 
classified for their contribution to the haematopoietic system, although 
their expression of CD123 would imply that they are involved in pDC 
differentiation. However, in a limited number of patient samples with 
Blastic Plasmacytoid Dendritic Cell Neoplasm, I have seen varied 
expansions of the GMP, CMP and MLP fractions rather than the 
CD123highfraction (data not shown). In this thesis, a relative expansion of 
the CD123high and GMP fractions were seen in the LCH patients, a normal 
level of CD123high but expansion of GMP in an ECD patient and a 
complete absence in an HCL patient. This could imply a role in myeloid 
haematopoiesis from this fraction, as it correlates with the myeloid 
compartment expansion in LCH, varied but averaging as normal levels of 
myeloid cells in ECD and an almost complete lack of myeloid cells in HCL 
patients. In contrast, no AML patients were seen with expansions of the 
CD123high fraction, suggesting that CD123high cells may be a later 
maturation stage of GMPs which AML cells are unable to differentiate into. 
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7.1.5. FLT3-L as a Biomarker for Haematological Disorders 
In this thesis, it was seen that serum levels of Fms-related tyrosine 
kinase 3 ligand (FLT3L), were significantly increased in DCML deficiency 
patients, while significantly decreased in AML patients. Therefore FLT3L 
monitoring may be useful as a diagnostic test in this setting; excessive 
levels of FLT3L would identify DCML deficiency patients and FLT3L below 
the normal range would identify AML patients to a high sensitivity and 
specificity. There is a possibility that FLT3L may be used for a biomarker 
for DCML deficiency and AML, by means of such clinical interventions as 
simple as a finger prick test. This could be a useful, minimally invasive, 
first assessment in AML, which is predominantly a disease of the elderly, 
where assessment based on bone marrow examination is not always 
available. Additionally to a diagnostic test, it may be possible to assess 
levels of FLT3L over time, to monitor response to treatment. 
 
7.2. Dendritic Cell Development in Histiocytosis 
7.2.1. Mononuclear Cell Profiles in Histiocytosis 
Flow cytometry revealed some differences in mononuclear cell 
development between different types of histiocytic disorder. Interesting 
findings in the mononuclear cell profiles of the histiocytic disorders include 
an apparent expansion of CD14+ monocytes in LCH and loss of 
lymphocytes and CD141+ mDCs in ECD patients. CD11c+1c+ mDCs 
were increased, as has previously been described (Rolland et al., 2005), 
most particularly in the multi-system LCH (msLCH) patients. 
 
7.2.2. Tracking BRAFV600E in Histiocytic Disorders 
BRAFV600E mutation was detected in the myeloid lineages of the 
bone marrow and peripheral blood of msLCH patients using a modified 
mutation detection PCR assay. BRAFV600E or NRASQ61R mutations 
detected in the myeloid lineages of the bone marrow and early myeloid 
precursors and innate lymphoid cells of peripheral blood in some ECD 
patients. As far as I am aware, this is the first time that CD1a+Langerin+ 
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LCH cells have been specifically sorted from LCH lesions to confirm levels 
of BRAFV600E positivity and to assess morphology. 
 
7.2.3. Peripheral Blood DC Langerhans Cell Potential 
CD1c+ mDCs can be induced to bear a Langerhans cell (LC) like 
phenotype in response to GM-CSF with TGF and/or BMP7, suggesting a 
second pathway of LC differentiation through a monocyte-independent 
route.CD14+ monocytes express low langerin and do not make Birbeck 
granules (BGs) under the same conditions. This is contradictory to 
previous results where CD14+ monocytes were thought to induce langerin 
highly (Geissmann et al., 1998; Mohamadzadeh et al., 2001; Guironnet et 
al., 2002), however these studies employed negative isolation techniques, 
which I have shown to likely be contaminated with CD1c+ mDCs. More 
recent studies where CD14+ monocytes have been positively isolated, 
have reported expression of Langerin and CD1a and Birbeck granules 
(Hoshino et al., 2005; Shibasaki et al., 2007; Musso et al., 2008). These 
studies used Notch Ligand Delta-1 (with TGFβ) or Activin A (a TGFβ 
family member as inducers. Interestingly Notch has recently been reported 
to be active in LCH (Hutter et al., 2012). These results indicate that CD1c+ 
mDCs and monocytes may both be able to become LCH like under 
different conditions.  
 
7.2.4. Possible Origins of Histiocytic Cells 
Although this study goes some way to identifying the potential 
precursors of LCH, ECD and HCL, there is still a lot of work to do to for 
complete certainty. A diagrammatic representation of the potential 
mutational pathways seen in the thesis for LCH, ECD and HCL is given in 
Figure 7.2. A caveat of this model is that even though the mutation has 
been seen in a number of different cell types represented, this does not 
necessarily prove a lineage link between the circulating cells and lesional 
LCH cells.  
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I have seen in this study what at first appear to be contradictory 
findings about the potential origins of LCH cells. The study by Berres et al, 
reported that CD11c+ and CD14+ circulating cells of LCH patients 
expressed BRAFV600E.  In this thesis I saw that although CD1c+ mDCs and 
CD14+ monocytes carried the BRAFV600E mutation in LCH patients, it was 
the non-classical CD16+ monocytes which carried the highest level of 
mutation at up to 45%. Given the heterozygous nature of the mutation, this 
would imply that ~90% of CD16+ monocytes in that particular patient 
carried the mutation and therefore this cell type would be a key contender 
as the cell of origin in LCH.  
 
It is tempting to speculate that the expansion of and enrichment of 
BRAFV600E in monocytes in LCH patients indicates that they are the 
precursors of LCH cells in multisystem disease, as has been previously 
suggested by several authors (Geissmann et al., 1998; Rolland et al., 
2005).  However, there is unlikely to be a simple correlation between the 
frequency of BRAFV600E and the precursor potential of a given population.  
Rare cells such as CD1c+ mDCs, which were seen to be increased in this 
and other studies (Rolland et al., 2005) might accumulate through strong 
selective mechanisms operating in the periphery while other more 
abundant monocyte fractions such as the non-classical monocyte might 
accumulate a high level of BRAFV600E even if they are devoid of precursor 
potential. However I found that CD16+ monocytes were decreased in LCH 
patients, possibly due to migration into LCH lesions. 
 
It was seen in chapter six, that although CD14+ and CD16+ 
monocytes are able to induce langerin expression with stimulation from 
BMP7, it is only the CD1c+ mDCs which can be induced to express 
langerin and CD1a to the high levels seen in LCH, at least under the 
conditions tested. The in vivo experimentation for langerin induction was 
performed on healthy control samples, so this does not rule out the 
possibility that the monocytes of LCH patients may be able to aberrantly 
express high levels of langerin and CD1a in the disease state. The low 
levels of BRAFV600E seen in the circulating CD1c+ could indicate that the 
CD1c+ cells bearing the BRAFV600E mutation have already migrated from 
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the blood to the lesions, whereas the monocytes bearing the mutation may 
be bystanders which remain in the blood. This is clearly an area which 
could be further explored in the future as samples become available. 
 
In this study on adult patients, BRAFV600E was only seen in the 
circulating blood of multi-system, high-risk disease patients. This is in 
keeping with a recent report in children,  where BRAFV600E was only 
detected in the peripheral blood of patients with active MS or ‘risk disease’ 
involving liver, spleen or bone marrow (Berres et al., 2014). The 
expression of BRAFV600E in mouse models results in the formation of LCH-
like lesions and LCH cells with characteristics which may be dependent on 
the differentiation state of the cells in which the mutation is initiated; 
expression in immature bone marrow progenitor cells (BRAFV600E-CD11c 
mice) leads to features of high-risk LCH, whereas expression in more 
mature myeloid cells (BRAFV600E-Langerin mice) leads to a low-risk LCH 
phenotype (Berres et al., 2014). These findings could also give some 
indication as to why one mutation can lead to multiple different disease 
presentations such as LCH, ECD and HCL. The presenting features of the 
disease may be dependent on the stage of haematopoietic development 
at which the originating cell was at when it developed the BRAFV600E (or 
alternate MAPK pathway) mutation. 
 
Recent work in mice investigating LC reconstitution after conditional 
ablation, has demonstrated that in inflammation, LCs may be reconstituted 
in two distinct waves; a primary short-term monocyte derived langerin-low 
LC, and a secondary long-term bone marrow derived langerin-high LC 
(Nagao et al., 2012; Seré et al., 2012). These data, together with the vast 
heterogeneity seen in LCH patients, could indicate that there may be 
multiple different precursor populations from which LCH cells may arise 
under different conditions, such as the differentiation levels of the initial 
cells carrying the mutation, and whether the disease is high/low risk or 
multi/single-system. 
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Figure 7.2. Model of Mutational Pathways in LCH, ECD and HCL 
HCL = Hairy Cell Leukaemia; msLCH = multi-system Langerhans Cell 
Histiocytosis; ECD = Erdheim Chester Disease 
Coloured Lines = Potential pathways of disease haematopoiesis; full lines are 
based on disease associated mutation detection (see chapter 5); dashed lines 
are based on in vitro differentiation studies (see chapter 6).  
Coloured Lightning Symbols = Theoretical sites of disease-specific second hits. 
Grey Lightning Symbols = Theoretical sites of tissue-specific second hits. 
HSC = Haematopoietic Stem Cell; MLP = Multi-Lymphoid Progenitor; B/NK = 
B/NK Cell Progenitor; CMP = Common Myeloid Progenitor; MEP = 
Megakaryocyte/Erythroid Progenitor; GMP = Granulocyte Macrophage 
Progenitor; RBC = Red Blood Cell; T = T Cell; B = B Cell; NK = Natural Killer 
Cell; mDC = Myeloid Dendritic Cell; pDC = Plasmacytoid Dendritic Cell; Mono = 
Monocyte; Baso = Basophil; LC = Langerhans Cell; Mo-MAC = 
Monocyte/Macrophage; MΦ = Macrophage. 
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7.2.5. Bone Marrow Origins of Histiocytosis 
Previously, BRAFV600E has been seen in CD34+ cells of the bone 
marrow of LCH patients(Berres et al., 2014), and the HCSs of HCL 
patients (Chung et al., 2014). One of the most interesting aspects of this 
thesis is that the disease associated mutations (BRAFV600E/NRASQ61R) 
have been seen in the HSCs of selected patients of LCH, ECD and HCL. 
This indicates that at least some subtypes of the diseases are likely to be 
leukaemic disorders of early haematopoiesis.  
 
These observations could explain some of the discrepancies in 
potential originating cells. A recent review speculated on CMPs as a 
common cellular origin in LCH and ECD (Badalian-Very, 2014), however in 
this thesis I have seen that the BRAFV600E mutation can be found as far 
back in haematopoiesis as the HSCs. This early stage would allow the 
mutation to be perpetuated into different mononuclear subset progeny 
which may or may not play active roles in the diseases. Recent studies 
have reported the possibility of more than one wave of LC recruitment 
(Seré et al., 2012), therefore It could be possible that both CD16+ 
monocytes and CD1c+ mDCs play pathogenic roles in LCH.  
 
7.2.6. BRAFV600E Monitoring in Histiocytic Disorders 
It was seen in this thesis that the use of allele specific PCR is very 
useful in the detection of low-level BRAFV600E in patient samples of PBMC, 
BM, or tissues. This method could also be used for sequential monitoring 
over time, and therefore may be a useful method for minimal-residual 
disease testing. Recently new methods of detection of BRAFV600E and 
other related mutations have been developed for the analysis of cell free 
DNA in plasma and urine (Janku et al., 2013; Hyman et al., 2014). These 
methods would obviously be less intrusive to patients, and very useful for 
disease monitoring, but are unlikely to be useful for further elucidation of 
the cells of origin in these diseases. 
 
222 
 
7.2.7. The LCH-ECD-HCL Paradox 
The presence of BRAFV600E in LCH, ECD and HCL, brings the 
question of how a single mutation can cause such different diseases. As 
seen in this thesis, the levels of mutation can be very low in the BM, but 
very high in lesions. This could suggest that the BRAF mutation itself is 
not enough to cause a high proliferation rate, which is only achieved once 
the cells are located in the lesions. This along with the noticeable 
observation that the three diseases have vastly different presentations, 
likely means that there must be some other pathological event that takes 
place to drive the specific disease phenotype which occurs.  
 
There are variations in the median age of onset of patients; LCH is 
generally a childhood disease while ECD and HCL have late adult average 
ages of onset (with the caveat that adult LCH is thought to be 
underdiagnosed). This could suggest that the time of mutation acquisition 
is indicative of the disease type.  
 
Few studies have been performed to examine whether additional 
somatic mutations are involved in pathogenesis; MAP2K1 and ARAF 
mutations have been implicated in whole exome sequencing studies in 
LCH, but they are independent of BRAFV600E (Chakraborty et al., 2014; 
Nelson et al., 2014). Another study found no somatic mutations in one 
ECD patient and extremely low rates of somatic mutations (median 1 
mutation per sample) in all histiocytic lesions (Nelson et al., 2014), which 
contrasts with high amounts of somatic mutations seen in most 
leukaemias including HCL (Tiacci et al., 2011). The propensity for single 
somatic mutations of the MAPK pathway, with low global frequency of 
other somatic mutations, indicates that mutations in this pathway are 
crucial for the initiation of LCH and ECD. The MAPK pathway is clearly 
also important in HCL patients where 100% of patients carry the 
BRAFV600E mutation (Tiacci et al., 2011), and in HCL variant patients 
where BRAF is wild-type but up to 50% of patients have a mutation in 
another member of the MAPK pathway, MAP2K1 (Waterfall et al., 2014). 
The presentation seen in HCL may be different to that seen in LCH due to 
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somatic mutations appearing alongside BRAFV600E in the HCL patients. 
These mutations may potentially skew the maturation of BRAFV600E+ cells 
into the more lymphoid-like HCL cells rather than the monocytes and DCs 
which I have seen to carry the BRAFV600E mutation in LCH patients in this 
thesis.  
 
No recurrent cytogenetic or epigenetic abnormalities have been 
observed in LCH or ECD, whereas HCL patients have been seen to have 
recurrent cytogenetic abnormalities, particularly in chromosome 5 
(Haglund et al., 1994), aberrant but uniform gene expression profiles 
(Vanhentenrijk et al., 2004) and differences in methylation status of -C-
phosphate-G- (CpG) sites of DNA  (Rinaldi et al., 2013).  
 
These deregulated features of HCL patients could indicate that HCL 
is caused by a primary somatic BRAFV600E mutation, with secondary 
cytogenetic or epigenetic changes, possibly brought on by age, whereas 
LCH and ECD might be caused by a primary somatic mutation related to 
the MEK/ERK pathway, with disease promoting events of a non-genetic 
cause. 
 
One possible disease-promoting pathological event would be a role 
of an infectious agent, similar to the roles of HHV and EBV which have 
been implicated in the histiocytic disorders RDD and HLH (Luppi et al., 
1998; Mehraein et al., 2006; Bohne et al., 2013). An interaction of an 
infectious agent with cells carrying MEK/ERK pathway associated 
mutations, such as BRAFV600E/NRASQ61R, may promote the hyper-
activation of the MEK/ERK pathway in a tissue-specific manner. This could 
suggest why the same mutation could lead to lesions in widely dispersed 
and varied organs in different patients, dependant on where interaction 
with an infectious agent has occurred. Recent studies have potentially 
identified Merkel cell polyomavirus as a contributing factor in high-risk LCH 
pathogenesis (Murakami et al., 2014; Murakami et al., 2015b), while no 
pathogens have been associated with low-risk LCH. 
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It is a very likely possibility that HSCs are a heterogeneous 
population, thus a second possibility is that the different disease types are 
caused by mutations which occur at different maturation stages of the 
HSCs, with slightly different lineage bias. Although this study had limited 
patient BM samples, it was interesting to see some slight differences in the 
patient types. HCL patient A7264 had a large increase in HSCs, while all 
other BM progenitor types were reduced. Both LCH and ECD had 
mutations in the HSCs, CMPs and GMPs, though relative abundance 
differed; BRAFV600E was seen to be highest in the CMPs of both LCH 
patients, and NRAFQ61R was seen most highly in the GMPs of the ECD 
patient. Confusingly, the expansion of BM progenitor cells in LCH and 
ECD gave a conflicting picture, with highest expansions of GMPs in LCH 
patients and CMPs in the ECD patient. This could suggest that the 
negative effects of the mutations could become apparent at different 
states of maturation of progenitor cells, leading to separate disease 
entities. This theory has been incompletely tested at present; more BM 
from each patient type would have to be examined to see the relative 
abundance of mutation in the progenitor types. 
 
LCH was first described from the union of three diseases; 
eosinophilic granuloma, Hand–Schüller–Christian disease and Letterer–
Siwe disease due to related cellular morphology. The research in this 
thesis and from recent publications would again point to divisions in the 
pathology of different subtypes of LCH and also ECD. From this thesis it 
would seem that LCH and ECD may have a haematopoietic stem cell 
origin in multi-system disease, or a tissue-specific origin in single-system 
disease. Overall, I have seen that LCH and ECD are highly heterogeneous 
diseases, and that it is likely that each will be parsed back into subtypes in 
future studies. 
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7.3. Future Work 
7.3.1. Haematological Malignancies 
An interesting future goal would be to test whether the progenitor 
phenotype subset associates with prognosis. Currently there is a need to 
refine the ‘intermediate’ risk group of AML. In this thesis I have seen that 
CMP/MPP leukaemia relates to 15;17 translocations specifically, and 
accounts for a proportion of patients with ‘normal’ cytogenetics. It may be 
possible to split patients with normal cytogenetics by the 
immunophenotypic type of their blasts, and correlate this to outcome.  
 
To strengthen this analysis, more patient samples could be 
collected, but also, it will be possible to combine mean fluorescence 
intensities (MFIs) of the markers in the mature and progenitor cell flow 
cytometry panels in order to strengthen the clustering of AML samples. 
 
Another question to be answered is whether the mononuclear cells 
seen in the AML patients are preserved elements of normal 
haematopoiesis or are part of the AML clone. It may be possible to exploit 
the cytogenetic mutations seen within the AML cells to answer this 
question, by seeing if these mutations are within the differentiated 
mononuclear fractions. This could be achieved through the use of similar 
technology as discussed in this thesis for histiocytic disorders. 
 
 
7.3.2. Histiocytic Disorders 
This study has gone a long way to observing the potential cells of 
origin in multi-system LCH, although the origins of ECD are less clear. 
Further studies with more explicit analysis of the subsets in the HLA-DR-
Lineage- fraction in ECD patients are needed, as well as confirmatory 
studies to show that the cells seen to carry the mutation can indeed bear 
the phenotypes ECD. 
 
Although I have seen that CD1c+ mDCs can be induced to display 
an LC phenotype under the conditions tested, there may be other 
conditions which can induce the same phenotype in monocytes, such as 
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Notch ligation, and these should be explored. Also, further expression 
profiling and functional analysis should be performed on the LC-like cells 
formed to truly define the possibility of a precursor-progeny relationship 
between these cells and LC/LCH cells. 
 
It is interesting to note that on day 7 of my langerin induction data, 
Birbeck granules (BGs) and thumbprint organelles could be observed 
coexisting in the same cells cultured with GM-CSF and TGFβ/BMP7 
(Figure 7.3). The presence of the thumbprint organelles and BGs 
coexisting in the same cells does not in itself imply a relationship between 
the two; however, It would be interesting to study the two organelles in 
more detail. 
 
 
Figure 7.3. Coexistence of Birbeck Granules and Thumbprint 
Organelles 
Example EM images of Birbeck granules and thumbprint organelles coexisting 
in the same CD1c+ myeloid dendritic cell at day 7 of culture. The experiment 
was performed twice with 2 different donors with GM-CSF and BMP7.  The 
entire culture was processed for EM. 
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